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Abstract
Offspring of diabetic and obese mothers (ODOM) have greater risks of heart disease
at birth and later in life. However, prevention is hindered because underlying
mechanisms are poorly understood. Mounting studies in the Developmental Origins of
Health and Disease field suggest that mitochondria play key roles in developmentally
programmed heart disease similar to the roles they play in cardiomyopathy in adults
with diabetes and obesity. However, whether mitochondria are responsible for the shortand long-term cardiac disease seen in ODOM remains unknown. Here, we sought to
delineate the roles of mitochondria in the hearts of ODOM, determine whether
mitochondria are playing central or secondary roles in previously found bioenergetic
dysfunction, and tease apart the different mitochondrial mechanisms in pregestational
vs late-gestation diabetes exposure.
This body of works shows that mitochondrial and cardiac dysfunction are present at
birth, soon normalize, but then reappear later in life. Importantly, mitochondrial
dysfunction per impaired bioenergetics precedes the declining cardiac function in
diabetes-exposed offspring, supporting a causative mitochondrial role. These same
offspring, particularly males, suffer from greater mitochondria-mediated cell death under
metabolic stress that may translate to faster, more robust tissue damage during
ischemia-reperfusion, thus increasing the risk of death from myocardial infarction. We
resumed study of newborns to understand mitochondria-mediated mechanisms of
programmed heart disease, including heritable risk and effect on earlier cardiac
development. To do this, we adapted our late-gestation diabetes model to study
pregestational diabetes alongside maternal high-fat diet. Although there were similar
and overlapping changes in cardiac structure and function, distinct mitochondrial
impairments resulted from pregestational diabetes exposure. Rather than impaired
bioenergetics contributing to cardiac dysfunction as in our late-gestation model,
pregestational diabetes exposure impaired ATP production, increased oxidative
damage, and reduced cardiomyocyte capacity for surviving metabolic stress. This could
have profound effects on cardiogenesis and ageing. Mitochondrial transplantation was
used to understand whether mitochondria play a primary role rather than programmed
changes in fuel storage or flux. This technique provided male diabetes-exposed cells
with both a respiratory boost and improved viability. Taken together, findings support a
central, pathogenic, and potentially targetable role of mitochondria in developmentally
programmed heart disease.

Dissertation Advisor
Michelle L. Baack, MD
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Chapter 1: Introduction
Background
Cardiovascular disease (CVD) is the leading cause of death in the United States
and kills over 800,000 people per year (1). Diabetes and obesity are well-known risk
factors of CVD and are growing at alarming rates. Worse yet, many epidemiologic
studies indicate that infants born to diabetic and obese mothers are also at risk of heart
disease at birth and throughout life (2-6), presumably by developmental programming. It
is increasingly recognized that mitochondria play a significant role in both cardiac
development and disease. Despite mounting evidence that mitochondria play a role, a
poor understanding of pathophysiologic mechanisms hinders effective prevention and
treatment. We hypothesize that prenatal exposure to excess circulating fuels incites
mitochondrial dysfunction in the developing offspring’s heart resulting in impaired
cardiac bioenergetics, mitophagy, and stress responses that increase the risk of heart
disease throughout life.
Our lab previously used a rat model to show that gestational diabetes and
maternal high-fat (HF) diet during pregnancy are associated with mitochondrial
dysfunction, metabolic impairment, and systolic and diastolic dysfunction in the
developing offspring’s heart, including through epigenetic influences (7-10) (discussed
at length below). Specifically, newborn offspring born to mothers with late-gestation
diabetes exhibit impaired bioenergetics that are worsened in combination with maternal
HF diet (7). Our lab also found that both maternal diabetes and HF diet impair
mitochondrial dynamics in newborn cardiomyocytes (CM), and these effects vary by
individual and combined prenatal exposure as well as offspring sex (9). Further, we
1

found that diabetes-exposed CM have fewer mitochondria while HF diet-exposed CM
have greater mitochondrial numbers which increases reactive oxygen species (ROS)
production and the risk of cell damage or death (7). Together, these findings
demonstrate that mitochondrial dysfunction may be contributing to heart disease in
offspring of diabetic and obese mothers (ODOM), setting up a vicious, multigenerational
cycle of adverse cardiometabolic function which adds to the growing burden of CVD in
the future.

The Role of Mitochondria in Cardiac Development and Disease
In utero and during the perinatal period, glycolysis is the predominant energy
source for the heart (11). With increased workload, oxidative stress, and interruption of
placental fuel supply after delivery, there is a significant shift from glycolysis to oxidative
phosphorylation (OXPHOS) for energy (11, 12). Simply put, at birth mitochondria must
take over as the primary producers of cardiac energy. This postnatal shift is associated
with a normal increase in mitochondrial biogenesis and respiratory efficiency (13) which
can be disrupted by dysfunctional mitochondria. Although adult CMs primarily oxidize
fatty acids (FA) (14), healthy adult CM must be able to use a variety of fuels
(carbohydrates, proteins, ketones) and retain the ability to ramp up OXPHOS and
glycolysis during times of increased energetic demand or relative ischemia, such as
during exercise, ischemia-reperfusion injury, or advanced heart failure (12). This ‘fuel
flexibility’ is highly dependent upon myocardial mitochondria and is essential for the
large amount of ATP production needed for ongoing contractile function over a lifetime.
Cell metabolism is not only reliant on mitochondria number, but also on mitochondrial
efficiency or function. Dysfunctional mitochondria are unable to maintain a well-charged
2

membrane potential necessary for ATP production, leading to increased oxygen
consumption, ROS generation, and oxidative damage. Poorly charged, dysfunctional
mitochondria are normally culled by physiologic mitophagy which recycles proteins and
mitochondrial (mt)DNA to improve the cell’s overall mitochondrial quality. When cells
are overloaded with dysfunctional mitochondria and can no longer meet their energetic
needs, they undergo mitochondria-mediated cell death, which in the case of nonregenerative organs like the heart can be detrimental. It is therefore unsurprising that
disruptions in respiration, oxidative stress, or mitochondrial quality control have serious,
damaging effects on cardiac health.
Dyslipidemia and hyperglycemia are well-known features of diabetes and obesity
and have damaging effects on myocardial and mitochondrial function, particularly
metabolism and bioenergetics (15-17). Diabetes and obesity have been repeatedly
linked to CVD including heart failure, coronary and peripheral artery disease,
cerebrovascular disease, and a host of other systemic complications (18, 19). The
underlying and overlapping mechanisms are not fully understood, but mitochondrial
dysfunction—often bioenergetic—is almost always involved. Further, adult hearts
affected by long-standing diabetes and obesity show myocardial lipid accumulation and
impaired fuel flexibility with nearly total reliance on FA oxidation for cardiac ATP
production (17, 20, 21). Diabetic cardiomyopathy, which is a combination of diastolic
leading to systolic dysfunction, hypertrophy, and heart failure in the absence of other
cardiac risk factors (22), has been tied to mitochondrial dysfunction in human patients.
Increasing evidence demonstrates diabetic cardiomyopathy is associated with impaired
cellular respiration alongside increased oxidative damage in myocardium (17). Animal
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models used to study underlying mechanisms demonstrate mitochondrial ultrastructural
defects (23) and reduced ability to handle ROS (24) in the diabetic or insulin resistant
heart.
Besides impaired bioenergetics and cardiometabolic inflexibility, diabetes and
obesity are associated with oxidative stress and cellular damage, both of which lead to
cardiac dysfunction (25, 26). Mitochondrial complexes are the primary generators of the
ROS superoxide (O2•−) which is broken down to hydrogen peroxide (H2O2) and hydroxyl
radicals (27). Dysfunctional mitochondria produce excess O2•− leading to damaged
mitochondrial complex proteins, mtDNA, and lipid membranes that impair FA oxidation
and other normal mitochondrial functions (27, 28). Obesity, diabetes, and most (if not
all) cardiac diseases are associated with increased ROS in the heart, and these ROS
are a central, causative component of diabetic cardiomyopathy and obesity-related heart
failure (17, 29-31).
Last but just as important, mitochondrial quality control is an essential component
of cardiac homeostasis. In order to produce ATP to fuel other cellular reactions,
mitochondria maintain a strong electrochemical gradient across their inner mitochondrial
membrane (IMM) known as the mitochondrial membrane potential (MMP). When
mitochondria are damaged or dysfunctional, they lose their MMP and signal for their
own degradation via lysosomal-mediated macroautophagy (hereafter “mitophagy”).
Physiologic mitophagy is essential for culling dysfunctional mitochondria and recycling
mtDNA and proteins to optimize cellular respiration (32). However, impaired ability to
undergo mitophagy can lead to accumulation of these damaged or dysfunctional
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mitochondria and increase risks of stress-induced damage and development of heart
failure (33-35).
Given the many important roles mitochondria play in cardiac health and the
pathogenic dysfunction found in diabetic cardiomyopathy, we hypothesized that diabetic
pregnancy could have similar detrimental effects on the developing fetal heart. Diabetic
pregnancy exposes the developing fetus to maternal hyperglycemia, hyperlipidemia and
fetal hyperinsulinemia (Table 1) which could incite mitochondrial defects similar to those
present with diabetic cardiomyopathy. Indeed, infants born to mothers with diabetes can
be born with diastolic and systolic dysfunction and pathologic hypertrophy (36-47) that
clinically resembles cardiomyopathy found in adults with long standing diabetes and
hyperlipidemia. We also hypothesized that if diabetic pregnancy alters mitochondrial
function, this could alter cardiac development, leading to lasting changes that increase
the risk of disease throughout life.

The Influence of Prenatal Conditions on Mitochondrial Function
In light of the diverse roles mitochondria play in development and disease, it is important
to determine the factors that influence both short- and long-term mitochondrial function. This is
especially true considering that diabetic and obese pregnancies expose the developing fetal
heart to excess circulating glucose and lipids (48-51) and incite a state of fetal hyperinsulinemia
(2, 43, 52). In normal development, a low level of ROS is necessary in driving cardiac
developmental, function, and differentiation of CM (53, 54) and their mitochondria (55).
However, excess ROS have detrimental effects on the heart (32, 56). In another similarity with
diabetic cardiomyopathy, diabetes and obesity during pregnancy increase ROS levels in ODOM
hearts. Indeed, our own work has demonstrated cardiac ROS damage per increased lipid
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peroxidation in rat ODOM (7), but whether these elevated ROS levels persist throughout life is
not yet known.

Like ROS, mitophagy in the developing fetal/newborn heart is an essential
component of development and bioenergetic maturation (13, 57). We have already
identified alterations in mitochondrial dynamics and proteins mediating mitophagy in
newborn ODOM hearts (9), so an essential piece of the long-term puzzle is determining
whether adult ODOM have impaired responses to cardiac stress per altered mitophagy
rates, differences in MMP, or a lower threshold for mitochondria-mediated cell death.
These important unanswered questions are discussed below, but it is first important to
consider what we do know about developmental programming in the hearts of ODOM.

Developmentally Programmed Heart Disease in ODOM
History of Developmental Programming
The concept of developmentally programmed heart disease fits within the
Developmental Origins of Health and Disease (DOHaD) hypothesis, which evolved from
the work of English epidemiologist Dr. David JP Barker (58). Dr. Barker noticed that
undernutrition during pregnancy, leading to low birth weights, was associated with
higher rates of death following ischemic heart disease in middle-aged men. His 1989
proposal, which came to be known as the ‘Barker hypothesis,’ Fetal Origins of Adult
Disease (FOAD) hypothesis, or the rather frank ‘thrifty phenotype hypothesis,’ states
that undernutrition during early development increases offspring’s long-term risk of
developing coronary artery disease, hypertension, and diabetes (59). Although Dr.
Barker’s original hypothesis, i.e. the inverse relationship between birthweight and
coronary artery disease later in life, has been repeatedly supported (60-63), the DOHaD
6

hypothesis has expanded to include a variety of exposures as well as the total pre-,
peri-, and postnatal periods.
Two giants in the field of diabetes-related programming are Drs. Jørgen
Pedersen, Danish epidemiologist, and Norbert Freinkel, professor at Northwestern
University and former president of the American Diabetes Association. In 1952, Dr.
Pedersen formally hypothesized that maternal diabetes and hyperglycemia lead to fetal
hyperglycemia, which causes pancreatic islet hypertrophy and resultant fetal
hyperinsulinemia (64, 65) which is primarily responsible for the pathologic changes in
newborn offspring of diabetic pregnancies. While Dr. Pedersen’s hypothesis is true, it
has been expanded upon and deepened.
Dr. Freinkel recognized that the consequences of diabetes during pregnancy
were much more complex, and he emphasized two major points (66). First, outcomes of
offspring born to diabetic pregnancies depend on the timing and severity of the disease.
For example, pregestational diabetes mellitus (PGDM) includes type 1 and type 2
diabetes present before conception. PGDM therefore affects oocyte health and
fertilization as well as embryogenesis and organogenesis. Gestational diabetes mellitus,
hereafter late-gestation diabetes mellitus (LGDM), purportedly appears around the
beginning of the third trimester, at which point organogenesis is nearly complete and
maternal hyperglycemia has a greater effect on growth, rather than malformation given
its smaller window of pathogenic potential. Second, maternal diabetes affects all
macronutrients – particularly lipids – rather than solely glucose. Although the neonatal
outcomes following PGDM vs LGDM are now clinically recognized, lipid management in
PGDM and LGDM is not yet a focus of standard clinical practice guidelines (67, 68).

7

Paralleling the rise of diabetes (69), American obesity rates have risen at
alarming rates since the 1950s and 1960s (70). These trends are unsurprising
considering that a positive predictive relationship exists between maternal BMI and
LGDM risk (71, 72), i.e. the higher the maternal BMI the higher the LGDM risk. Like
diabetes (48, 49), maternal obesity is associated with altered lipid profiles including
significantly elevated serum triglyceride levels throughout pregnancy (50, 51) as well as
increased risk for CVD in both mothers and their offspring. A combination of
retrospective and prospective cohort studies in humans demonstrate profound shortand long-term developmental programming of the ODOM cardiovascular system (Table
1), and increasing numbers of controlled, randomized studies in animals support a
central, pathogenic role of mitochondrial dysfunction (Table 2).

Developmental Programming in Human Populations
The clinical consequences of maternal PGDM, LGDM, and obesity on
cardiovascular function in the developing fetus and subsequent disease risk are similar.
In the perinatal period, cardiac consequences of maternal diabetes appear to be more
clinically apparent while those due to maternal obesity are more subtle, i.e. risk factors.
Diabetes-exposed newborns not only suffer from higher rates of pathologic structural
abnormalities (37, 73-77) and perinatal mortality (72, 75, 76, 78), but even in the
absence of lethal congenital defects they consistently have diastolic or systolic
dysfunction and progressive pathologic ventricular hypertrophy of the interventricular
septum and outer walls (Table 1). Although not as well documented due to the lack of
routine screening, functional deficits occur even in the absence of detectable
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hypertrophy (40-43). As mentioned above, current clinical guidelines for managing
diabetic pregnancies focus on glycemic control (67, 68). However, well-managed and
euglycemic diabetic pregnancies can still manifest structural and functional
consequences for the fetal heart (37, 45-47, 79) even as early as 20 weeks into
gestation (44, 80). Like diabetes, maternal obesity increases perinatal mortality rates
(81-85), causes cardiac defects (86), and has been associated with systolic and
diastolic dysfunction and ventricular hypertrophy (87).
Maternal diabetes and obesity may also increase the risk of adult CVD in ODOM
by programming systemic cardiometabolic consequences that indirectly affect heart
health. Both maternal diabetes and obesity increase rates of macrosomia or large for
gestational age (LGA) births (GDM > PGDM), as well as insulin resistance and adiposity
(Table 1). Later in life the infants born LGA have greater risks of developing insulin
resistance (88-90) and obesity (91, 92), both well-known risk factors for CVD.
Importantly, few studies have focused on offspring exposed to the combination of
maternal diabetes and obesity, but those that have paint a grim picture. In a 2016 study
by Langer et al evaluating LGDM by maternal weight (normal, overweight, or obese),
offspring born to mothers with LGDM but a normal BMI had a 2-fold increase in
“composite outcomes” including stillbirth, LGA, and neonatal hypoglycemia and a 7-fold
increase in metabolic complications (78). When diabetic mothers were obese (BMI >30),
the number of composite outcomes increased to 10-fold the levels of healthy women. In
another study evaluating offspring of mothers with T2DM (PGDM) or LGDM, authors
found increased risks of structural abnormalities, congenital heart disease, and
pathologic ventricular hypertrophy (37). However, the average BMI of PGDM mothers
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with T2DM was 33.4, and the average BMI of mothers with LGDM was 27.1. BMI was
not accounted for in calculations and therefore may have confounded results. In our
lab’s own studies (discussed below), we found that combination-exposed ODOM have
significantly more perturbations in the cardiac transcriptome (10) and profoundly
impaired cardiac and bioenergetic function (7).
While most studies have focused on the neonatal period, compelling evidence
has emerged indicating greater risk for developing programmed heart disease later in
life. Prepubertal children born to diabetic mothers (both PGDM and LGDM) have higher
BMI, increased adiposity with greater waist circumference, a higher risk of developing
T2DM, higher blood pressures, and decreased glucose tolerance suggesting early
stages of metabolic syndrome (93-98) that can affect life-long heart health. Interestingly,
in a genetically predisposed population, infants born to Pima Indian mothers before and
after the mother developed T2DM, there was an increased risk of T2DM and greater
BMI in the exposed children compared to their non-exposed siblings (97). Findings are
similar in offspring exposed to maternal obesity. Obesity-exposed prepubertal offspring
have increased BMI, total and abdominal fat mass, blood pressures, T2DM risk, and
insulin levels (99-102). Like in the above Pima Indian population study (97), a welldesigned study by Kral et al looked at the offspring of mothers who had children while
obese and then again following significant weight loss (103). 40% of the offspring born
while mothers were obese were also obese themselves, and this number dropped to
19% for offspring born after significant maternal weight loss. In an interesting study by
Cade et al comparing one month old offspring of obese mothers with and without
comorbid T2DM, neither cardiac function nor structure was different from infants of
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obese mothers without comorbid T2DM (99). However, one month old offspring born to
mothers with both obesity and T2DM had cardiac septal strain with impaired systolic
and diastolic function. Once again, combination exposure was worse than either obesity
or diabetes alone.
Cardiometabolic consequences in ODOM increase in severity as offspring age
into early and late adulthood. Following patterns present in childhood, adolescents and
young adults born to diabetic mothers have higher BMI and obesity rates, pre-diabetes
and T2DM rates, metabolic syndrome risks, and risks for non-malformation cardiac
disease (4, 5, 104-108). At this time, the longest, published follow up study of infants
born to diabetic mothers is 36 years (106), but it is plausible to expect the
consequences to continue to grow in severity with more advanced age. Retrospective
population studies examining risk from maternal obesity (based on BMI) include
subjects up to 80 years old (109). These epidemiologic studies show that infants born to
obese mothers have higher BMIs and rates of T2DM and CVD; most concerning they
are more likely to die from CVD events including myocardial infarction (109-112).
Although not exclusive to CVD, offspring of obese mothers have a 5% increase in allcause mortality by the age of 60 (112).
An interesting series of papers from the Shulman lab at Yale University highlight
not only metabolic parameters, but also skeletal muscle mitochondrial pathology in
offspring of mothers with T2DM (113-116). Subjects included adult offspring born to
mothers with T2DM, and they were compared on the basis of insulin
resistance/sensitivity in the absence of other health problems. 25 to 30 year old insulinresistant participants consistently had elevated fasting insulin and glucose levels with
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intramyocellular lipid stores. Compared to insulin-sensitive controls, skeletal muscle
mitochondria from insulin-resistant participants had blunted insulin-stimulated
phosphorylation; levels were 85% lower in affected offspring (114). They also had
significantly lower muscular mitochondrial content per electron microscopy and
mitochondrial protein expression (115), as well as decreased tricarboxylic acid cycle flux
and a 30% reduction in basal oxidation rates, indicating severe mitochondrial
dysfunction (116). While these studies were performed in skeletal rather than cardiac
muscle, they do demonstrate a role of mitochondrial programming by maternal diabetes
and compel further mechanistic study.
Mechanisms of Developmental Programming Elucidated by Animal Models
Despite many remaining questions, a combination of short-term, long-term, and
transgenerational animal studies have helped bring us closer to understanding
developmentally programmed heart disease. Indeed, a variety of models and
experiments have demonstrated primary and secondary roles of mitochondria in
ODOM, and pathologic effects of glucolipotoxicity are detectable even before birth.
Further, even transient maternal fuel excess can negatively impact the developing
offspring’s heart, as demonstrated in a 2015 rat study by Gordon et al which found that
in utero exposure to hyperglycemia for 24 hours induces cardiac septal overgrowth,
even when the mother is non-diabetic (117). Cardiac consequences appear to be more
profound if diabetes exposure is present before conception and throughout pregnancy;
maternal hyperglycemia in rodents (induced by HF diet or streptozotocin (STZ)) leads to
larger fetal hearts, increased interventricular septum and LV thickness (118), and
diastolic dysfunction (119). In a 2016 macaque study of HF (Western style) diet by
12

McCurdy et al, the effects in offspring depended not only on maternal diet itself, but the
overall intake, i.e. becoming obese or staying lean (yet remaining on HF diet) (120). On
gestational day 130 (of 165), all exposed offspring had increased skeletal muscle
oxidative stress, and offspring of overtly obese mothers also had increased mitophagy
(per higher PGC1α expression amongst decreased mitochondrial mass) and lower
respiration and glycolysis (120). The short-term effects do not resolve after birth.
Mitochondrial and cardiac consequences in newborn ODOM have been welldefined by the Baack lab’s studies thus far. To clarify, we have investigated the
mechanisms of maternal diabetes, Western style HF diet, and the combination in
programming offspring cardiac and mitochondrial health. We have used Sprague
Dawley rats to model: 1) late-gestation diabetes, i.e. LGDM induced with STZ on
gestational day 14 (of 22) and treated with insulin to maintain glucose levels from 200400mg/dL, 2) Western style HF diet of approximately 40% calories from fat, primarily
saturated and monounsaturated fatty acids and 3) combined exposure to LGDM and
maternal HF diet. Offspring were evaluated by echocardiography on postnatal day 1
(P1) before hearts were collected for interrogation of cardiac bioenergetics, lipid
storage, ROS generation, protein and gene expression, epigenetics, transcriptomics,
and mitochondrial morphology, dynamics, number, and mitophagy rates (7-10, 121).
Consequences found thus far are both profound and concerning.
Major strengths of our studies are that they 1) compare both the individual and
combined effects of maternal diabetes and HF diet exposure, 2) our model uses a
realistic HF diet reflecting typical Western diets high in saturated and monounsaturated
fats vs. more lipotoxic diets with 60% fats, 3) our diets have similar omega-3 to omega-6
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ratios, and 4) we carefully characterized placental lipid processing and maternal:fetal
circulating lipids to better understand the exposure itself (122). Overall we found that
prenatal exposure to LGDM leads to greater heart:body weight ratios, systolic and
diastolic dysfunction (per reduced fractional shortening and E:A ratios, respectively),
bioenergetic dysfunction (per reduced OXPHOS, glycolysis, and fatty acid oxidation
(FAO)) indicating mitochondrial dysfunction, and reduced mtDNA copy number (7).
Hearts from diabetes-exposed offspring also have fewer, shorter, wider mitochondria
with a pro-fission balance, compared to balanced fusion and fission in controls (7, 9).
Offspring prenatally exposed to maternal HF diet also have higher heart:body weight
ratios and diastolic dysfunction, accompanied by increased perinatal mortality,
pulmonary hypertension (per lower ratio of pulmonary artery acceleration time to right
ventricular ejection times), myocardial lipid deposition, increased CM lipid peroxidation
(indicating mitochondrial ROS generation), and a greater number of short, fragmented
mitochondria (7, 9, 121). The combination-exposed suffer from exaggerated
hyperinsulinemia and perinatal mortality, increased heart:body weight ratios, systolic
and diastolic dysfunction, pulmonary hypertension, myocardial lipid deposition, CM lipid
peroxidation, and impaired respiratory, glycolytic, and FAO capacities that are worse
than with either exposure alone; further, they have increased numbers of fragmented,
depolarized and adynamic mitochondria (7, 9, 121). Additional evidence from past
studies suggests the cardiac phenotype improves after birth, just as it does in humans,
but we hypothesized that ODOM would have long-term and sex-specific cardiac
consequences in later adulthood that would also be worse following combined prenatal
exposures (see Chapter 2).
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Many current animal models employ diets with unrealistically high fat content
(>60%), making them extremely lipotoxic but not translatable to human populations.
Additionally, the effects seen with these diets could be caused by limiting other nutrients
including essential amino acids or micronutrients required for heart health. Dietary fat
content, FA balance in mother and offspring, and placental effects of diet are also
seldom reported; something we carefully analyzed in our model (122). That said, animal
studies of maternal high fat diet have repeatedly found lasting cardiovascular and
mitochondrial effects in offspring long past the neonatal period (Table 2). Similar to
prepubescent humans, young rodents (up to three months old) have higher rates of
CVD risk factors, cardiac structural and functional changes, and strong evidence of
mitochondrial dysfunction. Although baseline differences in cardiac function were not
detected in the study, Gao et al found that 2 month old PGDM-exposed male mice who
experience a myocardial infarction have significantly larger infarcts, greater decline in
systolic function, more mitochondria-mediated apoptosis, mitochondrial swelling, and
greater accumulation of ROS, reactive nitrogen species (RNS), and MDA (indication
lipid peroxidation) than control offspring (123). In young HF diet-exposed offspring,
cardiac studies have found ventricular hypertrophy, systolic and diastolic dysfunction,
and signs of premature heart failure (124, 125) with underlying disorganized
mitochondria with complex I and II dysfunction (126). Young HF diet-exposed offspring
also have a higher rate of risk factors that predispose adult offspring to CVD including
greater weights and adiposity with glucose intolerance, hyperinsulinemia, and
hypertriglyceridemia (127-129), arterial dysfunction (130, 131), and increased blood
pressure (125). Unfortunately, few of these studies isolated cardiac consequences or
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examined myocyte mitochondria. However, a few studies have examined mitochondrial
programming in skeletal muscle to demonstrate that HF diet-exposed offspring have
structurally disorganized mitochondria with complex I, II, and III dysfunction, impaired
FAO, and increased oxidative stress (127, 132). Interestingly these studies showed sexspecific differences, particularly following HF diet exposure.
In mid-adulthood (4-6 months), diabetes-exposed rodents are at increased risk
for hypertension (133) and overt diabetes (134), both well-known risk factors for CVD.
Although these studies were well-designed, they have yet to examine cardiac function
of diabetes-exposed offspring after six months of age. HF diet-exposed offspring, on the
other hand, have been studied up to at least one year after birth. As in humans born to
obese mothers, HF diet-exposed adult rodents have serious CVD risk factors including
increased adiposity with hypertriglyceridemia and hyperinsulinemia, vascular
dysfunction with aortic lipid deposition, and higher blood pressures (129, 131, 135-137).
A recent study by Vaughan et al found diastolic dysfunction in HF diet-exposed offspring
of both sexes at 6 months (128). Many of these same cardiac risk factors have been
found in aged adult (12 month old) HF diet-exposed offspring (131, 138). While neither
cardiac structure nor function has been evaluated in exposed animals at this time point,
mitochondrial complex I and II dysfunction has been found in the skeletal muscle of
aged adult females (138). This finding is important because it establishes plausible
mitochondrial dysfunction later in life that may predispose ODOM to developing cardiac
disease.
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Mechanisms of Transgenerational Developmental Programming
A fascinating series of studies led by Dr. Kelle H. Moley, MD of the Washington
University School of Medicine (126, 127) demonstrated that the consequences of
maternal fuel excess and fetal hyperinsulinemia may be transgenerational. The first
study compared oocytes and skeletal muscle of F1-F3 offspring spawned from F0 dams
on a HF, high-sucrose diet; F1 offspring were exposed to a glucolipotoxic in utero
environment that caused fetal hyperinsulinemia. Importantly, only F0 dams were on the
HF/high-sucrose diet, and all breeder males were on a control diet. F1 offspring had
impaired glucose tolerance with higher fasting insulin, skeletal muscle with disorganized
mitochondria with impaired FAO and lower respiratory control ratios (indicating
respiratory impairment), and oxidative stress. Further, F1 oocytes had fewer (per lower
mtDNA) yet enlarged mitochondria with disorganized IMM and abnormal (‘less round’)
morphology (127). F2 offspring were also glucose intolerant, and their skeletal muscle
mitochondria had similar defects but also lower DRP1 phosphorylation implying
impaired dynamism (a vital mitochondrial function; discussed at length in Chapter 2).
Although less severe, mitochondrial changes were still present in F3 mitochondria
suggesting direct maternal inheritance of dysfunctional mitochondria.
The second study by Dr. Moley went further to examine F1-F3 hearts and cardiac
mitochondria using important scientific controls. Exposed F1 offspring of both sexes had
greater LV mass and disorganized cardiac mitochondria with abnormal morphology and
complex I and II dysfunction (126), but F1 females had thinner LV walls and systolic
dysfunction (~dilated cardiomyopathy) while F1 males had thicker LV walls
(~hypertrophic cardiomyopathy). LV changes persisted to F2 females and F3 males, but
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the changes to cardiac mitochondria were present in F3 offspring of both sexes. The
first experimental control used in vitro fertilization (IVF)/embryo transfer of F0
oocytes/embryos to determine the contribution of the in utero environment. Surprisingly,
these IVF-F1 offspring still had the greater LV mass and mitochondrial complex
impairments seen in natural-born F1 offspring; this suggests direct maternal inheritance.
Going further, the second experimental control used male F1 offspring to produce
paternal F2 offspring (i.e. experimental F1 male offspring bred with control females).
Once again, the greater LV mass and mitochondrial complex impairments were present,
supporting the theory that nuclear epigenetic changes are responsible for programmed
mitochondrial dysfunction in ODOM. Although these findings should be confirmed in
additional models, these animal studies provide a foundation of knowledge needed to
understand and break the vicious, multigenerational cycle of adverse cardiometabolic
function in humans.

Unanswered Questions and Dissertation Aims
Although many questions about the role of mitochondria in developmentally
programmed heart disease remain, I intended to address three key questions in the
form of my Dissertation Aims (Figure 1). First, although we have shown significant
mitochondrial and cardiac dysfunction in newborn hearts exposed to LGDM that is
worsened with maternal HF diet (7, 9), my studies set out to determine 1) whether
mitochondria-mediated effects persist long-term to increase aged adults’ risk of heart
disease, 2) what are the specific mitochondria-mediated mechanisms of impaired
mitochondrial bioenergetics and cardiac dysfunction in exposed newborns, and 3) does
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the observed myocardial mitochondrial dysfunction vary based on critical inheritable
time points impacted by diabetes exposure (i.e. PGDM vs LGDM). As discussed above,
mounting evidence supports long-term programmed cardiovascular effects of diabetes
and obesity during pregnancy (2-6, 101, 106, 112, 139). However, these key questions
remain and must be answered in order to develop and time preventative strategies that
will impact offspring and the next generations.
To answer Aim 1, we used offspring from our validated model of late-gestation
STZ-induced diabetes and HF diet during pregnancy (7-9, 121, 122) that were crossfostered to control dams in equal sized litters. Because diabetes is not induced until the
last 1/3 of pregnancy and pups are reared by non-diabetic mothers, this model tests an
isolated effect of LGDM on adult outcomes, negating maternally inherited mitochondria
and lactational/rearing differences in the diabetes only-exposed offspring group. We
evaluated cardiac structure and function, risk factors for CVD, mitochondrial
bioenergetics and complex function and expression, cellular stress responses, and
expression of key players in mitophagy and mitochondria-mediated cell death from birth
to 12 months of age. Interestingly, we found sex-specific differences in mitochondrial
function that may explain clinical differences in CVD between male and female patients.
This first Aim is discussed in Chapter 2.
For Aim 2 and 3, we evaluated offspring exposed to PGDM and maternal HF diet
which extends the critical window of risk to include the periconceptual and
embryogenesis periods. This was purposeful so data could be compared to previous
studies and begin examining inheritance risks. For Aim 2, we attempted to
mechanistically isolate mitochondria-mediated pathogenesis from other cellular
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metabolic alterations including fuel stores and enzymatic flux by using mitochondrial
transplantation followed by evaluation of CM bioenergetics, mitophagy, ROS
generation, and viability. Mitochondrial transplantation has recently shown therapeutic
potential in the treatment of myocardial damage (140, 141) despite the fact that
mechanisms of this evolutionarily beneficial process remain to be fully delineated (142,
143). In order to use this technique in vivo, it was first necessary to work out the
methods in primary CM, explore the mechanisms of mitochondrial internalization, and
determine cellular benefits of this mitochondrial treatment. Findings from Aim 2 are
discussed at length in Chapter 3.
In order to translate work to clinical guidelines that will help prevent programmed
CVD in ODOM, it will be necessary to identify the source of mitochondrial dysfunction
and determine critical windows for intervention. Mitochondria are maternally inherited,
but whether offspring directly inherit damaged mitochondria from mothers or rather
offspring inherit ‘normal’ mitochondria that are damaged in utero by fuel-mediated
influences remains uncertain. Environmental stressors, including diabetes, can incite
epigenetic modifications and program mitochondrial dysfunction and metabolic
consequences in offspring (8, 144-146). Mitochondrial function is regulated by both the
nuclear genome (80%) and the mitochondrial genome (20%). We have previously
described perturbations in the nuclear genome and epigenome, as well as some
exposure mediated and sex-specific downstream post-translational modifications that
are associated with mitochondrial dysfunction in our model (8-10), but we have not yet
examined mitochondrial inheritance. Increasing evidence suggests there is epigenetic
regulation of the mitochondrial genome through DNA methylation (147-150) and others
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have described mitochondria-mediated perturbations in the nuclear genome (126).
Methylation of mtDNA is the most-studied epigenetic change, and, like mtDNA
mutations, may cause impaired cellular respiration by decreasing complex protein
expression (151). It has been shown that histones are absent in mitochondria (152), and
methylation currently stands as the most likely direct epigenetic modification to mtDNA
despite studies suggesting the contrary (153-155). Additionally, nuclear and mtDNA can
be damaged by ROS through many oxidative modifications, the most common being
7,8-dihydro-8-oxodGuanosine (8-oxodG) (156). We isolated mtDNA from the hearts and
ovaries of control and experimental dams and the hearts of their newborn offspring of
both sexes to better answer the role of mitochondria in directing their own function and
that of their offspring’s. Although these experiments could not be completed, Chapter 4
discusses preliminary results and future experiments combining bisulfite sequencing for
mtDNA methylation patterns with 8-oxodG quantification. Taken together, these studies
will help us better understand the inheritance and genetic regulation of mitochondrial
dysfunction in ODOM, develop prevention strategies, and potentially identify therapeutic
targets to improve heart health in ODOM.
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Figure 1. Schematic representation of Dissertation Aims.
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Table 1. Human epidemiologic and pathophysiologic studies demonstrating
cardiovascular developmental programming following exposure to maternal
diabetes and/or obesity.
Authors,
Year

Assessed
Population
Age & Sex
Ethnicity /
Exposure
(unless
Region
both)
USA
Newborns PGDM (T1DM)
(mixed)

Miller et al
1981 (73)
Ylinen et al
Finnish
1984 (74)

Newborns

PGDM (T1DM)

Organ /
System

Notes & Outcomes (maternal condition
 offspring outcome(s))

Heart

PGDM  ↑ risk of cardiac malformations

Heart

PGDM  ↑ risk of cardiac malformations

Greene et
al 1989
(75)

USA
(mixed)

Newborns

PGDM (T1DM)

Heart

Macintosh
et al 2008
(76)

UK (>90%
white)

Newborns

PGDM (T1DM,
T2DM)

Heart

Patey et al
2019 (36)

UK (53%
white, 36%
Newborns
Asian, 11%
black)

PGDM, LGDM

Heart

Ullmo et al
2006 (37)

Swiss (71% Newborns
white, 11%
black, 7%
Asian, 7%
Hispanic)

PGDM (T1DM,
T2DM), LGDM

Heart

SchaeferGraf et al
2008 (49)

USA (white) Newborns

LGDM

N/A

ElGanzoury
et al 2012
(38)

Egyptian

Newborns

PGDM & LGDM Heart

Topcuoglu
et al 2015
(157)

Turkish

Newborns

LGDM

Heart

Garg et al
2014 (39)

East Indian

Newborn

LGDM (PGDM
excluded)

Heart
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PGDM  ↑ risk of cardiac malformations
and spontaneous abortions
The higher the maternal HbA1C, the
greater the risks
PGDM  ↑ risk of cardiac malformations,
stillbirths, perinatal and neonatal mortality;
similar outcomes for T1DM and T2DM
Of the DM cases, 7 (of 21) were insulincontrolled PGDM and 14 were metformintreated LGDM; offspring evaluated by
echo days before birth (fetal) and within
hours of birth (neonatal)
DM (pooled)  ↑ risk of tricuspid
regurgitation, cardiac geometric
deformation (shorter, narrower LV and
shorter RV), ↑ IVS, LV and RV outer wall
thickness, ↓ GLS (indicating HF risk),
systolic and diastolic dysfunction, ↑ LV
torsion
DM  ↑ risk of structural abnormalities at
birth (T1DM > T2DM > LGDM)
5% of exposed offspring developed CHD
and 13% PVH (of which half occurred in
ODM born to mothers with good glycemic
control)
***44% of the women in the study had a
BMI > 25
LGDM  ↑ Maternal TG & FFA  ↑ LGA
risk (positive correlation)
Cord blood Insulin & Insulin:glucose ratio
were positively correlated with birth
weight, BMI, and fat mass
Cord blood TG levels were higher in SGA
infants, whereas insulin, insulin:glucose
ratios, and FFA were lower in LGA infants
DM (pooled)  ↑ risk for hypertrophic
cardiomyopathy with impaired LV
contractility, thicker IVS and ventricular
walls
Most SGA IDM born to mother with T1DM,
while most LGA IDM born to mothers with
LGDM
LGDM  ↑ IVS and posterior wall
thicknesses and LV mass
Excluded mothers with obesity or family
history of DM and infants with structural
defects
LGDM  ↑ EF, IVS and outer V wall
thicknesses

Turkish

Newborns

PGDM, LGDM

Heart

Zablah et al USA
(mixed)
2017 (41)

Newborns

PGDM, LGDM

Heart

Newborns

LGDM (by
normal, over-,
and obese
weights)

N/A

Korean
Son et al
2010 (158)
Al-Biltagi et Egyptian
al 2015
(42)

Newborns

N/A

Newborns

LGDM,
Hyperlipidemia
PGDM, LGDM

Spanish

Newborns

LGDM

N/A

UK (white,
Asian,
Pacific
Islander)
Regnault et USA (70%
white)
al 2013
(94)

Newborns

PGDM & LGDM N/A
(pooled)

Newborns,
8y.o.

LGDM, IGI
(“intermediate
glucose
intolerance”)

Mitanchez
et al 2015
(72)

PGDM, LGDM,
Newborn,
up to young Obesity
adults

Çimen and
Karaaslan
2014 (40)

Langer
2016 (78)

Ricart et al
2008 (159)
Simmons
1995 (160)

USA (84%
Hispanic,
4% black,
12% white)

Human
(Review)

Heart

N/A

N/A
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No differences in congenital heart defects
seen
DM (pooled)  ↑ birth weight, systolic and
diastolic dysfunction (per ↓ systolic and
diastolic flow velocities) that was worse in
IDM with ↑ IVS thickness
All participants had normal standard
echocardiograms
DM cases were pooled, but of the 75
diabetic pregnancies: 60 LGDM, 2 T1DM,
and 8 T2DM (type of last 5 not recorded)
DM  systolic and diastolic dysfunction
(per ↓ systolic and diastolic flow velocities)
in absence of hypertrophy
Composite outcome defined by “stillbirth,
neonatal macrosomia/LGA, neonatal
hypoglycemia, erythrocytosis [and/or]
hyperbilirubinemia”
LGDM (normal weight)  2-fold ↑ in
composite outcomes, 7-fold ↑ in metabolic
complications
LGDM (+overweight)  2- to 3-fold ↑ in
composite outcomes and metabolic
complications
LGDM (+obese)  10-fold ↑ in composite
outcomes, 3-fold ↑ in LGA, 5-fold ↑ in
metabolic complications, and 9-fold ↑ in Csection deliveries
Takeaway: combination exposure
causes the worst possible outcomes
Hypertriglyceridemia  ↑ LGA risk
(positive correlation)
PGDM  systolic and diastolic
dysfunction (per ↓ FS, ↓ E/A ratio, and ↓
GLS), ↑ cardiac torsion, and IVS
thickening
LGDM (per glucose intolerance)  ↑
macrosomia & LGA risks (male only)
DM (pooled)  ↑ birth weights,
subcutaneous fat, and insulin levels
Excluded women with family history of DM
LGDM & IGI  ↑ birth weights, ↑ overall
adiposity with larger waist circumference
and more trunk fat at 8y.o. (despite similar
levels of physical activity and poor dietary
habits)
Male ODM were more severely affected
than females
Mothers with LGDM or IGI were more
likely to be black, Hispanic, and/or
smokers
Offspring adiposity/anthropometry
calculated by caliper skinfold exams and
DXA (dual X-ray absorptiometry)
Excluded women with PGDM
Overweight/Obese women are more likely
to develop LGDM
Newborn ODOM  ↑ rates of
macrosomia, stillbirth, IUGR, and
congenital malformations (including
cardiac)

Brite et al
2014 (86)
Patel &
Burns 2013
(77)

Depla et al
2020 (43)

Veille et al
1992 (161)

USA
(mixed)
Human
(Review of
1990-2013
Lit and
casecontrol
18MO
follow-up)
Human
(metaanalysis)

Newborns

Newborns

PGDM, LGDM

USA
(mixed)

Gestational
(fetuses at
20-41w.o.)
Gestational
(fetuses at
20-40w.o.)
Gestational
(fetuses at
20-40w.o.),
Newborns

PGDM (T1DM), Hearts
LGDM
Controlled DM
(likely PGDM +
LGDM pooled)
Controlled DM
(likely PGDM +
LGDM pooled)

Heart

Weber et al USA
1991 (44)
(mixed)
Weber et al USA
1994 (80)
(mixed)

LGDM, Obesity

Heart

PGDM, Obesity Heart
Newborn
up to 18mo

Heart

Heart

KozákBárány et
al 2004
(45)

Finnish

Newborn

Controlled
LGDM, PGDM
(T1DM)

Heart

Aman et al
2011 (46)

Swedish

Newborn

Controlled
LGDM, PGDM
(T1DM)

Heart,
adipose

Ghandi et
al 2018
(47)

Iranian

Newborn
(3-5d.o.)

Controlled
LGDM

Heart

Langer et
al 2005
(79)

USA (84%
Hispanic,
4% black,
12% white)

Newborns
(<5d.o.)

Untreated vs.
Controlled
LGDM

N/A

Nyrnes et
al 2018
(87)

Norwegian

Newborns
(1-3d.o.),
Infants (68w.o.)

Obesity

Heart
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Both LGDM & Obesity  ↑ risk of
congenital heart defects at birth
PGDM  ↑ risk of “ASD, atrioventricular
septal defect, CoA, double-outlet right
ventricle, pulmonary atresia, total
anomalous pulmonary venous return,
TGA, tetralogy of Fallot, truncus
arteriosus, and VSD”
Both PGDM and LGDM  ↑ IVS
thickness, ↓ overall cardiac function, and ↓
diastolic function (per ↓ E:A ratio)
Although less consistent, the majority of
studies have found systolic dysfunction
with LGDM
DM (pooled)  ↑ IVS thickness and
heart:(estimate)body weight ratios
Well-controlled DM  ↑ LV, RV, and IVS
wall thickness (“hypertrophic”), ↓ LV
diastolic diameter
IDM were not macrosomic
Well-controlled DM  delayed increase in
diastolic filling from 20 weeks-gestation to
newborn time point (that you would expect
with normal development)
Well-controlled T1DM & LGDM 
prolonged DT (indicates Diastolic
dysfunction), higher birth wts (~750g),
higher FS (34.7 vs 32.4 in controls), and
greater LV mass (10.4 vs 8.1g)
T1DM vs LGDM ODM were not different
Takeaway: Diastolic dysfunction in IDM
DESPITE euglycemia
Well-controlled T1DM & LGDM  5.6x &
3x ↑ risk of macrosomia, respectively,
40% ↑ body fat content and 20% ↑ IVS
thickness (both groups); Also higher Cpeptide and leptin in T1DM-exp. IDM
Well-controlled LGDM  ↑ IVS thickness,
↑ LV mass
Study excluded IDM with macrosomia or
IUGR
Untreated LGDM  ↑ rates of
macrosomia, LGA, erythrocytosis, and
hypoglycemia
The higher the maternal fasting glucose
and maternal BMI (analyzed
independently), the higher the risks of
adverse outcomes
Controlled LGDM (“treated”) infants were
similar to controls
Obesity  at both birth and 6-8wk,
subclinical systolic and diastolic
dysfunction, ↑ IVSd thickness, ↓ LV and
RV GLS
Having obese mothers begin moderate
exercise routines did not improve cardiac
function in offspring

Obesity  ↑ preterm births and perinatal
mortality (all causes), grades 2 (BMI 3539.9) & 3 (BMI >40) obesity more than
doubled mortality risk and increased rates
of congenital anomalies and SIDS
Commentary on (81)
Johansson et al 2014 study was
conducted in Sweden, which has
fastidious follow up of maternal weight
gain during pregnancy, so obesity may
have an even worse effect on perinatal
mortality elsewhere in the world (162)
Obesity  ↑ neonatal fat mass and body
fat percentage (but NOT lean mass)
Obesity  no differences in weight or lean
mass, but ↑ fat mass, ↑ body fat %, ↑
Ponderal index, insulin resistance, ↑
placental weight, and ↑ cord blood insulin,
glucose, leptin, and IL-6 levels
Results were adjusted for “maternal race,
smoking, [and] medical problems, such as
hypertension”
Obesity  ↑ birth weight, ↑ PGC1α
promoter methylation (positive correlation)
Note: women in this study smoked ~3
cigarettes/day
Hypertriglyceridemia  ↑ LGA risk (High
mat. TG at 24-36wk  ORLGA=11.6)
Excluded women with PGDM or LGDM
Hypertriglyceridemia  ↑ LGA and
macrosomia risk (positive correlations)
Maternal TG levels (during 1st, 2nd
trimesters) were positively correlated with
risk of LGDM; HDL-C was negatively
correlated with LGDM.
Excluded women with PGDM or LGDM
Hypertriglyceridemia  ↑ LGA risk
Excluded women with PGDM or LGDM

Johansson
et al 2014
(81)

Swedish

Newborns

Obesity

N/A

Reynolds
2015 (82)

Swedish

Newborns

Obesity

N/A

Sewell et al
2008 (163)
Catalano et
al 2009
(164)

USA
(mixed)
USA
(mixed)

Newborns

Obesity

N/A

Newborns

Obesity

N/A

Gemma et
al 2009
(165)

Argentinean Newborns

Obesity

Umbilical
cord blood

Kitajima et
al 2001
(166)
Jin et al
2016 (167)

Japanese

Newborns

Obesity
N/A
(Hyperlipidemia)

Chinese

Newborns

Obesity
N/A
(Hyperlipidemia)

Vrijkotte et
al 2012
(168)
Wang et al
2018 (169)

Dutch
(68%)

Newborns

N/A
Obesity
(Hyperlipidemia)

Chinese

Newborns

N/A
Obesity
(Hyperlipidemia)

Hypertriglyceridemia  ↑ macrosomia risk
(positive correlation); macrosomia risk
was higher in males
Maternal HDL-C levels were negatively
correlated with macrosomia
Excluded women with PGDM or LGDM

Newborn

Obesity

Obesity  small but absolute ↑ in risk of
neural tube defects, CV anomalies, septal
defects, and many other structural defects

Stothard et Human
al 2009
(metaanalysis of
(85)
1966-2008
literature)

N/A

Pitchika et
al 2018
(170)

Unspecified 3m.o.-6y.o. PGDM (T1DM), N/A
LGDM

Hoodbhoy
et al 2019
(171)

Pakistani

2-5y.o.
(born AGA
only)

LGDM

Heart
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T1DM  ↑ BMI (association grows as
child ages)
LGDM  ↑ BMI dependent on maternal
BMI (higher in mother  higher in
children)
No differences in cardiac structure,
function, or vasculature were detected in
children born AGA

Manderson Irish
et al 2002
(95)

5-11y.o.

PGDM (T1DM)

N/A

Page et al
2014 (96)

Mexican

5-16y.o.

LGDM, Obesity

N/A

Dabelea et
al 2000
(97)

Pima Indian 6-12y.o.

PGDM (T2DM;
siblings before
and after Dx)

N/A

Rijpert et al Dutch
2011

6-8y.o.

Controlled
PGDM (T1DM)

Heart

Rijpert et al Dutch
2011 (172)

7-8y.o.

PGDM (T1DM)

Heart

Tam et al
2017 (98)

Chinese

7y.o.

LGDM

N/A

Cade et al
2017 (99)

USA (85%
black, 14%
white, 1%
other)

1m.o.

Obesity +/PGDM (T2DM)

Heart

Kral et al
2006 (103)

Canadian

2-18y.o.

Obesity

N/A
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Caveats: these children did not have
echoes done at birth, and SGA and LGA
ODM were excluded from analysis
PGDM  ↑ IGF-1 (may suggest higher
risk of HTN), HDL-C, LDL-C, PAI-1 (linked
to vascular disease), VCAM-1, & Eselectin; also ↑ triceps skinfold thickness
(if adjusted for birthweight at gestational
age)
ODM that had begun puberty (determined
by serum estradiol or testosterone) were
excluded
Mothers with LGDM or family Hx of any
type of DM were excluded from the control
group
LGDM  significantly ↑ BMI and adiposity
in 5-16y.o. offspring (even after
accounting for Mat obesity, offspring age,
sex, Tanner stage, birth wt, breastfeeding,
and Mat prepreg. BMI and wt gain)
T2DM  ↑ risk of T2DM and higher BMI
in ODM compared to their siblings who
were born prior to their mother’s diagnosis
of diabetes (OR of T2DM = 3.7); Paternal
diabetes status did not affect offspring
T2DM risk or BMI
Well-controlled PGDM  ↑ rates of
preterm births and macrosomia, but only
difference at 6-8y.o. was ↑ sBP (all other
metabolic parameters were similar to
controls)
PGDM  ↑ rates of congenital
malformations and hypertrophic
cardiomyopathy at birth, but no
differences in cardiac structure or function
at 7y.o. (even in those born with
hypertrophic cardiomyopathy)
LGDM  ↓ glucose tolerance, ↑ BMI (in
female IDM, not males), and ↑ BP
Associations were independent of
maternal BMI, childhood obesity, or IDM
born LGA
No differences seen in LV mass, LV wall
thickness, IVS thickness, systolic function
(per EF or FS)
Obesity (no DM)  no statistical
differences from controls
Obesity+PGDM  ↓ IVS, LV, and RV
GLS (indicates LV systolic dysfunction), ↓
RV and IVS GLSRe (indicates diastolic
dysfunction)
Takeaways: 1) 1m.o. ODOM had septal
strain with systolic (IVS, LV, & RV) and
diastolic (IVS & RV) dysfunction in the
absence of structural changes; 2) the
combination (obesity+PGDM) is worse
than obesity alone
Maternal weight reduction surgery
(biliopancreatic bypass)  ↓ BMI and
obesity of offspring (reduction was greater
in males)

Castillo et
al 2015
(100)
Gaillard et
al 2014
(101)
LahtiPulkkinen
et al 2019
(102)

Brazilian

6y.o.

Obesity

N/A

Obesity  ↑ BMI, ↑ fat mass, lean mass,
and body fat percentage

Dutch

6y.o.

Obesity

N/A

Scottish

Obesity
7-68y.o.
(2018
analysis
using 19502011 EMR)

N/A

Obesity  ↑ BMI, total body and
abdominal fat mass, sBP, and insulin and
lower HDL-C levels
Rates of obesity during pregnancy rose
from 3.1% (1950) to 15.7% (2000)
Obesity  ↑ T2DM risk (adjusted
HRoverweight=1.4; HRobese=3.5); the
association was stronger in Female
OOMs
Results significant even when adjusting
for “maternal history of diabetes before
pregnancy, maternal history of
hypertension, age at delivery, parity,
socioeconomic status, and sex of the
offspring”

Li et al
2017 (104)

Human
12-25y.o.
(>92%
white –
USA)
Pima Indian 15-19y.o.

LGDM

N/A

LGDM  ↑ birth weight, ↑ weight & 47% ↑
obesity risk at 12-25y.o. (males only)
Excluded women with PGDM

LGDM

N/A

Swedish

17-36y.o.

PGDM

Heart

18y.o.

LGDM & PGDM N/A
(T1DM, T2DM)
pooled
LGDM, PGDM N/A
(T1DM)

LGDM  markedly ↑ obesity rates in 1519y.o. ODM
PGDM  25x ↑ risk of non-malformation
CVD (risk may be the result of impaired
insulin signaling (IDDM))
GDM excluded
DM  ↑ BMI

Pettitt et al
1983 (105)
Stuart et al
2013 (106)

Lawlor et al Swedish
2011 (107)
Clausen et
al 2008 (4)

Danish

18-27y.o.

Clausen et
al 2009 (5)

Danish

18-27y.o.

Pettitt et al
1988 (108)

Pima Indian 20-24y.o.

LGDM, PGDM
(T1DM)

LGDM

Petersen et Human
al 2004
(USA)
(113)

~25-30y.o.

PGDM (T2DM)

Petersen et Human
al 2005
(USA)
(114)

~25-30y.o.

PGDM (T2DM)

LGDM  OR of 7.76 for ODM developing
T2DM/pre-diabetes
T1DM  OR of 4.02
N/A
LGDM  2x risk of overweight, 4-fold ↑
risk of metabolic syndrome
T1DM  2x risk of overweight, 2.5-fold ↑
risk of metabolic syndrome
Metabolic syndrome risk increased with
increasing maternal fasting blood glucose
N/A
LGDM  ↑ rates of T2DM (per higher
fasting glucoses) in offspring at age 20–24
years
ODM with baseline insulin resistance (per
Skeletal
↓ insulin sensitivity index) and family Hx of
muscle,
adipose, and T2DM (but no other health conditions)
have ↑ fasting glucose, ↓ performance on
liver
OGTT (slower declining blood sugars
despite ↑ insulin secretion), ↑
intramyocellular lipid stores in skeletal
muscle (but not liver), and skeletal muscle
mitochondrial dysfunction (per ↓
mitochondrial phosphorylation of
phosphocreatine)  ultimately, ODM at
greater risk for developing T2DM even
when they show subclinical insulin
resistance
ODM with baseline insulin resistance (per
Skeletal
↓ insulin sensitivity index) and family Hx of
muscle
T2DM (but no other health conditions)
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Morino et al Human
2006 (115) (USA)

~25-30y.o.

PGDM (T2DM)

Skeletal
muscle

Befroy et al Human
2007 (116) (USA)

~25-30y.o.

PGDM (T2DM)

Skeletal
muscle

Petersen et Human
al 2012
(USA)
(173)

~25-30y.o.

PGDM (T2DM)

Skeletal
muscle

Razaz et al Swedish
2020 (174)

Newborns Obesity
followed up
to 25y.o.

Heart

Scottish
Reynolds
et al 2013
(112)
Eriksson et Finnish
al 2015
(110)

34-71y.o.

Obesity

Heart

62y.o.

Obesity
(Maternal BMI)

N/A

Forsén et
al 1997
(111)

67-73y.o.
(males
only)

Obesity

N/A

Human
(Finnish)

29

showed ↓ insulin-stimulated whole-body
glucose metabolism, ↑ intramyocellular
lipid stores in skeletal muscle (3x control
levels), ↓↓↓ insulin-stimulated
mitochondrial phosphorylation
(ADPATP) in skeletal muscle (only
5% rise with insulin vs 90% rise in
controls) supported by ↓↓↓ increases in
intramyocellular Pi
ODM with baseline insulin resistance (per
↓ insulin sensitivity index) and family Hx of
T2DM (but no other health conditions)
showed ↑ glucose and insulin levels on
OGTT, ↓ insulin-stimulated glucose
uptake, ↑ intramyocellular lipid stores in
skeletal muscle (60% higher), 38%
↓skeletal muscle mitochondrial density
(per EM) with 50% ↓ MTCOI protein
expression despite differences in
neither PGC-1α, PGC-1β, or TFAM
mRNA or protein expression nor
mtDNA copy number, and ↑ IRS-1
phosphorylation alongside ↓ Akt
phosphorylation (supporting insulin
resistance)
ODM with baseline insulin resistance (per
↓ insulin sensitivity index) and family Hx of
T2DM (but no other health conditions)
showed ↑ baseline glucose and insulin
levels, ↑ insulin release on OGTT, ↑
intramyocellular lipid stores in skeletal
muscle (70% higher), ↓ TCA cycle flux
with 30% ↓ in basal oxidation rates
(indicated mitochondrial dysfunction)
~4kg weight loss (per caloric restriction) in
“ODM with baseline insulin resistance (per
↓ insulin sensitivity index) and family Hx of
T2DM (but no other health conditions)” 
↓ intramyocellular lipid content but ↑ lipid
droplet density, ↓ insulin resistance (per
30% ↑ in insulin-stimulated glucose
uptake, ↓ basal glucose and insulin
levels),
Obesity  ↑ rates of CVD
(cerebrovascular diseases > heart failure
> ischemic heart disease)
Rates of CVD positively correlated with
maternal early pregnancy BMI
Excluded offspring with congenital defects
or CVD diagnosed before 1y.o.
Obesity  ↑ risk of CVD and death from
“all CVD events” & 5% ↑ risk of all-cause
mortality by 60y.o.
Maternal BMI was positively correlated
with offspring BMI, lean body mass, and
fat mass (both sexes) and body fat
percentage (in females), but not sBP,
dBP, fasting glucose, insulin, lipid levels,
inflammatory markers, or adipocytokines
Mean age at CAD death was 57y.o.
Men who were thinner at birth had higher
mortality rates from CAD

Eriksson et Finnish
al 2014
(109)

70-80y.o.

Obesity

N/A

Maternal BMI was positively correlated
with offspring mortality rates from CAD
Offspring Ponderal/Rohrer’s Index
(measure of Leanness) of the offspring
was negatively correlated with their CAD
mortality rates
Maternal BMI was positively correlated
with offspring rates of all-cause mortality,
cancer rates and death, CVD, stroke, and
T2DM (stronger association in female
offspring)
Strongest positive correlation was
between maternal BMI and CVD
*”All risk estimates [were] adjusted for
childhood socio-economic status, and
adult socioeconomic status, income, and
education”

Newborns in table defined as infants ≤5 days old with the exception of Zablah et al 2017 who
evaluated infants from up to 7 days old; most studies defined newborns as infants ≤3 days old.
Abbreviations: y.o., years old; m.o., months old; d.o., days old; FS, fractional shortening (%);
PVH, pathologic ventricular hypertrophy; DT, deceleration time; BP, blood pressure; TG,
triglycerides; TC, total cholesterol; LVEDP, LV end diastolic pressure; LVDP, LV developed
pressure; GLS, global longitudinal strain; ACh, acetylcholine; NE, norepinephrine. BMI (Body
Mass Index) = kg / m2. Ponderal/Rohrer’s Index (measure of Leanness) = (weight [g] / length
[cm2]) x 1000. GLS serves as an indicator of heart failure; the lower the GLS, the worse the
prognosis (175).
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Table 2. Animal studies investigating mechanisms of developmental
programming following exposure to maternal diabetes and/or obesity.
Authors,
Year

Study
Subjects

Lehtoranta
et al 2013
(119)

Rat (Sprague
Dawley)

Lin et al
2017 (118)

Mouse
(C57Bl/6J)

Gordon et al
2015 (117)

Assessed
Age & Sex
(unless
both)
Fetal
(GD13-14,
16-17, and
19-21 of
22)

Exposure

Cell /
Tissue

PGDM
(STZinduced)

Heart

Fetal
(GD17.5 of
19.5)

PGDM
(T2DM;
induced with
HFD; 60%
calories from
fat)

Heart

Rat (Sprague
Dawley)

Fetal
(GD20 of
22)

LGDM
(glucose
infused
GD19-birth)

Heart

McCurdy et
al 2016
(120)

Japanese
Macaques

Fetal
(GD130 of
165)

Obesity
(Western
style diet,
37% calories
from fat)

Skeletal
muscle

Mdaki et al
2016 (7)

Rat (Sprague
Dawley)

Newborn
(1d.o.)

LGDM,
Obesity

Heart
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Outcomes & Notes
Dam glucoses 450-520 mg/dL before
and through pregnancy
PGDM  larger hearts (per area on CT
scan and heart:body weight ratio) due
to myocardial hyperplasia, ↑ fetal
holosystolic AV valve regurgitation at
GD13-14 (in 98% of DM-exposed
fetuses but only 26% of controls),
diastolic dysfunction at GD19-21
Authors claim model is T2DM, but
model relies on a lipotoxic and
obesogenic diet leading to obesity and
insulin insensitivity
PGDM (HFD-induced)  ↑ fetal heart
size, ↑ IVS, LV outer wall thickness, and
cardiomyocyte thickness supported by ↑
expression of β-MH, ANP, and desmin,
↑ cardiac collagen staining with ↑
expression of genes regulating collagen
synthesis, ↑ apoptosis (per ↑ TUNELpositive cells, ↑ BAX and ↓ Bcl-2
expression)
24hr fetal hyperglycemia (GD19-GD20)
but mothers did not develop diabetes or
hyperglycemia  cardiac septal
overgrowth (due to hyperplasia) at
GD20 that outpaced fetal growth (per
normalizing to body weight at C-section)
Some of the macaques on WSD
became obese (body fat >30%) while
others stayed lean (<25%) leading to
sub-stratification to three groups: CD,
WSD/lean, WSD/obese
WSD/obese  ↓ intramuscular TG, ↑
intramuscular FFA, ↑ CPT-1β, PGC1α,
and SIRT1 expression, ↓ glycolysis,
and ↑ ETC Complex I & IV activity (but
not II or III) despite ↓ mitochondrial
mass (per ↓ citrate synthase activity and
↓ mtDNA:nDNA) and ↓ OXPHOS (both
sexes)
In all groups, intramuscular FFA in
males > females
WSD (both lean and obese)  ↑
VLCAD but ↓ SCHAD expression, ↑
oxidative stress (lipid peroxidation per
↑ TBARS and 4HNE-modified levels, ↑
GADD45, SIRT3, UCP2 [males only],
and UCP3 expression)
No differences in TFAM or MFN2
expression
LGDM  ↓ birth weights, ↑ heart:body
weight, ↓ systolic & diastolic function, ↓

(40% HFDinduced)

Baack et al
2016 (121)

Rat (Sprague
Dawley)

Newborn
(1d.o.),
3w.o.

LGDM,
Obesity
(40% HFDinduced)

Heart,
lunges

Larsen et al
2019 (9)

Rat (Sprague
Dawley)

Newborn
(1d.o.)

LGDM,
Obesity
(40% HFDinduced)

Heart

Koukkou et
al 1998
(130)

Rat (Sprague
Dawley)

15d.o.,
2m.o.(femal
es only)

~PGDM
(STZinduced on
GD1),
Obesity
(Lard, HFDinduced)

Vasculature
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respiratory, glycolytic, and FAO
capacities, ↓ mtDNA copy number
HFD  ↓ birth weights, ↑ heart:body
weight, ↓ HR, ↓ diastolic function,
myocardial lipid deposition, ↓ basal
respiration, ↑ lipid peroxidation, ↑
number of shorter, fragmented
mitochondria, ↑ mtDNA copy number
GDM+HFD  ↓↓ birth weights, ↑ serum
insulin, ↑↑ heart:body weight, ↓ HR, ↓↓
systolic & diastolic, myocardial lipid
deposition, ↓↓ respiratory, glycolytic,
and FAO capacities, ↑ lipid
peroxidation, fragmented, depolarized
mitochondria, ↑ mtDNA copy number
ODOM were cross-fostered on P1 to
normal dams
LGDM  ↑ serum insulin
HFD  ↑ serum triglycerides and
insulin, ↑ perinatal mortality, ↑ 3wk
weight, ↑ heart weight at birth, ↓
PAAT/RVET (HFD caused pulmonary
HTN in P1 offspring), impaired
pulmonary vasculogenesis and
alveolarization
LGDM+HFD  ↑ serum insulin, ↑
perinatal mortality, ↓ birth weight and
3w.o. weight, ↑ heart weight at birth and
3w.o., ↓↓ PAAT/RVET (at P1)
ODOM were cross-fostered on P1 to
normal dams
LGDM  50% ↓ in fusion events, 30% ↓
in fission events, shorter & wider
mitochondria, similar impairments by
sex
HFD  50% ↓ in fusion events, 44% ↓
in fission events, shorter & wider
mitochondria, females more severely
affected, ↑ Mfn mRNA and MFN2 &
OPA1 protein expression (males only),
altered OPA1 band ratios in males
suggest impaired respiration and
mitophagy
LGDM+HFD  50% ↓ in fusion &
fission events, but mitochondria were
fragmented, depolarized, shorter, wider,
and adynamic
Higher fusion protein & VDAC
expression in females than males
Pro-fission balance in males supported
by changes in MFN1 in LGDM- and
HFD-exposed heart and ↑ DAP3, ↑
MTFP1, and DRP1 phosphorylation in
HFD-exposed hearts
HFD maintained through lactation, but
pups weaned to CD
Only obesity effects evaluated at 2m.o.
PGDM+HFD (glucolipotoxicity)  ↑↑
perinatal mortality, ↑ arterial responses
to NE at 15d.o. (i.e. greater

Cerqueira et
al 2019
(176)
Loche et al
2018 (125)

Mouse
(Ins2+/C96Y;
Akita mouse)
Mouse
(C57BL/6)

~1m.o.
(34d.o.)

PGDM
(T1DM)

Kidneys

8w.o.
(males
only)

Heart

Gao et al
2016 (123)

Mouse
(C57BL/6)

8-10w.o.
(Males
only)

Obesity
(diet-induced
with
sweetened
lard, see
(129))
PGDM
(STZinduced
≥1wk before
breeding),
Melatonin Tx
(daily from
E0.5-term)

Gonzalez
2020 (177)

Mouse (CD1)

2-3m.o., 56m.o.

N/A

Theys et al
2011 (178)

Rat (Wistar)

3m.o.

Obesity (HF
and high
sucrose dietinduced)
Obesity
(HFDinduced with
lard)

Vessières et
al 2016
(179)

Rat (Sprague
Dawley)

3 to 18m.o.

DM (STZinduced on
GD0)

Kidneys
Arteries

Vaughan et
al 2018
(128)

Mouse
(C57/BL6J)

3 & 6m.o.

Obesity
(dietinduced;
40% lipid,

Heart
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Heart

Pancreas

constriction), ↓ ACh-stimulated arterial
relaxation at 15d.o.
HFD (alone)  ↑ perinatal mortality, ↓
birth weights, ↑ arterial responses to NE
at 2m.o. (i.e. greater constriction), ↓
ACh-stimulated arterial relaxation at
15d.o. and 2m.o.
PGDM  impaired kidney/nephron
differentiation
Obesity  systolic dysfunction (per ↓
EF and ↓ FS), ↑ sBP, ↑ IVS thickness
Gestational obesity + weaning OOM to
same diet  above changes + cardiac
fibrosis (per Picrosirius Red staining)
and ↑↑ sBP
PGDM  significantly larger infarcts
with greater ↓EF, ↑apoptotic cells, ↑
caspase-3 activity, ↑ cytochrome C
release to cytoplasm, ↑ mitochondrial
swelling, ↑ caspase-9 activity alongside
↑BAX:Bcl-2 ratio (both indicate mitomediated intrinsic apoptosis), ↑ CHOP
expression with ↑ caspase-12 activity
(both indicate ER stress-mediated
apoptosis), ↑ accumulation of ROS,
RNS, and MDA, and impaired IRS1/AKT signaling following MIR that was
improved by maternal melatonin Tx
No differences in morphology (Ex.
Hypertrophy), fibrosis, cardiomyocyte
size, HF markers, FAS expression, or
caspase-8 activity (FAS and caspase-8
indicate death receptor pathway) were
found  supports a mitochondrial
cause for the MIR differences
In PGDM mice (8-10w.o.), EF was not
lower than controls before MIR
DM in dams defined by fasting glucose
>252mg/dL
HFD  increased weight gain with
insulin resistance (both sexes)
Obesity  ↑ weight and β-cell mass
(females only), ↓ serum insulin levels
(males only), ↓ β-cell responses to
glucose (per insulin secretion not
increasing with increasing glucose
concentrations; both sexes)
LGDM  excessive vasoconstrictor
tone in mesenteric arteries at 3m.o.
(may indicate ↑ HTN risk)
DM was not treated, just checked every
other day of pregnancy to ensure blood
sugar levels were 15-25mmol/L (170450mg/dL)
Obesity  increased weight with
hyperinsulinemia (both sexes) [see
(180)], diastolic dysfunction in male
OOM (per ↓ E/E’ ratio at 3 & 6m.o. and
↓ E’/A’ ratio at 3m.o.) and female OOM

20%
sucrose)

(per ↓ E’/E’ ratio at 6m.o.), ↑ LVEDV in
female OOM at 3m.o.
Offspring differences were prevented
with maternal Adiponectin
supplementation from E14.5-E18.5
(term = 19.5 days)
Obesity  ↑ birth (both sexes) and
weaning weights (males only); ↑
adipose mass, ↓ skeletal muscle, and
glucose intolerance at 3 and 6m.o.; ↑
plasma TG, insulin, sBP, and MAP
(mean arterial pressure) at 3m.o., ↑
sBP, MAP, and HR, and hyperglycemia
with ↓ insulin (due to beta-cell failure) at
6m.o. (both sexes)
Obesity-exposed females had a greater
↑ sBP than males
Dams were on HF diet for 6wk before
mating and through lactation; pups
weaned to CD
Obesity  ↓ linked complex II-III activity
in males (but not females) despite no
differences in muscle fiber density; ↓
IRS-1 expression in females

Samuelsson
et al 2008
(129)

Mouse
(C57Bl/6J)

3 & 6m.o.

Obesity
(diet-induced
with
sweetened
lard)

Heart,
adipose,
liver,
pancreas
skeletal
muscle

Shelley et al
2009 (132)

Mouse
(C57BL/6J)

3m.o.

Skeletal
muscle

Blackmore
et al 2014
(124)

Mouse
(C57BL/6J)

3, 5, 8 and
12w.o.
(males
only)

Obesity
(diet-induced
with
sweetened
lard, see
(129))
Obesity
(diet-induced
with lard +
sweetened
simple
sugar)

Heart

No differences found in OOM weight,
serum TG, TC, or FFA at any time point
Obesity  at 3-8 w.o. OOM had larger
hearts with hypertrophied CM,
increased ratio of MHY7:MYH6
(indicating cardiac stress); at 12w.o.
OOM had systolic dysfunction (per ↓
LVDP and ↓ contraction velocity) and
diastolic dysfunction (per ↑LVEDP and ↓
relaxation velocity), increased
sympathetic dominance (both inotropic
and chronotropic; indicating heart
failure)

Turdi et al
2013 (135)

Mouse (FVB
albino)

4m.o.
(males
only)

Obesity
(HFDinduced;
45% calories
from fat);
Postweaning
HFD

Heart,
adipose

Four groups: Mat. LFD weaned to LFD
(MLPL), Mat. HFD weaned to LFD
(MHPL), Mat. LFD weaned to HFD
(MLPH), and Mat. HFD weaned to HFD
(MHPH)
MHPL & MHPH  ↓ litter size and
birthweights, ↑ weaning weight,
adipocyte hypertrophy, ↑ sBP and dBP
(MHPH only; at 4m.o.), ↓ speed of CM
contraction and relaxation, abnormal
mitochondrial morphology on EM
(MHPH only)
Consequences of post-weaning HFD
(lipid droplet accumulation, ↑ LV mass,
systolic dysfunction [per ↓ FS], ↑
GATA4 expression, ↓ PGC-1α
expression, ROS production) were
worsened when preceded by maternal
HFD  Take-home: Maternal HFD +
HFD in offspring MUCH WORSE
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Ghosh et al
2001 (136)

Rat (Sprague
Dawley)

5m.o.
(females
only)

Obesity
(Lard, HFDinduced)

Vasculat
ure

Khan et al
2003 (131)

Rat (Sprague
Dawley)

80d.o.,
6m.o.,
12m.o.

Obesity
(Lard, HFDinduced)

Heart,
vasculatu
re

Nehiri et al
2008 (133)

Rat (Sprague
Dawley)

1, 6, and
18m.o.

Khan et al
2005 (137)

Rat (Sprague
Dawley)

6m.o.

DM (STZinduced on
GD0)
Obesity
(Lard, HFDinduced)

Kidneys,
vasculatu
re
Heart,
vasculatu
re

Boloker et al
2002 (134)

Rat (Sprague
Dawley)

6m.o.
(26w.o.)

LGDM
(IUGRinduced)

N/A

Khamoui et
al 2018
(138)

Mouse
(C57BL/6J)

12m.o.

Obesity
(HFD [45%
calories lipid]
induced),
OOM
weaned to
control or
HFD

Skeletal
muscle

Saben et al
2016 (127)

Mouse
(C57BL/6)

F1-F3
generations
at 8w.o.

Obesity (HF
[59%
calories as
lipid] + highsucrose dietinduced)

Ovaries
(oocytes)
, skeletal
muscle

35

HFD maintained through lactation, but
pups weaned to CD
HFD  ↑ serum TG, ↓ ACh-stimulated
arterial relaxation, ↑ aortic lipid
deposition (with ↑ saturated FA and ↓
DHA fractions)
HFD maintained through lactation, but
pups weaned to CD
HFD  ↑ weight in 12m.o. (only
females), ↑ sBP, dBP, and MAP at
6m.o. and 12m.o. (only females), ↓
ACh-stimulated arterial relaxation at
80d.o. and 6m.o. (both sexes; 12m.o.
not tested), ↑ fasting glucose and serum
TG at 12m.o. (only females)
No significant differences in weight, BP,
MAP, or HR in male offspring
DM  HTN at 6m.o. onwards (at least
up to 18m.o.)
Dams on CD or HFD, then pups crossfostered to dams on either CD or HFD
(four groups); all pups weaned to CD
HFD (prenatal HFD +/- HFD during
lactation)  ↓ HR (in males), ↑ sBP &
dBP (in females), ↓ ACh-stimulated
arterial relaxation (both sexes), ↑ fasting
insulin levels, and ↑ abdominal and total
body fat (both sexes)
LGDM  overt diabetes by 26 weeks
old;
To generate ODM, they use IUGR
offspring (F1) that become diabetic by 2
months old, at which point they're bred
to produce F2 ODM
Obesity  ↑ body weight, ↑ body fat,
and ↓ lean mass at 1y.o. (both sexes);
in Females, 20% ↓ Mito Complex I
State3 respiration and ↓ Complex I+II
OXPHOS that was worsened by
weaning to HFD (Male OOM were NOT
affected by Maternal HFD, just weaning
to HFD)
Dams were on HFD from weaning (their
own) through lactation
F0 dams and exposed F1 & F2 females
were bred with control males, but F0
females were the only generation
exposed to the HFD
F0 dams on the diet were obese,
hyperlipidemic (↑ TG & ↑ TC), and
hyperglycemic with glucose intolerance
F1 offspring had impaired glucose
tolerance with higher fasting insulin,
skeletal muscle with disorganized
mitochondria with impaired FAO, ↓
RCR, and oxidative stress, and large
oocyte mitochondria with disorganized
IMM, abnormal (‘less round’)
morphology, ↓OPA1 expression, and
↓mtDNA

Ferey et al
2019 (126)

Mouse
(C57BL/6)

F1-F3
generations
at 8w.o.

Obesity (HF
[59%
calories as
lipid] + highsucrose dietinduced)

Heart

F2 offspring skeletal muscle had
enlarged mitochondrial with
disorganized IMM and abnormal (‘less
round’) morphology, ↓ DRP1
phosphorylation on Ser-616
phosphorylation (implying ↓dynamism),
↓OPA1 expression, and ↓ETC complex
protein expression; F2 oocyte
mitochondria similarly had ↓DRP1 and
OPA1 expression
F3 offspring skeletal muscle had larger
mitochondria but less severely affected
IMM (but still abnormal cristae), ↓DRP1
and OPA1 expression
***insulin signaling had normalized by
F3, implying that the effects were
Inherited  HOWEVER, see Ferey et al
2019 (126)
Same model as Saben et al 2016 (127)
Body weight did not differ in F1-F3
offspring
F0 dams on HFD had no structural or
function cardiac changes
F1 offspring of both sexes had greater
(10%) LV mass, disorganized
mitochondria with circular (rather than
elongated) morphology and Complex I
and II dysfunction, and ↓ p-MFF and
SIRT3 expression
IVF/embryo transfer (2-cell stage) F1
offspring of both sexes still had the
greater LV mass and cardiac
mitochondrial defects (same
morphologic and ETC complex
impairments as F1)  suggests
periconceptual rather than in utero
environment of F0 dam was likely
Female F1 had thinner LV walls, ↓ FS,
and ↑ myocardial performance index
Male F1 had thicker LV walls
F2 females and F2 & F3 males had ↑
LV mass, but all F2 & F3 offspring had
the same F1 morphologic and ETC
complex impairments
Paternal F2 offspring (F1 Male +
Control Female) ALSO had the greater
LV mass and cardiac mitochondrial
defects (same morphologic and ETC
complex impairments as F1)  Implies
EPIGENETIC CHANGES within
nuclear genome are responsible for
transgenerational
cardiac/mitochondrial defects

Abbreviations: PGDM, pregestational diabetes mellitus; LGDM, late-gestation diabetes mellitus;
GD, gestational day; d.o., days old; w.o., weeks old; m.o., months old; y.o., years old; FS,
fractional shortening; DT, deceleration time; s/dBP, systolic/diastolic blood pressure; TG,
triglycerides; TC, total cholesterol; LVEDP, LV end diastolic pressure; LVDP, LV developed
pressure; GLS, global longitudinal strain; ACh, acetylcholine; NE, norepinephrine. BMI (Body
Mass Index) = kg / m2.
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Chapter 2: Mitochondrial Dysfunction Persists into
Adulthood and Precedes Cardiac Dysfunction in Diabetesexposed Offspring

This chapter, including figures where referenced, has been adapted from:
EJ Louwagie, TD Larsen, AL Wachal, TCT Gandy, JA Eclov, TC Rideout, KA Kern, JT
Cain, RH Anderson, KS Mdaki, ML Baack. Age and sex influence mitochondria and
cardiac health in offspring exposed to maternal glucolipotoxicity. iScience. 2020 Oct 28.
DOI: 10.1016/j.isci.2020.101746. PMID: 33225249. PMCID: PMC7666357.

The original article is an open access article licensed under a Creative Commons
Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND
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Abstract
Infants of diabetic mothers are at risk of cardiomyopathy at birth and myocardial
infarction in adulthood, but prevention is hindered because mechanisms remain
unknown. We previously showed maternal glucolipotoxicity increases the risk of
cardiomyopathy and mortality in newborn rats through fuel-mediated mitochondrial
dysfunction. Here we demonstrate ongoing cardiometabolic consequences by crossfostering and following echocardiography, cardiomyocyte bioenergetics, mitochondriamediated turnover and cell death following metabolic stress in aged adults. Like
humans, cardiac function improves by weaning with no apparent differences in early
adulthood but declines again in aged diabetes-exposed offspring. This is preceded by
impaired oxidative phosphorylation, exaggerated age-related increase in mitochondrial
number, and higher oxygen consumption. Prenatally exposed male cardiomyocytes
have more mitolysosomes indicating high baseline turnover; when exposed to metabolic
stress, mitophagy cannot increase and cardiomyocytes have faster mitochondrial
membrane potential loss and mitochondria-mediated cell death. Details highlight ageand sex-specific roles of mitochondria in developmentally programmed adult heart
disease.
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Introduction
Babies born to mothers with diabetes or obesity are at greater risk of
cardiovascular disease (CVD) (2, 181) including cardiomyopathy at birth (41, 182) and
premature death from acute myocardial infarction (AMI) in adulthood (5, 106, 112, 183).
This is particularly alarming because over 10% of pregnancies are complicated by
gestational diabetes (184) and over 25% by maternal obesity (185), adding to a growing
burden of CVD estimated to affect 40% of the US population and cost $818 billion by
2030 (186). Developmental consequences are purportedly caused by in utero exposure
to maternal hyperglycemia and hyperlipidemia (together termed glucolipotoxicity) which
incite fetal hyperinsulinemia to program long-term cardiometabolic risks (52, 66, 187189). We previously showed that newborn rats born to diabetic mothers have larger
hearts, diastolic and systolic dysfunction, impaired cellular bioenergetics and
mitochondrial dysfunction at birth and maternal high-fat (HF) diet-exacerbated cardiac
pathology and perinatal mortality (7, 9, 121, 122). Here long-term studies assess risks
over a lifetime to highlight age- and sex-specific alterations in cellular bioenergetics,
mitophagy, and cell death and resolve underlying mitochondria-mediated mechanisms of
adult heart disease, specifically as it relates to cardiac damage following AMI.
Mitochondria play pivotal roles in cardiac development and disease (190, 191).
During and after development they directly influence metabolism and cell fate (192-194).
As the primary producers of ATP, mitochondria play an especially important role in the
heart which uses 5-10 times its weight in ATP each day to support contractile function
(14, 195). Even the slightest decrease in efficiency can have a profound impact on cardiac
function (196) causing hypertrophy, systolic and diastolic dysfunction (22). Mitochondria
serve as regulatory hubs to balance fuel supply and energy demand through oxygen-,
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fuel-, and insulin-mediated pathways that orchestrate tissue-specific metabolic
homeostasis through self-replication and respiratory complex assembly (197). Metabolic
adaptability is essential to maintain cardiac ATP production during metabolic shifts during
rest, exercise, fed, fasting, aerobic, and anaerobic states.
Over the course of development, cardiac metabolism shifts from glycolysis to
oxidative phosphorylation (OXPHOS) (11, 198). With a relatively low workload and
oxygen supply but a continuous source of fuel, the fetal heart relies on glycolytic
metabolism. At birth, cardiac metabolism must transition to OXPHOS of stored fuels. This
switch is supported by mitochondrial biogenesis, formation of a densely packed
mitochondrial reticulum and tighter respiratory coupling (13, 199). While this
developmental shift is necessary, a higher number of dysfunctional mitochondria would
consume more oxygen at baseline, have lower reserve capacity, and increase ROS
production which could incite more cardiac damage during metabolic stress. When
mitochondria are damaged, mitochondrial membrane potential (MMP) loss signals
degradation via mitophagy (200). Physiologic mitophagy is beneficial for culling
dysfunctional mitochondria to optimize cellular respiration (32), and overload of
dysfunctional mitochondria can cause cell death by several pathways including
mitochondria-mediated intrinsic apoptosis or mitochondrial permeability transition (MPT)driven necrosis (201) (Figure 2). The elaborate balance between mitochondrial
biogenesis and mitophagy maintains mitochondrial quality control and is tightly controlled
by the mediators of mitochondrial dynamism (202). Thus, with aging, mitochondrial
dysfunction contributes not only to poor contractile function from impaired bioenergetics
but also greater risk of permanent damage following ischemia-reperfusion injury.
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Figure 2. Schematic representation of mitochondria-mediated cell death pathways
following FCCP-induced stress.
MPT, mitochondrial permeability transition; CypD, cyclophilin D; mPTP, mitochondrial
permeability transition pore. This figure has been adapted from Louwagie, E.J., et al.
iScience (2020).

The mediators of mitochondrial dynamics, mitophagy, and mitochondriamediated cell death each play unique and complex roles. Dynamin-related protein 1
(DRP1) is a cytosolic GTPase essential in driving mitochondrial fission (203, 204). It is
recruited to outer mitochondrial membrane (OMM) binding partners including
mitochondrial fission factor (MFF) (190). Mitochondrial fission process protein 1
(MTFP1), an inner mitochondrial membrane (IMM) protein, also influences fission and
mitophagy through recruitment of DRP1 (205). Mitofusins 1 and 2 (MFN1, MFN2) and
optic atrophy 1 (OPA1) regulate mitochondrial fusion. MFN1 and MFN2 are both located
on the OMM and form homotypic and heterotypic bonds needed for fusion (204). MFN2
has additional non-canonical roles in PINK1-Parkin-mediated mitophagy (191, 204),
opening of the mitochondrial permeability transition pore (mPTP) (206), and cell death
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following ischemia/reperfusion injury (207). OPA1, located on the IMM, influences
fusion, cristae structure, and mitophagy-induced apoptosis(204). Death associated
protein 3 (DAP3), voltage-dependent anion channel (VDAC), and cyclophilin D (CYPD)
play regulatory roles in mitophagy and mitochondria-mediated cell death. DAP3, a
mitoribosomal protein, functions similarly to MTFP1 by regulating mitophagy through
DRP1 activation (208). VDAC, also called mitochondrial porin, is canonically involved in
anion exchange between the cytoplasm and mitochondria but also influences
apoptogen release and interaction with anti-apoptotic proteins (209). CYPD, also known
as cyclophilin F and peptidylprolyl isomerase D, regulates many mitochondrial functions
including mPTP opening in MPT-driven necrosis (210).
This study builds upon previous work to determine whether fuel-mediated
mitochondrial dysfunction found in prenatally-exposed offspring at birth disturbs
cardiometabolic maturation or mitochondrial quality control during normal development
and aging to increase the risk of CVD in adulthood. To assure long-term differences were
caused by fetal rather than postnatal exposures, pups were cross-fostered to normal
dams in equalized litters for evaluation at predetermined endpoints. Cardiac morphometry
and function was followed using echocardiography at newborn (postnatal day 1 (P1)),
weaning (3 weeks (WK)), young- (10WK), mid- (6 months (MO)), and aged-adult (12MO)
time points. Bioenergetics were measured using extracellular flux analyses of whole and
permeabilized primary CM and temporal relationships were examined to detect
developmental aberrations which is important because change in bioenergetics may be
causal or responsive to changes in cardiac function. Adapting reported methods to study
MMP (211), mitophagy (212), and cell death (213) we developed a reproducible assay to

42

quantify baseline physiologic mitophagy and stress-induced mitochondria-mediated CM
death as a cellular ‘heart attack in a dish’. Here, we demonstrate that fetal exposure to
maternal glucolipotoxicity alters normal developmental shifts in cardiac metabolism and
increases the risk of heart disease in adulthood through mitochondria-mediated
mechanisms.

Materials and Methods
Experimental Animals
This study followed guidelines of The National Institutes of Health Guide for the
Care and Use of Laboratory Animals and the Animal Welfare Act and was approved by
the Sanford Institutional Animal Care and Use Committee (protocols 40-10-14B, 93-0817B, and 131-06-20B). Facilities were temperature-controlled and light-dark cycled.
Animals had free access to chow and water. Female Sprague Dawley rats (Envigo,
Indianapolis, IN) were placed on either control diet (TD2018 Teklad, Envigo; 18% fat,
24% protein, 58% carbohydrates) or HF diet (TD95217 custom diet Teklad, Envigo;
40% fat, 19% protein, 41% carbohydrates) at least 28 days before breeding and
throughout pregnancy. Females were bred with normal males fed control diet and
monitored by vaginal swab for spermatozoa. Following ultrasound to confirm pregnancy
on gestational day 14, dams received intraperitoneal injection of either citrate-buffered
saline (Thomas Scientific, Swedesboro, NJ) diluent or 65mg/kg streptozotocin (SigmaAldrich, Inc., St. Louis, MO) to induce diabetes. Thereafter, dams were partially treated
with twice-daily sliding scale insulin (regular and glargine, Eli Lilly and Co., Indianapolis,
IN) to keep blood glucose levels at 200-400mg/dL. Tail-nick whole blood sampling was
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done to measure ketones and blood glucose (Precision Xtra ketone meter and
glucometer, Abbott Laboratories, Abbott Park, IL). Dams not manifesting diabetes
(blood glucose >200mg/dL) within 48 hours were excluded from this study. While
maternal diabetes was induced by pancreatic damage, the developing offspring were
consistently exposed to maternal hyperglycemia, hyperlipidemia and fetal
hyperinsulinemia in the last 1/3 or pregnancy (7, 121, 122) (Figure 3; Tables 3 and 4).
Dams delivered spontaneously to yield offspring of both sexes from four distinct
groups: controls, diabetes-exposed, HF diet-exposed, and combination-exposed as
previously described in detail (7, 8, 11, 122). Litter size included live and dead pups as
defined by counting the number of live and dead pups in the cage alongside direct
uterine examination to count placentations, resorptions, or retained stillborns in each
uterine horn. Perinatal mortality was calculated as: (litter size – live pups)/litter size x
100. On P1, litter size was equalized (8 pups/dam) and offspring were cross-fostered to
normal timed pregnant dams fed a control diet and delivering 0-7 days prior to
corresponding experimental offspring. To ensure that exposure to diabetes and/or diet
was only prenatal, all pups were weaned to a control diet before being aged to preset
time points (3WK, 10WK, 6MO, or 12MO). At all five time points, hearts were collected
under 5% isoflurane anesthesia and immediately used to isolate primary ventricular
cardiomyocytes (CM) or snap frozen in liquid nitrogen and stored at -80oC.
Isolation of Primary Cardiomyocytes
Primary ventricular CM were isolated from offspring as previously described (11).
In brief, newborn (P1) hearts were collected immediately following euthanasia and
transferred to Hank’s Balanced Salt Solution on ice. Atria were removed before mincing
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ventricles. Ventricular pieces were digested via 5-6 alternating cycles of: 1) stirring for 5
min at 50rpm in 0.1% trypsin with 0.02% DNase I (in 0.15M NaCl), and 2) trituration at
1-2mL/sec for 5 min. Trypsin/DNase I mix was deactivated with bovine serum before
centrifuging cells at 1600rpm at 22C for 10 min (centrifuge: Eppendorf Centrifuge 5810
R). Cell pellets were resuspended in DMEM-1 (DMEM supplemented with 10% BS and
1% penicillin/streptomycin) with 0.0002% DNase I, seeded to uncoated 35mm dishes,
and incubated for 1 hr in humidified 37C, 5% CO2 to allow fibroblast attachment. CM
were then gently detached, resuspended in DMEM-1, and counted with Trypan Blue
and hemocytometer before seeding to 0.1% gelatin-coated Seahorse XF24 V7 PS cell
culture microplates at 150,000 viable CM/well for Extracellular Flux Analyses (see
below) or at 40,000 CM/well for Permeabilized Extracellular Flux Analyses (see below).
CM were allowed to adhere overnight (12-16 hr) before experimentation.
To isolate CM from 3WK, 10WK, 6MO, and 12MO offspring, following euthanasia
hearts were placed in Perfusion Buffer (PB; 120.4mM NaCl, 14.7mM KCl, 0.6mM
KH2PO4, 0.6mM Na2HPO4, 1.2mM MgSO4-7H2O, 10mM HEPES, 4.6mM NaHCO3,
30mM taurine, and 5.5mM glucose) on ice. Still-beating hearts were then cannulated
and perfused for 5 min with PB before digestion with type 2 collagenase (Worthington
Biochemical Corp., Lakewood, NJ) in PB. Following approximately 35 min digestion,
ventricles were cut away from atria, teased into smaller pieces, and transferred to PB
supplemented with 12.5µM CaCl2 and 1% bovine serum albumin. Following 10 min of
gravity sedimentation at room temperature, CM were reintroduced to calcium with stepwise additions of 0.25mM, 0.25mM, 0.5mM, 0.5mM, and 0.3mM CaCl2 to ensure
calcium-tolerant CM for plating. Viable CM were counted with Trypan Blue and
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hemocytometer before seeding to 18µg/mL laminin-coated 35mm glass-bottom
FluoroDishes (World Precision Instruments) at 51,000 CM/dish or to Seahorse XF24 V7
PS cell culture microplates (3WK at 17,000 CM/well; 10WK and 6MO at 10,000
CM/well; 12MO at 6,000 CM/well) for Extracellular Flux Analyses or 3,000 12MO
CM/well for Permeabilized Extracellular Flux Analyses in MEM (Gibco Cat. #11575032,
Grand Island, NY) containing 2mM L-glutamine and 5.6mM D-glucose. CM were
allowed to attach for at least 1 hr before experimentation. As authors observed
functional and morphologic differences in CM (particularly from 12MO offspring) with the
amount of time in culture, consistent experimental timing was prioritized.
Echocardiography
Structural and functional cardiac physiology was followed over time using serial
echocardiography at P1, 3WK, 10WK, 6MO, and 12MO as previously detailed (7, 121).
In short, echocardiography was done using the Vevo 2100 Imaging System (FUJIFILM
VisualSonics Inc., Toronto, Canada). While under light (1-3%) isoflurane/oxygen
anesthesia, hair was removed from the ventral chest, and offspring were secured on a
prewarmed (37C) imaging stage with embedded electrocardiogram leads. Temperature
and EKG were monitored continuously to assure physiologic stability. Parasternal long
axis (PLAX), parasternal short axis (PSAX), and the apical four chamber views were
acquired in B mode (brightness), M mode (motion), and pulsed-wave (PW) Doppler
mode using MS700 (P1), MS400 (3WK), or MS250 (10WK-12MO) MicroScan highfrequency transducers according to animal size (FUJIFILM VisualSonics Inc.). All
echocardiograms were acquired by one trained individual, and image analysis was done
by a separate technician using the Vevo LAB analysis software (FUJIFILM VisualSonics
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Inc.). Reported ventricular measurements are from left ventricular trace in PLAX,
systolic function (ejection fraction and fractional shortening) is from M mode in PSAX,
and diastolic function (E:A ratio) is from PW Doppler apical images. Right ventricular
function is reported as the ratio of pulmonary artery acceleration time (PAAT) to right
ventricular ejection time (RVET) as calculated from PW Doppler modified PLAX images
of the right ventricular outflow tract (RVOT).
Hepatic Lipid Analyses
Whole livers were weighed and snap frozen in liquid nitrogen immediately upon
collection and stored at -80C for future processing and analyses. For hepatic TG
analysis, liver tissue (100mg) was homogenized in 1mL of an aqueous 5% NP-40
solution, heated at 90C for 10 min, and spun at top speed in a microcentrifuge for 2 min.
TG concentrations in liver extracts were quantified with a commercial kit (Zenbio, STG1-NC) according to manufacturer’s instructions. Hepatic cholesterol was extracted and
analyzed by gas chromatography as previously described (214).
Serum Analyses
Blood was collected from dams and offspring via venipuncture or intracardiac
puncture under anesthesia or immediately following humane euthanasia. Whole blood
and serum fractions were stored at -80C for analysis. To validate fetal hyperinsulinemia,
a subset of P1 offspring (n=40-68 pups/group) was delivered by cesarean section with
immediate jugular venous sampling prior to cutting the umbilical cord as previously
described (122). Milliplex MAP Magnetic Bead Panels (MilliporeSigma, Burlington, MA)
with Luminex 200 Analyzer (Luminex Corp, Austin, TX) were used to measure serum
concentrations of insulin, C-peptide, and leptin (Cat. #RMHMAG-84K) as well as
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adiponectin, E-selectin, and ICAM-1 (Cat. #RV2MAG-26K). Serum HbA1c levels were
measured with Rat Hemoglobin A1C Assay Kit (Cat. #80300, Crystal Chem, Elk Grove
Village, IL), brain natriuretic peptide with Rat BNP 45 ELISA Kit (Cat. #ab108816,
Abcam, Cambridge, MA), serum TG with Pointe Scientific colorimetric assay and TG
standards (Cat. #23-666-410 and #23-666-422, Thermo Fisher Scientific, Waltham,
MA), and NEFA levels with Wako HR Series NEFA-HR Colorimetric Kit (Wako
Diagnostics, Richmond, VA). Serum total and HDL cholesterol was measured using
EnzyChrom AF HDL and LDL/VLDL Assay Kit (Cat. # E2HL-100, Universal Biologics,
Cambridge, UK); non-HDL cholesterol (representing VLDL, IDL, LDL, chylomicron
remnants and lipoprotein) was calculated by subtracting HDL from total cholesterol.
Serum renin concentrations were measured with SensoLyte 520 Rat Renin Assay Kit
(Cat. #AS-72140, Anaspec, Fremont, CA). All assays were run per manufacturer’s
instructions and read on Cytation3 plate reader (BioTek, Winooski, VT) unless
otherwise noted.
Extracellular Flux Analyses
CM bioenergetics were assessed using a mitochondrial stress test (MST),
glycolytic stress test (GST), and fatty acid oxidation test (FAOT) on Seahorse XF24
extracellular flux analyzer at all five time points. Methods have been previously
described in detail (7, 11). Specifically, before beginning each assay CM were washed
twice in assay media and incubated for 1hr in absence of CO2. Oxygen consumption
rates (OCR) and extracellular acidification rates (ECAR) were measured at baseline and
following injections to determine respiratory, glycolytic, and FAO capacities. All media
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were heated to 37C with pH adjusted to 7.40. Assays used the following injection
strategies (listed concentrations are final) and media types:
MST: 2µM Oligomycin, FCCP (0.3µM for P1, 0.6µM for 3WK-6MO, 0.9µM for
12MO), and then 2µM rotenone plus 4µM Antimycin A; XF assay medium
supplemented with 10mM glucose and 1mM pyruvate.
FAOT (P1-6MO): 0.15mM Palmitate-BSA conjugate followed by two injections of
40µM etomoxir; KHB medium (111mM NaCl, 4.7mM KCl, 1.25mM CaCl2, 2mM
MgSO4, 1.2mM NaH2PO4) supplemented with 0.5mM carnitine, 2.5mM glucose,
and 5mM HEPES.
FAOT (12MO): 4µM Oligomycin, 0.9µM FCCP, and then 2µM rotenone plus 4µM
Antimycin A. Run in four different conditions (with 0.15mM Palmitate-BSA
conjugate or BSA control +/- 30 min 40µM etomoxir pretreatment) to determine
both basal and palmitate-stimulated oxidation as well as reserve capacities for
endogenous and exogenous FA oxidation (215); KHB medium supplemented
with 0.5mM carnitine, 2.5mM glucose, and 5mM HEPES.
GST: 10mM Glucose, 2µM Oligomycin (P1-6MO) or 2µM rotenone plus 4µM
Antimycin A (12MO), and then 100mM 2-deoxyglucose (P1-6MO) or 100μM
Monensin (12MO) to additionally ascertain maximal and glycolytic reserve
capacities (216); XF base medium. Proton production rate (PPR) was calculated
as described by Mookerjee et al (217).
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Oil Red O Staining and Quantification
Following euthanasia, right ventricle section from 12MO hearts were frozen in
optimal cutting temperature (O.C.T.) tissue preservative (Sakura Finetek) and stored at
-80C. Batched hearts were sectioned (10μm), fixed with 40% formaldehyde, stained for
10 min with Oil Red O (Sigma-Aldrich) suspended in 98% isopropanol, stained with
hematoxylin (background), and blued in ammonia water before mounting. Five to six
images per heart were systematically captured using an Aperio Versa 8 microscope
(Leica Biosystems) at 40x magnification. Oil Red O was systematically quantified using
ImageJ (NIH) with Color Threshold settings of Hue at 119-210 (no pass), Saturation at
4-255, and Brightness at 66-195.
Mitochondrial DNA Copy Number
Snap-frozen hearts from all five time points were used to isolate total DNA using
a Qiagen DNeasy Blood and Tissue Kit according to manufacturer’s instructions.
Relative mtDNA copy number was then determined using real-time PCR as previously
described (7). All reactions were performed in triplicate using ABsolute Blue QPCR Mix
(Thermo Fisher Scientific) and a Stratagene Mx3000P thermocycler (Agilent
Technologies). Primers were designed for cytochrome-c oxidase I (Mt-co1; Thermo
Fisher). Methods were previously validated using a second primer for mitochondrial
control region (D-loop; Integrated DNA Technologies) as previously described (7).
Gene-specific standard curves were generated with MxPro software (Agilent
Technologies) and used to calculate relative mtDNA copy number.
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Permeabilized Cell Analyses
To determine mitochondrial electron transport chain complex function, CM from
P1 and 12MO CM mitochondria were evaluated using extracellular flux analyses after
permeabilization via 1nM Seahorse XF Plasma Membrane Permeabilizer as described
by Salabei et al (218). CM isolation was as described for MST, GST, and FAOT above
and methods were technically similar and illustrated in Figure 11A. Key exceptions
include: CM were only washed once and assay was started immediately following wash.
MAS assay medium (220mM mannitol, 70mM sucrose, 10mM KH2PO4, 5mM MgCl2,
2mM HEPES, 1mM EGTA, 0.6% FA-free BSA) was heated to 37C with pH adjusted to
7.20 before washing. Seeding density, fuel and drug doses were validated at each time
point according to the manufacturer’s recommendations. Injection strategies were as
follows (listed concentrations are final):
P1 CM: (10mM methyl pyruvate plus 2mM dichloroacetate plus 1mM malate) or
(4mM glutamine plus 1mM malate) or (40µM palmitoyl-L-carnitine plus 1mM
malate) or (10mM succinate) or (0.5mM duroquinol) or (0.1mM N,N,N′,N′tetramethyl-p-phenylenediamine (TMPD) plus 5mM ascorbate) with 4mM ADP
and 1nM XF PMP permeabilizer, next 2µM Oligomycin, and then lastly (2µM
rotenone plus 4µM Antimycin A for complex I and II wells) or (40mM sodium
azide for complex III and IV wells).
12MO CM: Modification to P1 CM methods include the following differences:
50µM palmitoyl-L-carnitine, 0.5mM TMPD, and 2mM ascorbate. ADP and
permeabilizer were added to final wash step, prior to the run (rather than with first
injection as in P1 CM). This was done to ensure more time for complete
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permeabilization. Lastly, while evaluating complex III oxidation of duroquinol, a
second injection of 40mM sodium azide was done to ensure complete inhibition
prior to TMPD/ascorbate.
FCCP Challenge
Staining and Imaging: 12MO CM were transferred from MEM to 2mL confocal
solution (Seahorse XF Assay Medium [Agilent] + 10mM D-(+)-glucose [Sigma] + 1.0mM
sodium pyruvate [Sigma]) containing 1.0μM MitoTracker Green FM (Invitrogen,
Waltram, MA) + 2.0μM Hoechst 33342 (AnaSpec, Fremont, CA) + 15nM
Tetramethylrhodamine Ethyl Ester Perchlorate (TMRE) (Invitrogen) or 1.0μM
LysoTracker Red DND-99 (Invitrogen) and incubated for 20 minutes at 37C with
humidified, 2% CO2. CM were washed twice with 1xPBS and given fresh confocal
medium for imaging. All staining procedures were conducted in minimal lighting with
dark tubes and light-protected culture dishes to minimize photobleaching.
Images were captured using a Nikon A1 TIRF Ti-Eclipse inverted confocal
microscope (Nikon Instruments Inc., Melville, NY) equipped with a live cell chamber
(37C with humidified 5% CO2), Nikon Perfect Focus System, injection apparatus, and
NIS-Elements AR image acquisition software (version 5.02; Nikon). Individual CM were
selected for imaging in a standard manner by a single technician based on morphology
and stain quality at the start of imaging. Baseline images were obtained and video was
captured using Perfect Focus System throughout. Two minutes after beginning video
acquisition, FCCP was cautiously injected (final concentration = 0.6µM) as not to
interrupt the cells. Imaging was maintained through cell death. Importantly, each video
capture was performed using standardized parameters at x60 magnification and
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1024x1024 pixels with 1.1µs pixel dwell (6.27 seconds/frame). Representative videoimages are shown in Figures 13 and 14. Representative videos of mitophagy, MMP
loss, and cell death can be found online at the following URL:
https://www.sciencedirect.com/science/article/pii/S2589004220309433
Image Analyses: NIS-Elements’ Measure tool was used to estimate baseline cell
morphology and time to cell death by retraction, defined as the first post-FCCP frame in
which cell length became 50% of baseline. Videos were exported as sequential Tagged
Image Format (TIF) files into High-Content Screening (HCS) Navigator software
(version 6.6.0; PerkinElmer, Waltham, MA) using the Image Import and Conversion
Tool. Following conversion, videos were analyzed using HCS Colocalization.V4 protocol
for TMRE intensity, colocalization, and time to cell death by pyknosis, defined as the
first post-FCCP frame in which nuclear area became 90% of baseline. ROI recognition
settings were adjusted to place a mask around the CM of interest from each frame. This
step was necessary to remove artifacts and focus on individual CM. ROI settings were
standardized between all samples. Data were exported using the HCS Data/Image
Export Tool.
Protein Isolation and Western Blotting
Left ventricle sections were homogenized and sonicated in RIPA (150mM NaCl,
50mM Tris (pH=7.5), 1% Triton X, 0.5% deoxycholate, 0.1% sodium dodecyl sulfate)
supplemented with cOmplete Protease Inhibitor Cocktail (Roche, Indianapolis IN) and
phosphatase inhibitor cocktail (Sigma-Aldrich, St. Louis, MO). Proteins were quantified
using DC Protein Assay (Bio-Rad, Hercules, CA) and Cytation3 plate reader (BioTek,
Winooski, VT). Western solutions were prepared with Laemmli and beta53

mercaptoethanol, heated at 95C for 5 min, and run through 4-15% Criterion TGX gels
(Bio-Rad) alongside EZ-Run Prestained Rec Protein Ladder and MagicMark XP
Western Protein Standard (Thermo Fisher, Waltham, MA). 20µg protein was loaded per
lane. Transfer to PVDF membranes was performed using Trans-Blot Turbo Transfer
System (Bio-Rad). Membranes were blocked for 10 min in 10% Clear Milk Blocking
Buffer (Thermo Fisher) before overnight incubation with primary antibody at 4C.
Following TBS-T washes, membranes were again blocked and incubated 1 hr in
secondary antibody. Membranes were washed four times before imaging with Luminata
Forte HRP Chemiluminescence Substrate (Thermo Fisher) and ChemiDoc MP Imaging
System (Bio-Rad) with Image Lab Touch Software (version 2.2.0.08; Bio-Rad).
Densitometry was performed using VisionWorks LS Analysis Software (version 8.1.2,
UVP, Upland, CA). Before analysis, image brightness and contrast was uniformly
adjusted using Adobe Photoshop (version 13.0; Adobe Inc., San Jose, CA) to capture
bands in their entirety. Beta-actin served as reference protein (Figure 16D). All
antibodies are shown in Table 5.
Experimental Optimization
Non-experimental rats were used to optimize cell seeding densities, reagent
concentrations, and staining/imaging parameters. To do this, CM were isolated from
each time point as described above and seeded onto Seahorse XF24 V7 PS cell culture
microplates or FluoroDishes. MST (see above) was used to determine the FCCP
concentrations that elicit maximal respiratory capacities. MST methods have previously
been described in detail (7, 11), but optimization steps for this study compared 0.11.2μM FCCP. Although 0.9μM FCCP elicited the maximal respiratory capacity in plated
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12MO CM, the concentration causing the second-highest response (0.6μM) was chosen
to prevent over-stressing and immediate cell death under harsher confocal imaging
conditions.
Statistical Analyses
All statistical analyses were conducted using Prism 7.05 (GraphPad Software)
and are represented as mean ± standard error of the mean. Statistical parameters
including replicate numbers (n) are shown in tables and figure legends. Diabetes, diet,
and interaction effects were evaluated by two-way ANOVA. When a significant
interaction was present, data were analyzed by one-way ANOVA with Dunnett post-test
to compare each treatment group (diabetes, HF diet, or combination) to controls. Sexspecific comparisons were interrogated by two-tailed, unpaired t-test. For mitolysosome
formation, Pearson correlation coefficient values were calculated from baseline to time
of cell death for each video frame and interrogated by linear regression analysis.
Baseline levels of mitolysosomes and rate of mitolysosome formation were analyzed by
ANOVA as described above. Rate of mitochondrial biogenesis, defined as the rise in
mitochondrial copy number over time (P1 to 12MO), was also interrogated using similar
linear regression analyses. To compare age-related differences, one-way ANOVA was
used to compare time points within exposure groups and linear regression analysis and
two-way ANOVA were used to compare rates of change between groups from P1 to
12MO. Statistical significance was set to P<0.05 for all cases.
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Results
In utero exposure to maternal glucolipotoxicity increases offspring mortality, even when
newborns are reared by normal mothers and metabolic syndrome is absent
We have used a well-characterized rat model to study individual and compounding
consequences of late-gestation diabetes, maternal HF diet, and the combination on
maternal, placental, and newborn offspring outcomes (7-9, 121, 122). To date, we have
evaluated 1265 offspring from 118 litters (29 controls, 29 diabetes-exposed, 32 dietexposed, and 28 combination-exposed). The model consistently exposes developing
offspring to a triad of maternal hyperglycemia, hyperlipidemia and fetal hyperinsulinemia
in the last third of pregnancy. All live-born offspring had cardiac function evaluated by
echocardiography on P1. Litters were culled to equal size and cross-fostered to normal
dams for follow-up at 3WK, 10WK, 6MO, and 12MO (Figure 3). The complete course of
72 offspring (n=15-21/group) from 21 litters (n=5-6/group) was followed from P1 to 12MO.
Maternal characteristics are shown in Table 3, and offspring characteristics are shown in
Table 4 and Figure 4. Consistently, dams on HF diet (n=60) gain more weight than peers
on control diet (n=58). Diabetic dams (n=57) have hyperglycemia in the last third of
pregnancy; blood glucose levels are maintained at 200-400mg/dL using twice-daily sliding
scale insulin. HF diet in combination with streptozotocin-induced diabetes increases
insulin needs (22±3 total units from GD15-21 vs 19±3 units with diabetes alone), but with
sliding scale treatment, diabetic and combination dams have no significant diet-related
difference in blood glucose. Ketone, serum triglyceride (TG) and non-esterified fatty acid
(NEFA) levels are higher in diabetic and HF diet-fed dams; TG and NEFA are
approximately 2-fold higher in diabetic dams, 2- to 3-fold higher in HF-fed dams, and 4to 5-fold higher in combination. Total and HDL cholesterol are not different, but dams on
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HF diet have higher non-HDL cholesterol. Although litter size does not vary by group
(Table 3), newborn offspring born to HF-fed dams have a 13% higher perinatal mortality
rate regardless of diabetic status (Tables 2.4). Perinatal mortality is attributed to a
combination of stillbirths (122), pulmonary hypertension (121), and cardiomyopathy (7).
After P1, surviving diet-exposed offspring trend towards higher natural mortality over time
(p=0.086) with most deaths occurring between P1 and 3WK and combination-exposed
offspring at greatest risk (10%).

Figure 3. Schematic representation of Sprague Dawley rat model for maternal
late-gestation diabetes and high-fat diet.
GD, gestational day; STZ, streptozotocin; P, postnatal day; WK, weeks; MO, months.
Figure has been adapted from Louwagie, E.J., et al. iScience (2020).
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Figure 4. Offspring cardiometabolic characteristics over time show absence of
metabolic syndrome in adulthood.
(A) Offspring weight (B), serum triglyceride levels (C), and whole blood glucose levels (E)
over time with 12MO offspring delineated by sex. (D) Neonatal insulin, C-peptide, and
12MO hemoglobin A1C levels. Although not marked, body weight (A) and TG levels (B)
were significantly higher in males than females. Data represent mean ± SEM. P ≤ 0.05:
+diabetes

or *diet effect by 2-way ANOVA, ^group effect by 1-way ANOVA and Dunnett

post hoc test when interaction by 2-way ANOVA was significant. NP1=216-250
offspring/group, N3WK=27-41, N10WK=21-35, N6MO=4-9, N12MO=15-20 (A, C); NP1=32-57,
N3WK,10WK=14-24, N6MO=9-10, N12MO=15-16 (B). NP1=75-137, N12MO=8 (D). Figure has
been adapted from Louwagie, E.J., et al. iScience (2020).
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Maternal glucolipotoxicity increases cardiac mass and impairs function in newborn and
aged offspring with an intermediate normalization period
Full morphometric and functional measurements are detailed in Table 7 and agerelated differences are summarized in Table 8. As expected, normal rats have significant
growth over time with a ~60- and 100-fold increase in body weight for females and males
respectively. Heart size increases correspondingly with a ~35- and 40-fold increase in
heart weight and ~30- and 50-fold increase in left ventricular mass from P1 to 12MO.
Although smaller at birth, diet-exposed females gain more weight over time (p=0.014). At
P1, HF diet-exposed offspring have ~13% larger heart:body weight ratios than controls
(Figure 5A). The difference is largely found in combination-exposed males and associated
with higher mortality (Figure 6; Table 6). Like in human infants born to diabetic mothers,
cardiac mass normalizes after birth (38, 39, 171) with no apparent differences from 3WK
to 6MO. In normal females, heart weight increases steadily up to 12MO, but diabetesexposed females lose 20% of heart mass from 6 to 12MO (p=0.019). In contrast, normal
male heart mass increases until 6MO then declines; diabetes- and diet-exposed male
hearts continue to increase in mass from 6 to 12MO. This results in diet-exposed males
having significantly larger heart:body weight ratios at 12MO. Left ventricular mass and
cardiac function by echocardiography follow a similar pattern (Figure 5B-D). As expected,
both diastolic and systolic function increase with growth. Control females and males have
~14% and 7% increases in Ejection Fraction, ~16 and 10% increases in shortening
fraction, and 3- and 2-fold increases in E:A ratio from P1 to 12MO respectively with the
biggest changes from P1 to 3WK (Figure 5). Cardiac output increases 12- and 14-fold for
females and males over a lifetime.
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Both systolic and diastolic function are poorer in diabetes- and diet-exposed P1
offspring (Figure 5C-D). Systolic function is more negatively affected by maternal HF diet
in females and by maternal diabetes in males (Table 7). Diastolic function is poorer in
diet-exposed newborns, especially females. Combination-exposed P1 offspring (of both
sexes) have the poorest function, suggesting dietary fat is a modifiable risk factor. Cardiac
function improves after birth with no apparent differences until late adulthood. At 12MO,
diabetes-exposed, but not diet-exposed females have poorer systolic function (Figure 5C)
and males have poorer diastolic function (Figure 5D). Despite measurable differences in
cardiac function, frank heart failure leading to differences in serum brain natriuretic
peptide (BNP) levels is not found (Table 4). As in previous studies (121), diet-exposed P1
offspring of both sexes have pulmonary hypertension (Table 7); this is not found in
surviving offspring at later time points but may be confounded by early mortality. Overall,
diabetes- and diet-exposed offspring have larger hearts and cardiac dysfunction at birth,
intermediate improvement, and reemerging dysfunction in late adulthood. As shown
below, the P1 and intermediate normalization corresponds with initial improvement in
bioenergetics (Figures 7, 8, and 9), however a second decline in bioenergetics at 6MO
precedes cardiac dysfunction at 12MO.
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Figure 5. Exposed offspring are born with cardiomyopathy that improves after
birth but reemerges at 12MO.
(A) Heart:body weight ratios over time with 12MO offspring separated by sex. NP1=216250 offspring/group; N3WK=27-41; N10WK=21-35; N6MO=4-9; N12MO=15-20. (B-D) LV mass
(B), systolic function per ejection fraction (C), and diastolic function per E:A ratio (D) over
time with 12MO offspring separated by sex. NP1=119-144 offspring/group; N3WK=18-30;
N10WK=10-19; N6MO=17-28; N12MO=15-18. Although not marked, heart:body weight and
ejection fraction are both significantly higher in normal females than males while LV mass
is higher in males. Data represent mean ± SEM. P ≤ 0.05: +diabetes or *diet effect by 2way ANOVA, ^group effect by 1-way ANOVA and Dunnett post hoc test when interaction
by 2-way ANOVA. Figure has been adapted from Louwagie, E.J., et al. iScience (2020).
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Figure 6. Perinatal mortality in exposed offspring is associated with significantly
larger hearts.
(A) Perinatal mortality was calculated as: (litter size – live pups)/litter size x 100. N=2026 litters/group. Litter size was confirmed by post-mortem evaluation of both uterine horns
to count obvious placentation points, retained fetuses and dead P1 offspring as well as
the number of live pups found in the cage. (B) Heart:body weight ratios of live P1 offspring
with sexes combined and divided. N=216-243 offspring/group. (C) Heart:body weight
ratios of both living and dead P1 offspring. N=257 living, 42 dead offspring. Data represent
mean ± SE. P ≤ 0.05: +diabetes or *diet effect by 2-way ANOVA, χsignificant difference
by Student’s T-test. Figure has been adapted from Louwagie, E.J., et al. iScience (2020).
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Aged offspring exposed to maternal glucolipotoxicity during fetal development have
cardiomyocyte specific phenotype that cannot be explained by systemic metabolic
disease
Offspring’s metabolic phenotype is detailed in Figure 4 and Table 4. At birth,
combination-exposed P1 offspring have higher whole blood glucose levels (Figure 4C).
While circulating TG, total and HDL cholesterol are not different between groups, diet- but
not diabetes-exposed P1 offspring have higher non-HDL cholesterol (Figure 4B; Table
4). Diabetes- and HF diet-exposed offspring have higher serum insulin and C-peptide
levels (Figure 5D; Table 4) at birth with combination-exposed being most affected with 2to 4-fold higher levels. Diet-exposed offspring weigh less at birth, but diet-exposed
females gain weight faster, catching up to peers at 3WK (Figure 4A). Past 3WK, adult
males from all groups weigh more than group-matched females. By sex, weight is similar
across groups at 10WK and 6MO, but by 12MO diet-exposed females weigh more than
controls. This difference is not seen in males or diabetes-exposed offspring that develop
cardiac dysfunction. Although neither fasting insulin nor euglycemic clamps were
performed, our adult offspring do not appear to develop frank diabetes (blood glucose
>200mg/dL; Figure 4C), and glycated hemoglobin (HbA1c) levels are not different by sex
or exposure (Figure 4D). On average, adult males have 2-fold higher TG than groupmatched females (Figure 4B); this sex-specific difference reaches significance at 12MO
(p<0.03). By group, offspring have similar circulating lipids at 3WK. At 10WK, diabetesand diet-exposed offspring have transiently higher serum TG levels (Figure 4B) that
dissipate at 6 and 12MO. Offspring do not have evidence of fatty liver (Table 4).
Adipocytokine levels (leptin or adiponectin) are similar until 6MO when diet-exposed, but
not diabetes-exposed offspring develop transiently higher adiponectin levels (Table 4).
This is not seen at 12MO. Neither renin nor soluble adhesion molecules (E-selectin and
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ICAM-1), known markers of vascular disease (219), are higher in exposed adult offspring.
Overall, cardiac disease in diabetes-exposed adults is not explained by evidence of
metabolic syndrome or markers of vascular disease. This suggests intrinsic cardiac
pathology and supports our hypothesis that mitochondrial dysfunction plays a central role.

Impaired cellular bioenergetics and an exaggerated age-related increase in
mitochondrial number precede poorer cardiac function in aged offspring
Respiratory, fatty acid oxidation (FAO), and glycolytic capacities of primary CM
from each exposure group were followed over time using extracellular flux analyses and
are detailed in Figures 7, 8, and 9. Over the course of development, basal respiration and
palmitate oxidation respectively increase 70- and 30-fold in control CM alongside a 5-fold
increase in mitochondrial copy number. As in previous studies, diabetes-exposed P1 CM
have lower basal, maximal, and reserve respiratory capacities (Figure 7A-C) which
translates to a lower respiratory control ratio (RCR; Figure 7D) (7). Diet-exposed P1 CM
also have lower basal respiration so that combination-exposed CM have the poorest
respiratory capacity. After P1, prenatally exposed 3WK CM still have poorer basal
respiration, but no differences remain by 10 weeks. With further maturation and
increasing reliance on OXPHOS, 6MO diabetes- and diet-exposed CM have significantly
lower maximal and reserve respiratory capacities than controls so that combinationexposed CM have a 5-fold lower RCR and little to no respiratory reserve. Importantly,
impaired bioenergetics precede cardiac dysfunction at 12MO. Between 6MO and 12MO,
there is an exaggerated increase in mitochondrial copy number (Figures 7D) so that
12MO diet-exposed CM have higher basal respiration and consume more oxygen to
make ATP (Figure 7A and E). This is especially pronounced in diet-exposed females and
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combination-exposed males. Proton leak does not increase with mitochondrial number
(Figure 7F), which suggests higher oxidative stress and risk of mitochondria-mediated
cell death.

Figure 7. Diabetes- and HF diet- exposed newborns have impaired mitochondrial
respiration that initially improves but reemerges at 6MO as developmental
reliance on OXPHOS increases.
(A-C) Basal (A), FCCP-stimulated maximal (B), and reserve (C) respiratory capacities
over time with 12MO offspring separated by sex. Reserve capacity was calculated by
subtracting basal from maximal respiration. (D-F) Mitochondrial stress test was used to
calculate respiratory control ratios (D), ATP-linked oxygen consumption (E), and
mitochondrial proton leak (F) over time with 12MO offspring separated by sex. Assay
medium was supplemented with glucose and pyruvate. NP1=4-7 per group; N3WK=4-5;
N10WK=3-4; N6MO=3; N12MO=7-11. Data represent mean ± SEM. P ≤ 0.05: +diabetes or
*diet effect by 2-way ANOVA, ^group effect by 1-way ANOVA and Dunnett post hoc test
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when interaction by 2-way ANOVA, and δsex-specific effect by Student’s T-test. Figure
has been adapted from Louwagie, E.J., et al. iScience (2020).

In line with respiration, diabetes-exposed P1 and 6MO offspring have impaired
ability to oxidize palmitate (Figure 8). In all groups, response to palmitate is lowest at P1,
and palmitate-stimulated oxidation steadily increases 30-fold from P1 to 12MO (Figure
8A; Table 8). At 12MO, FAO is primarily of endogenous or stored lipids with minimal ability
to increase with exogenous palmitate (Figures 8B-C). Diet-exposed female CM have
higher basal and maximal endogenous FAO leaving little additional reserve capacity
(Figure 8B). Conversely, diabetes- and diet-exposed male CM have lower endogenous
FAO than group-matched females (P=0.001), yet combination-exposed male CM have
very little FAO reserve capacity. Although tissue staining does not detect differences in
lipid droplet count between groups (Figure 9A-D), diet-exposed hearts of both sexes have
lower expression of adipose differentiation-related protein (ADRP), a lipid droplet
associated protein (Figure 9E) which correlates with less endogenous storage in this
exposure group. (220). In females, this could be explained by depletion due to greater
basal and maximal endogenous FAO (Figure 8B). Conversely, diabetes- and dietexposed male CM have lower FAO than age-matched females (p=0.001); paired with
fewer stores and impaired FAO reserve capacity, findings suggest programmed
perturbations in cardiac lipid metabolism.
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Figure 8. Diabetes-exposed newborns have impaired palmitate oxidation that
reemerges at 6MO, but at 12MO diet-exposed have higher endogenous FAO
associated with higher depleted reserves and mitochondrial biogenesis.
(A) Basal OCR of CM in media without pyruvate, palmitate-stimulated OCR, and
calculated responses to palmitate estimate FAO at each developmental time point. (BC) Basal, maximal, and reserve capacity for endogenous (B) and exogenous FAO (C)
at 12MO. Endogenous vs exogenous FAO determined by the methods of Rogers et al
2014 (215). (D) Mitochondrial DNA copy number at each time point was used to
estimate mitochondrial biogenesis from P1 to 12MO. NP1=4-7 per group; N3WK=4-5;
N10WK=3-4; N6MO=3; N12MO=7-11 (A-C); NP1=10-15 per group; N3WK=4; N10WK=4; N6MO=34; N12MO=6-9 (D). Data represent mean ± SEM. P ≤ 0.05: +diabetes or *diet effect by 2way ANOVA, ^group effect by 1-way ANOVA and Dunnett post hoc test when
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interaction by 2-way ANOVA, and δsex-specific effect by Student’s T-test. Figure has
been adapted from Louwagie, E.J., et al. iScience (2020).

Figure 9. Differences in endogenous FAO levels may be related to altered lipid
storage.
(A) Representative histological images of 12MO right ventricle sections (40x
magnification) stained with Oil Red O and hematoxylin. Endogenous lipid droplets were
quantified using Image J (NIH) to compare numbers of lipid droplets (B), total area of
droplets per section (C), and average droplet sizes (D) from 12MO hearts by sex and
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exposure group. (E) As a surrogate marker for lipid droplets, Western blotting was used
to determine relative expression of adipose differentiation-related protein (ADRP), a
lipid-droplet coating protein that correlates with lipid deposition. Expression was
normalized to the loading control (LC) β-actin. NA-D=6-9; NE=3 per sex per group. Data
represent mean ± SEM. P ≤ 0.05: δsex-specific effect by 2-tailed Unpaired T-test. Figure
has been adapted from Louwagie, E.J., et al. iScience (2020).

Glycolysis is the primary ATP-generating pathway in the newborn heart. Here we
demonstrate that glycolysis remains an important component of cardiac metabolism at all
stages of development. Indeed, older CM have higher basal, glucose-stimulated, and
maximal extracellular acidification rates (ECAR) than P1 CM. At 12MO, a relatively high
rate of basal glycolysis limits response to additional glucose (Figure 10A). In line with
previous findings, diabetes-exposed P1 CM have lower basal, glucose- and oligomycinstimulated ECAR (7). With the exception of a transiently higher oligomycin-stimulated
ECAR in diabetes-exposed 3WK CM, no group related differences remain beyond P1.
Group comparisons of maximal glycolysis in isolated CM over the course of development
should be interpreted carefully. Through multiple validation steps, we found that
oligomycin, which inhibits ATP synthesis by blocking the F0 subunit, results in maximal
ECAR in newborn but not adult CM. The highest ECAR or maximal glycolytic capacity in
adult rat CM is with rotenone/antimycin A respiratory complex inhibition combined with
increased cellular ATP demands using monensin (216) (Figure 10A). Indeed, 12MO rat
CM have a poor ECAR response with glucose or oligomycin, but they do have spare
anaerobic glycolytic reserve capacity under these conditions.

69

To fully interpret our glycolytic results, we calculated the proton production rates
(PPR) to categorize lactate (anaerobic glycolysis) and CO2 (aerobic respiration)
contributions to ECAR (221) (Figure 10B). In doing so, we confirmed previous findings
that fetal exposure to diabetes impairs both anaerobic and aerobic glycolysis in P1 CM
(7). With oligomycin, anaerobic glycolysis remains lower in diabetes-exposed P1 CM.
Beyond P1, basal and glucose-stimulated ECAR is primarily from aerobic respiration
(CO2). At 12MO, diet-exposed female CM have higher PPR from CO2 than controls in
both basal and glucose-stimulated conditions (Figures 10C); this is not surprising
considering the higher number of mitochondria, basal oxygen consumption, and
endogenous FAO in this group (Figures 7-8).
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Figure 10. Diabetes-exposed newborns have impaired glycolytic capacities that
normalize and naturally increase with aging.
Basal, glucose-stimulated, and maximal extracellular acidification rates (ECAR) with
cellular response to glucose (A) and proton production rates (PPR) over time (B) and at
12MO by sex (C). Maximal ECAR and PPR were stimulated with oligomycin in P1-6MO
CM and with rotenone/antimycin A + monensin in 12MO CM. NP1=4-7 per group;
N3WK=4-5; N10WK=3-4; N6MO=3; N12MO=7-11. Data represent mean ± SEM. P ≤ 0.05:
+diabetes

or *diet effect by 2-way ANOVA, ^group effect by 1-way ANOVA and Dunnett

post hoc test when interaction by 2-way ANOVA, and δsex-specific effect by Student’s
T-test. Figure has been adapted from Louwagie, E.J., et al. iScience (2020).
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Exposed offspring have sex-specific and fuel-related differences in complex function
and expression at P1 and 12MO time points
Using real-time extracellular flux analyses of permeabilized P1 and 12MO CM, we
measured oxidation of individual fuels specific to complexes I, II, III, and IV (Figure 11A).
Results, summarized in Table 9, highlight sex-specific differences in mitochondrial
function with aging. In P1 CM, there are no sex-specific differences at baseline or with
added complex fuels. At 12MO, permeabilized control male CM have higher OCR at
baseline (Figure 11B), but females have greater response to pyruvate (I), palmitoylcarnitine (I/III), and TMPD-ascorbate (IV) compared to group-matched males (Figure
11C) which suggests lower oxygen consumption at rest with greater reserve capacity that
is intrinsic to mitochondrial function. Fetal exposure to maternal glucolipotoxicity lowers
oxidation of complex I fuels in P1 CM from both sexes, but exposed females have lower
pyruvate (I) and palmitoyl-carnitine (I/III) oxidation capacity (RCR) while exposed male
CM have lower glutamine (I) oxidation capacity (Figure 11D). At 12MO, diet-exposed
female permeabilized CM have higher basal OCR but lower responses to pyruvate (I),
palmitoyl-carnitine (I/III), and succinate (II); diabetes-exposed 12MO females have lower
oxidation capacity for duroquinol (III) (Figure 11B-D). Interestingly, diabetes-exposed
males have lower basal OCR but higher oxidative response to TMPD-ascorbate (IV)
which may reflect relatively lower flow of electrons through complex I-III but retained
ability to directly oxidize complex IV fuels which requires more O2 (218).
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Figure 11. Diet-exposed females and diabetes-exposed males have fuel-specific
complex I dysfunction at birth and as OXPHOS increases with age consume more
oxygen.
(A) Schematic diagram of mitochondrial respiratory complexes and fuels feeding
electrons into each. OMM, outer mitochondrial membrane; IMM, inner mitochondrial
membrane. (B) Basal oxygen consumption rates (OCR) of permeabilized P1 and 12MO
CM. (C) Oxidative responses to various complex fuels at P1 and 12MO time points by
sex. State3 respiration (OCR) is shown as a percent change from basal OCR. (D)
Oxidation capacity per respiratory control ratios (RCR) at P1 and 12MO time points by
sex, calculated using raw State3 (E) and State4 respiration (F). Dashed lines (C-F)
separate fuels by complexes (I-IV). Data represent mean ± SEM. P ≤ 0.05: +diabetes or
*diet effect by 2-way ANOVA, ^group effect by 1-way ANOVA and Dunnett post hoc test
when interaction by 2-way ANOVA, and δsex-specific effect by Student’s T-test. NP1= 45 per group; N12MO = 4-6. Figure has been adapted from Louwagie, E.J., et al. iScience
(2020).

Although differences in expression of complex proteins are present in exposed P1
offspring hearts of both sexes (Figure 12A), they do not explain complex I dysfunction
observed in permeabilized XF analyses. Regardless, findings emphasize the role of fetal
sex in fuel-mediated cardiometabolic programming even at birth. By 12MO complex
protein expression does not vary by sex as it did at P1, but diabetes-exposed female
hearts have greater expression of SDHA (complex II) and COX5B (complex IV), and dietexposed females have greater expression of NDUFA2 (complex I) (Figure 12B). For
males, findings suggest that our model’s bioenergetic phenotype is due to mechanisms
other than complex protein expression. Taken together, permeabilized CM assays show
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higher O2 consumption for ATP production in diet-exposed female and combinationexposed male CM by different sex-specific mechanisms and suggests these groups are
at higher risk for ROS production and the need for mitochondrial turnover to prevent
mitochondria-mediated cell death.

Figure 12. Cardiac mitochondrial complex expression supports sex-specific
mitochondrial programming in newborns and supports intrinsic complex
dysfunction in aged adults.
Relative expression of mitochondrial complex proteins in P1 (A) and 12MO hearts (B)
by sex, normalized to beta-actin. For NDUFA2, lower (11kDa) band was used for
analyses. Dashed lines separate exposure groups. Data represent mean ± SEM. P ≤
0.05: +diabetes or *diet effect by 2-way ANOVA, ^group effect by 1-way ANOVA and
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Dunnett post hoc test when interaction by 2-way ANOVA, and δsex-specific effect by
Student’s T-test. NP1 = 4-6, N12MO = 3 per sex per group. Figure has been adapted from
Louwagie, E.J., et al. iScience (2020).

Fetal exposure and sex influence physiologic mitophagy in aged offspring CM
Previous work found diabetes- and diet-exposed P1 CM have impaired
mitochondrial dynamism and sex-specific differences in fission- and fusion-related protein
activity that could confer cardioprotection to females (9). Dynamism-related proteins also
regulate mitophagy and mitochondria-mediated cell death (204). To determine whether
fetal exposure- or sex-related differences in mitochondria influence the risk of adult heart
disease, we evaluated physiologic and stress-induced mitophagy in isolated 12MO CM.
Using real-time confocal live-cell imaging, CM were stained with MitoTracker Green,
Hoechst, and LysoTracker Red to quantify mitolysosomes (mitochondria co-localized with
lysosomes) at baseline and their rate of formation following exposure to carbonyl cyanide4-(trifluoromethoxy) phenylhydrazone (FCCP), a respiratory uncoupler which depletes
MMP to drive mitophagy (Figure 13A).
At baseline, there is no difference in the number of lysosomes (Figure 13B), but
the number of co-localized mitolysosomes varies by group and sex (Figure 13A-D).
Diabetes-exposed CM have a higher number of mitolysosomes compared to controls
(Figure 6C) which suggests a need for higher baseline physiologic mitophagy for
mitochondrial quality control. Following FCCP-induced stress, all CM gain a measurable
increase in mitolysosomes, but prenatal exposure influences the rate of formation. While
diet-exposed CM have the lowest number of mitolysosomes at baseline, the rate of
formation following stress is significantly faster (Figure 13E). Female and male offspring
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were analyzed separately. At baseline, control female CM have a higher number of
mitolysosomes than males which suggests higher rates of physiologic mitophagy for
mitochondrial quality control than males; this supports previous findings at P1 (9). Female
and male CM from control offspring have similar rates of mitolysosome formation
following metabolic stress. In females, diet-exposed CM have lower numbers of baseline
mitolysosomes but a significantly faster rate of stress-induced mitophagy (Figure 13D-E).
In males, diabetes-exposed CM have higher numbers of baseline mitolysosomes, but low
rates of stress-induced mitophagy. This is most apparent in combination-exposed male
CM and suggests impaired ability to further cull damaged mitochondria following
metabolic stress (Figure 13E).
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Figure 13. Baseline and stress-induced mitophagy in 12MO CM vary significantly
by sex and fetal exposure.
(A) Representative images of 12MO CM stained with MitoTracker Green, Hoechst, and
LysoTracker Red. Once treated with FCCP, mitochondria lose their membrane potential
and recruit lysosomes to undergo mitophagy. This is reflected by increasing number of
co-localized mitochondria-containing autolysosomes (mitolysosomes) indicated by
orange arrowheads (bottom row, middle-left image). (B) Number of lysosomes at
baseline, before FCCP treatment. (C-E) Computer analyses of live video images
quantified mitolysosome at baseline and over time (C) providing an estimate of
physiologic (D) and stress-induced mitophagy after FCCP (E). Data represent mean ±
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SEM (B, D-E) and linear regression of Pearson correlation coefficient over time (C). P ≤
0.05: +diabetes or *diet effect by 2-way ANOVA, ^group effect by 1-way ANOVA and
Dunnett post hoc test when interaction by 2-way ANOVA, and δsex-specific effect by
Student’s T-test. N=7-11 offspring/group. Figure has been adapted from Louwagie, E.J.,
et al. iScience (2020).

Diabetes-exposed male CM have faster MMP loss and mitochondria-mediated cell
death
Baseline and stress-induced rates of MMP loss and cell death were measured
using confocal live cell imaging and high-content screening analyses of 12MO CM stained
with MitoTracker Green, Hoechst, and TMRE, a marker of MMP (Figure 14A). At baseline,
there are no exposure-related differences in TMRE intensity although diabetes-exposed
CM trend lower (Figure 15A). Immediately after FCCP, CM from all groups lose 25% of
their MMP at similar rates; after this, diabetes-exposed male CM reach 50% and 75%
loss faster than peers (Figure 15B). Thus, the linear rate of MMP loss is significantly faster
in diabetes-exposed CM, particularly males (Figure 14B). There are no sex-specific
differences in baseline TMRE intensity or rate of MMP loss in controls. However,
diabetes-exposed males have a faster rate of MMP loss than group-matched females.
Stress-induced cell death was evaluated by two definitions, the time from FCCP to
CM retraction (50% from baseline) or to pyknosis (Figure 14A). By both definitions, fetal
exposure to maternal diabetes but not HF diet leads to faster cell death in 12MO CM
(Figure 14C-D). The time from 25% MMP loss to retraction or pyknosis is also shorter in
diabetes-exposed CM. Baseline cell length or width does not vary by exposure group but
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diabetes-exposed male CM are slightly longer at baseline compared to females (Figure
15A). Despite this, diabetes-exposed males have a shorter time from MMP loss to
retraction compared to females (p=0.017). Findings demonstrate that the risk of cardiac
cell death following metabolic stress is greater in adult offspring exposed to diabetic
pregnancy and that males are at highest risk.

Figure 14. Diabetes-exposed male CM have faster MMP loss and cell death
following metabolic stress.
(A) Representative images of 12MO CM stained with MitoTracker Green, Hoechst, and
TMRE. Once treated with FCCP, mitochondria lose their MMP and trigger cell death as
seen by retraction and pyknosis. (B) MMP loss (75% from baseline) following FCCPinduced stress and the rate of MMP loss, calculated by linear regression analysis. (C-D)
Retraction and pyknosis, markers of CM death, were defined as the time from FCCPinduced stress to 50% original cell length (C) or to 10% loss in nuclear area (D),
respectively. Time from start of MMP loss to either was calculated from a starting point
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of 25% MMP loss. Data represent mean ± SEM. P ≤ 0.05: +diabetes effect by 2-way
ANOVA, δsex-specific effect by Student’s T-test. N=8-11 offspring/group. Figure has
been adapted from Louwagie, E.J., et al. iScience (2020).
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Figure 15. Imaging 12MO adult rat CM have similar measured MMP and are
morphometrically similar before FCCP-induced stress.
(A) Before FCCP, there were no significant differences in TMRE fluorescent intensity,
cell length, or cell width with the exception of diabetes-exposed males being slightly
longer than their female peers. (B) Following FCCP injection, CM lose up to 25% of
their MMP at similar rates. Thereafter, diabetes-exposed male CM reach 50% and 75%
loss at significantly faster rates than controls. Data represent mean ± SEM. N=4-6
offspring/group per sex. Significant differences (p≤0.05): δsex-specific effect by 2-tailed
T-test. Figure has been adapted from Louwagie, E.J., et al. iScience (2020).

Dynamism- and mitophagy-regulating proteins vary by sex and prenatal exposure
We have shown that P1 CM have impaired dynamism by sex-specific differences
in fusion and fission proteins (9). Here we compare expression of fission (DRP1, MFF,
and MTFP1), fusion (MFN1, MFN2, and OPA1), and mitochondria-mediated cell death
(VDAC, DAP3, and CYPD) proteins in 12MO offspring hearts to understand potential
moderation of mitophagy and cell survival in adult CM (204) (Figure 2). For fission
proteins (Figure 16A), diet-exposed females had higher expression of DRP1 yet lower
expression of its binding partner, MFF. Diabetes-exposed males had higher expression
of DRP1 and diet-exposed males had higher expression of MTFP1. For fusion proteins
(Figure 16B), neither MFN1 nor MFN2 expression was significantly different, but OPA1
was lower in diet-exposed hearts of both sexes. Of the proteins regulating mitochondriamediated cell death (Figure 16C), DAP3 expression was 3-fold lower in combinationexposed females compared to controls.
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Sex-specific comparisons are detailed in Table 10. Normal males had 5-fold
higher expression of pro-fission DRP1 and 5-fold lower expression of MFF than females
(Figure 16A). Diabetes-exposed males also had 3.4-fold lower expression of MTFP1.
There were no differences in total (70+86kDa) MFN1 or 70kDa MFN1(Figure 16B), but
the expression of 86kDa MFN1 was higher in control and diabetes-exposed male
hearts. As a result, the ratio of 70:86kDa was 2- and 3-fold higher in control and
diabetes-exposed females compared to corresponding males. Diabetes-exposed males
had lower expression of MFN2. OPA1 expression was not different between sexes.
Importantly, regulators of mitochondria-mediated cell death varied by sex (Figure 16C).
Compared to females, male hearts had 2.8- to 3.8-fold lower expression of VDAC and
3- to 4-fold higher expression of CYPD. These findings, alongside lower physiologic
mitophagy, suggests poorer mitochondria quality control and higher risk of
mitochondria-mediated cell death by necrosis in males.
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Figure 16. Expression of proteins involved in mitochondrial dynamism and
mitochondria-mediated cell death in the adult offspring heart.
Western blots and densitometry analyses reveal exposure-dependent and sex-specific
differences in (A) fission proteins (DRP1, MFF, and MTFP1), (B) fusion proteins (MFN1,
MFN2, and OPA1), and (C) mitochondrial regulators of cell death (DAP3, VDAC, and
CYPD) involved in these pathways. (D) Protein expression was normalized to loading
control β-actin, and data points represent individuals from different litters. Ladder
locations are marked on the right side of each immunoblot. Blot borders are delineated
by black lines. Combined sexes analyses are not shown as intense sex-specific
differences are apparent. Data represent mean ± SEM. N = 3 offspring/group per sex.
Significant differences (p≤0.05): δsex-specific effect by 2-tailed T-test with >2-fold
expression difference, *diet effect by 2-way ANOVA, ^group effect significant by 1-way
ANOVA and Dunnett's post hoc test when interaction was significant by 2-way ANOVA.
Figure has been adapted from Louwagie, E.J., et al. iScience (2020).
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Discussion
This study shows that offspring exposed to glucolipotoxicity during fetal
development have mitochondrial dysfunction with disturbed cardiac bioenergetics
across development, even when postnatal influences are similar. Specifically, after birth
as the heart increasingly relies on OXPHOS, bioenergetic disturbances result in
exaggerated mitochondrial biogenesis, higher OCR, poor reserve capacity, and faster
mitochondria-mediated CM death as aged adults. Findings confirm and build upon
previous work showing mitochondrial dysfunction, cardiomyopathy and higher mortality
in exposed newborn offspring, and like humans, cardiac hypertrophy, dysfunction and
bioenergetics improve by weaning. However, impaired OXPHOS at 6MO precedes a
functional decline in cardiac function at 12MO. This indicates a causal rather than a
responsive change. Additionally, this study validates a reproducible and objective set of
imaging studies to quantify baseline and FCCP-induced mitophagy alongside rates of
mitochondria-mediated cell death. This ‘heart attack in a dish’ assay shows that
diabetes-exposed adult CM have faster MMP loss and mitochondria-mediated cell
death under metabolic stress that could impart more cardiac damage following AMI. Our
findings establish a role for mitochondria in myocardial programming and the fetal origin
of adult heart disease that is outside secondary cardiovascular risks like metabolic
syndrome or vascular disease.
Overall, findings add to mounting evidence that maternal glucolipotoxicity
negatively impacts offspring’s cardiac health into adulthood (106, 112, 123, 222),
partially through programmed changes in mitochondrial function (2, 132, 223, 224).
While lasting mitochondrial consequences following fetal exposure to hyperglycemia or
hyperlipidemia have been reported by others (123, 126, 178, 225), this study goes
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further to comprehensively evaluate individual and combined effects of fetal exposures
on mitochondrial function as it relates to cardiac health over time. Following
bioenergetic changes during maturation and aging confirms the increasing cardiac
reliance on OXPHOS over time. To support this energetic demand, mitochondrial copy
number increases over 5-fold from P1 to 12MO with the greatest rise between 6MO to
12MO. Importantly at 6MO when normal hearts rely on OXPHOS and FAO for ATP
generation (14, 226), prenatally exposed offspring have impaired respiratory and FAO
capacities. This leads to an exaggerated increase in mitochondrial copy number which
rises 5- to 7-fold in diet- and combination-exposed offspring respectively. Given the
combined data (mitochondrial copy number, basic bioenergetics assays and
permeabilized complex analyses), it is likely that prenatal exposures affect both number
and quality of mitochondria to influence cardiac risk over a lifetime. Authors propose
these exposure-related changes increase the risk of heart failure and cardiac damage
from AMI in aged adults. This is supported by poorer diastolic function, faster MMP loss,
and cell death under stress in diabetes-exposed adult males and poorer systolic
function in diabetes-exposed females. By permeabilizing plasma membranes,
mitochondrial complex function was evaluated independent of fuel transport and storage
differences. Even then we found increased oxygen consumption and blunted responses
to complex I fuels in 12MO diet-exposed female mitochondria. Taken together, limited
fuel flexibility and depleted oxidative reserve capacities alongside age-related reliance
on aerobic metabolism leaves little room for ATP production under ischemic conditions,
such as AMI, which are reportedly higher in adults exposed to diabetic or obese
pregnancy (112, 183).
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Mitochondrial function is an important component of ischemia/reperfusion injury
(227). Excessive mitophagy leads to CM death and loss of cardiac contractility, both
primary causes of cardiac damage and heart failure following AMI (228). It is well-known
that adults with long-standing diabetes suffer greater rates of diabetic cardiomyopathy
and higher mortality from AMI (229). It is plausible that in utero exposures incite similar
cardiac risks, and our study confirms lasting effects through mitochondria-mediated
pathways. While frank heart failure was not found, the faster stress-induced MMP loss
and cell death in 12MO diabetes-exposed male CM may translate to more robust
cardiac damage following increased energetic demands or AMI (228). Although these
consequences were not seen in diet-exposed offspring, their higher mortality rates
(Table 6) may have eliminated susceptible offspring. For this reason, we cannot
conclude that functional and in vitro data represent all HF diet-exposed offspring rather
than the least severely affected that survived to 12MO. Also, this may have contributed
to the seemingly higher systolic function in 10WK diet-exposed offspring. Another
explanation could be FA-induced mitochondrial biogenesis contributing to a faster
glycolytic-to-respiratory metabolic shift (11), boosting cardiac contractility at 10WK but
increasing oxidative stress and advancing “aging.”
We also identified sex-specific differences in mitochondria that explain relative
cardioprotection for females. We first identified sex-specific and exposure-related
differences in dynamism at birth (9) and here we report additional sex-specific
differences in complex I fuel oxidation (Figure 11) and complex protein expression at P1
(Figure 12). These findings emphasize the role of fetal sex in fuel-mediated cardiac
health, even as early as the perinatal period. We go further to describe programmed

88

differences in respiration, complex fuel preference, and mitophagy in aged adults.
Taken together, females appear to have better mitochondrial quality control
mechanisms. Additionally, adult females are more negatively affected by fetal exposure
to maternal HF diet while males are more negatively affected by diabetes. If this
translates to humans, dietary interventions could be clinically useful for personalized
risk prevention. Finding both exposure- and sex-specific differences in bioenergetics
and mitochondria-mediated cell death suggests that programmed mitochondrial
dysfunction is caused by damage from adverse in utero conditions rather than maternal
inheritance that would pass to both sexes alike. This is also supported by our model
which induces diabetes in the last 1/3 of pregnancy rather than prenatally.
To uncover additional mechanistic differences in mitophagy and cell death
between sexes and exposure groups, we used immunoblotting of key proteins that
regulate these mitochondrial pathways (Figure 16 and Table 10). DRP1-mediated
fission is important in culling damaged or dysfunctional mitochondria to maintain a
healthy mitochondrial network (191, 230). Because DRP1 is recruited to the OMM by
MFF (190), higher DRP1 expression alongside lower MFF in diabetes-exposed males
suggests impaired DRP1 recruitment (231). Indeed, DRP1 expression and mitophagy
were inversely related; lower physiologic mitophagy in diabetes-exposed males
corresponded to faster cell death following FCCP challenge. Purnell and Fox showed
that increasing cellular autophagy leads to lower DRP1 levels (232). Although their
study was not in cardiomyocytes, this relationship between DRP1 and autophagy
appears evident in our model. MTFP1 regulates fission through DRP1 phosphorylation
and recruitment (205), and MTFP1 overexpression induces mitochondrial fragmentation
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(233). MTFP1 expression was higher in HF diet-exposed male hearts yet did not reflect
a change in cell death.
Besides coordinating mitochondrial fusion, MFN1, MFN2, and OPA1 play
additional roles in cell death. MFN1 is phosphorylated by extracellular-signal-regulated
kinase (ERK) which increases susceptibility to apoptotic stimuli (234). Insulin and
insulin-like growth factors are well-known regulators of ERK. This warrants additional
study, especially since the 70:86kDa MFN1 ratio was lower in males and corresponded
with lower levels of physiologic mitophagy. MFN2 has roles in mitophagy(191) and MPT
under cardiac stress(206). Hamasaki et al. showed that a MFN2 knockout had impaired
autophagosome formation (235), an essential final step in mitophagy. In our model,
MFN2 expression was significantly lower in diabetes-exposed male hearts; alongside
lower rates of physiologic mitophagy, this supports faster cell death by necrosis rather
than apoptosis. OPA1 affixes IMM points to ensure cristae structure(204) and confer
resistance to physiologic stress(236, 237). HF diet-exposed hearts of both sexes had
lower expression of ‘short’ OPA1, but only diet-exposed females had faster stressinduced mitophagy which suggests dominance of other mitophagy regulators in male
CM.
DAP3, VDAC, and CYPD regulate mitochondria-mediated intrinsic apoptosis and
MPT-driven necrosis, the major cell death pathways following FCCP. DAP3 canonically
phosphorylates DRP1 at Ser637 (pDRP-Ser637) to reduce fission (208). DAP3 depletion
leads to mitochondrial fragmentation and sensitivity to intrinsic apoptosis (208).
Importantly, uncoupler-induced MMP loss is one such intrinsic signal. Combinationexposed female hearts had lower DAP3 expression (Figure 16C) suggesting
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predisposition to cell death by intrinsic apoptosis. Authors attempted repeatedly to
probe for pDRP-Ser637, but unlike in the neonatal heart(9), pDRP1-Ser637 expression
levels were undetectable. VDAC is a central player in intrinsic apoptosis through
apoptogen release (209). Overexpression induces apoptosis via mPTP opening, MMP
dissipation, and cytochrome C release; conversely, silencing VDAC inhibits apoptosis
(209, 238). While mPTP opening is the defining signal for MPT-driven necrosis, mPTP
opening triggered by VDAC (rather than CYPD) triggers apoptogen release, Bax
activation, and caspase 3 activation rather than necrosis (238). Female hearts of all
groups had higher VDAC expression than males. CYPD regulates MPT-driven necrosis
by controlling mPTP opening (210). Male hearts of all groups had higher CYPD
expression. Ultimately, having higher VDAC expression alongside lower CYPD could
play a cardioprotective role in our female hearts; this pattern supports higher physiologic
mitophagy and intrinsic apoptosis as the primary death pathway following FCCP. In
contrast, lower VDAC and higher CYPD expression in male hearts supports MPT-driven
necrosis as their primary route to cell death. Authors suspect this is why diabetesexposed male CM had faster cell death following FCCP challenge.
Strengths of our model include the ability to determine individual and combined
effects of late-gestation diabetes and maternal HF diet on offspring. Litter size was
normalized and offspring cross-fostered to normal dams to decrease confounding
beyond prenatal exposures. Combination exposure allows us to determine whether
prenatal glucolipotoxicity leads to more profound consequences than diabetes or diet
alone. This is important clinically because the current treatment for diabetic pregnancy
focuses on normalizing glucose but does not address hyperlipidemia or dietary fat

91

intake (48, 239). Considering the higher rates of AMI in adult men (240), the higher
baseline mitophagy alongside slower FCCP-induced cell death in normal females
supports a cardioprotective role of physiologic mitophagy (32) and reflects superior
mitochondrial quality observed in females (241, 242). Studies using chemical
compounds (243), preconditioning (244), and caloric restriction (245), all of which
stimulate mitophagy, further support a cardioprotective role and give insight regarding
preventative measures that could be used to improve life-long heart health. Although
future studies are needed, we propose male and female differences in fuel-mediated
programming are due to variable epigenetics (246, 247), placental fuel transport (248),
hormonal influences (249, 250), or a combination of these factors. Overall, our findings
highlight sex as a strong biological variable that should be accounted for in DOHaD
studies, especially when mitochondrial dysfunction is implicated.

Limitations of the Study
Mitochondrial findings are cardiac-specific and should not be extrapolated to
other tissues without further research. While we evaluated many markers of
cardiometabolic health over the course of development, this study did not directly
examine hypertension or subclinical insulin resistance which are reported in offspring of
diabetic mothers (2, 181, 223). Regardless, cardiac findings in diabetes-exposed 12MO
offspring could not be attributed to metabolic syndrome or circulating renin,
adipocytokines, or soluble adhesion molecules (Table 4). We further isolated myocardial
findings by developing live-cell confocal imaging assays to objectively measure cellular
responses to metabolic stress. Similar methods have been used to study mitochondria92

mediated cell death by others (211, 251, 252) but our approach facilitates reproducible,
quantitative, and adaptable methods to study mitophagy alongside rates of cell death.
To overcome potential isolation-induced stress, CM were seeded equally based on the
number of live (not total) cells. Despite equal culture times, we cannot discount potential
loss of more-stressed CM during incubation. However, we took care to measure
baseline numbers of lysosomes, mitolysosomes, MMP, and cell length and width; there
were only exposure-related differences before FCCP. Pyknosis is a well-known marker
for both necrosis and apoptosis, however bi-nucleation and the sheer volume of
mitochondria in adult cardiomyocytes (253) make it difficult to accurately grade
chromatin distribution to distinguish apoptotic from necrotic pyknosis (254). For this
reason and to further validate these methods, we included retraction, a morphologic
marker of cardiomyocyte apoptosis (255). Retraction was a more sensitive measure in
CM as it detected sex-specific differences, but this may not be true in all cell types.

Conclusions
In summary, this study shows that prenatal exposure to maternal diabetes
increases the newborn and adult offspring’s risk of mortality, impairs cardiac and
bioenergetic function, and increases the risk of stress-induced cardiomyocyte death by
sex-specific, mitochondria-mediated mechanisms. Considering the large number of
infants born to mothers with diabetes and obesity, it is critical to confirm mechanisms
and identify confounding factors so that pre- and post-natal prevention and intervention
can be developed to improve long-term cardiac health in this growing population.
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Table 3. Maternal characteristics.
Parameter Controls

Diabetesexposed

Dietexposed

Combination
-exposed

Diabetes
(P value)

Diet
(P value)

Interaction
(P value)

Baseline
weight, g
Postdiet
weight, g
Glucose,
mg/dL
Ketones,
mmol/L
TG, mg/dL
NEFA,
mg/dL
TC, mg/dL
HDL,
mg/dL
Non-HDL,
mg/dL
Litter size,
pups

207±6

195±5

198±7

204±6

0.651

>0.999

0.176

240±3

233±4

*263±4

*263±4

0.490

<0.0001

0.358

88±1

+323±18

106±11

+313±15

<0.0001

0.753

0.273

0.43±0.03

+0.55±0.04 *0.50±0.04

+*0.64±0.05

0.001

0.041

0.793

34±4
0.20±0.04

+64±9
*101±15
+0.41±0.13 *0.42±0.08

+*150±30
+*0.72±0.10

0.011
0.010

<0.0001
0.010

0.542
0.660

136.2±4.8
104.3±6.3

154.0±13.1 161.9±7.2
121.2±14.0 123.5±7.3

151.5±14.4
101.5±14.8

0.734
0.823

0.289
0.981

0.200
1.00

31.9±6.6

32.8±3.6

*38.5±4.6

*50.0±4.7

0.226

0.027

0.296

11±1

12±1

10±1

11±1

0.226

0.226

>0.999

Data represent mean ± SE. P ≤ 0.05: +diabetes or *diet effect by 2-way ANOVA. Maternal
whole blood glucose, ketone levels, and insulin need were from gestational day (GD)15
to GD21. Maternal lipid levels were measured on postnatal day 1. Ncontrols=29 litters;
Ndiabetic=29; NHF diet=32; Ncombination=28. Table has been adapted from Louwagie, E.J., et
al. iScience (2020).

94

Table 4. Offspring characteristics over time.

P1a

Age

Controls

Diabetesexposed

Dietexposed

Combinationexposed

Diabetes
(P value)

Diet
(P value)

Interaction
(P value)

6.2±0.1

6.2±0.1

*5.7±0.1

*5.9±0.1

0.114

<0.0001

0.291

77±1.3

74±1.4

81±0.0

^85±3.6

N/A

N/A

0.049

172±13

+308±49

*423±90

+*638±121

0.013

<0.0001

0.581

1293±81

1688±191

1285±111

^2632±264

N/A

N/A

0.011

107.2±7.2

93.9±6.8

106.7±9.4

89.7±13.3

0.098

0.799

0.838

63.0±8.7

62.3±6.7

72.9±6.5

65.2±5.1

0.609

0.437

0.669

12.4±3.5

11.6±1.4

11.5±2.4

9.8±2.0

0.636

0.604

0.853

38.7±3.2

50.6±5.8

^67.9±1.6

51.7±5.7

N/A

N/A

0.024

0.21±0.02

0.24±0.02

0.21±0.02

0.17±0.01

0.805

0.096

0.096

34.3±1.9

29.2±4.1

27.7±5.0

26.0±2.8

0.367

0.195

0.649

16.1±0.6

14.3±1.2

13.7±0.5

14.4±0.5

0.557

0.203

0.163

67.8±2.2

70.2±4.1

68.9±3.4

^55.3±3.5

N/A

N/A

0.012

27-41

166±6.1

170±5.4

167±3.3

157±5.3

0.570

0.244

0.164

14-24

63.2±6.9

74.0±7.6

63.5±8.6

96.6±23.3

0.079

0.355

0.370

124.2±9.5

107.6±6.5

124.0±11.2

124.1±7.9

0.367

0.372

0.362

6

68.9±4.7

62.7±3.9

63.5±4.1

57.5±4.3

0.165

0.226

0.983

4-6

55.3±6.3

54.2±4.5

44.9±3.3

62.6±2.5

0.101

0.843

0.066

14-18

2.4±0.4

2.8±0.6

3.7±0.5

2.9±0.6

0.700

0.202

0.307

2.98±0.24

3.07±0.15

2.65±0.10

2.61±0.30

0.907

0.072

0.761

12.8±1.1

10.8±1.1

10.9±1.3

11.8±1.6

0.670

0.725

0.292

16.0±0.8

16.0±0.7

15.0±0.5

16.0±0.8

0.502

0.451

0.511

287±10

279±10

265±13

271±16

0.947

0.205

0.589

21-35

129±4.6

158±14.8

132±7.5

117±2.5

N/A

N/A

0.043

14-24

42.1±3.9

^73.7±5.4

^76.9±13.3

70.3±11.0

N/A

N/A

0.026

TC, mg/dL

118.1±6.5

111.5±5.8

110.2±8.2

123.3±7.7

0.644

0.787

0.175

HDL, mg/dL
Non-HDL,
mg/dL
Leptin,
ng/mL

63.9±4.9

63.3±2.4

57.4±5.9

55.0±6.4

0.770

0.164

0.860

54.2±4.3

50.0±5.6

52.8±3.8

61.4±6.3

0.660

0.332

0.214

2.1±0.4

1.5±0.2

1.8±0.4

1.5±0.3

0.153

0.733

0.583

0.12±0.01

0.10±0.01

*0.08±0.02

*0.08±0.01

0.448

0.018

0.456

147.1±9.4

127.8±10.1

112.0±8.7

138.0±12.2

N/A

N/A

0.037

Parameter

N/
group

Weight, g
Glucose,
mg/dL
216-250
Insulin,
pmol/L
C-peptide,
75-137
pmol/L
Serum TG,
mg/dL
32-57
Serum TC,
mg/dL
Serum HDL,
mg/dL
Serum nonHDL, mg/dL
3-7
Liver wt, g
Liver TG,
mg/dL
Liver TC,
mg/dL
Weight, g
Glucose,
mg/dL
Serum TG,
mg/dL

4-8

3WK

TC, mg/dL
HDL, mg/dL
Non-HDL,
mg/dL
Leptin,
ng/mL
Liver wt, g
Liver TG,
mg/dL
Liver TC,
mg/dL

10WK

Weight, g
Glucose,
mg/dL
Serum TG,
mg/dL

4-8

5-7

Renin, nM
sE-Selectin,
ng/mL
sICAM-1,
ng/mL

12-24

13.3±1.5

+19.1±1.5

*6.0±1.0

+*7.0±1.1

0.024

<0.0001

0.107

Liver wt, g

4-8

9.6±0.4

10.1±1.0

11.1±0.9

10.3±1.1

0.850

0.382

0.491
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6MO

Liver TG,
mg/dL
Liver TC,
mg/dL
Weight, g
Glucose,
mg/dL
Serum TG,
mg/dL
Adiponectin,
ng/mL
Renin, nM
sE-Selectin,
ng/mL
sICAM-1,
ng/mL

12MO

Weight, g
Glucose,
mg/dL

aP1

HbA1c, %
Serum TG,
mg/dL
Adiponectin,
ng/mL

5.3±0.3

4.3±0.6

5.1±0.9

6.0±0.3

0.958

0.153

0.077

11.6±0.5

11.9±0.5

12.2±0.5

11.7±0.7

0.768

0.669

0.443

415±44

449±30

406±40

442±58

0.430

0.851

0.987

102±3.6

96±11.7

115±8.4

113±3.0

0.658

0.131

0.880

97.8±8.7

105.8±9.6

105.6±8.4

110.3±17.3

0.583

0.592

0.885

31.4±3.0

30.1±3.7

*33.4±1.8

*43.3±4.4

0.209

0.031

0.106

42.8±3.0

49.5±5.2

35.3±2.5

41.3±2.8

0.082

0.063

0.828

5.69±0.52

5.18±0.46

6.00±0.38

5.69±0.41

0.366

0.371

0.829

1.11±0.13

+0.88±0.08

0.96±0.09

+0.79±0.05

0.035

0.207

0.734

511±37

453±35

506±26

476±45

0.430

0.851

0.987

15-20

118±3.3

109±3.2

114±3.9

112±3.2

0.100

0.920

0.272

8

7.54±0.45

7.95±0.70

7.51±0.32

6.81±0.30

0.760

0.224

0.248

15-16

179.0±38.3

121.7±36.9

141.6±22.7

148.7±22.5

0.435

0.870

0.317

58.2±3.9

62.1±3.5

63.1±5.4

67.1±4.0

0.359

0.250

0.998

39.9±5.9

+34.0±2.8

*26.2±1.3

+*18.0±1.5

0.047

0.0001

0.734

5.1±0.5

5.2±0.3

5.9±0.7

6.0±0.8

0.897

0.162

0.915

4-9

8-10

Renin, nM
sE-Selectin,
ng/mL
sICAM-1,
ng/mL

8-10

2.1±0.7

1.5±0.2

1.4±0.2

1.6±0.4

0.543

0.464

0.349

BNP, ng/mL

7-9

0.18±0.02

0.22±0.06

0.19±0.03

0.19±0.05

0.637

0.864

0.620

serum leptin levels have been previously published (122) and are not different

between groups. P1, perinatal day one; WK, weeks; MO, months; N/A, not applicable;
HbA1c, glycated hemoglobin; TG, triglycerides; TC, total cholesterol; HDL, high-density
lipoprotein cholesterol; ICAM-1, intercellular adhesion molecule 1; BNP, brain natriuretic
peptide. Data represent mean ± SE. Significant differences (p≤0.05): +diabetes or *diet
effect by 2-way ANOVA, ^group effect remained significant by 1-way ANOVA and
Dunnett's post hoc test when interaction was significant by 2-way ANOVA. Table has
been adapted from Louwagie, E.J., et al. iScience (2020).
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Table 5. Antibodies used in Western blotting analyses.
Antibody
Anti-DRP1 (H-300), diluted 1:350
Anti-MFF, diluted 1:1000
Anti-MTFP1, diluted 1:1000
Anti-MFN1, diluted 1:200

Source
Santa Cruz Biotechnology
Cell Signaling Technology
Antibodies-online
Santa Cruz Biotechnology

Anti-MFN2, diluted 1:1000
Anti-OPA1, diluted 1:1000
Anti-DAP3, diluted 1:1000
Anti-VDAC1/Porin, diluted 1:1000
Anti-CYPD, diluted 1:1000

Sigma-Aldrich
Cell Signaling Technology
BD Biosciences
Abcam
Abcam

Anti-NDUFA2, diluted 1:500
Anti-SDHA, diluted 1:5000
Anti-UQCRH, diluted 1:5000

LifeSpan Biosciences
Abcam
Abcam

Anti-COX5B, diluted 1:10,000
Anti-ADRP, diluted 1:1000

Abcam
Abcam

Anti-β-Actin (HRP-conj.), diluted 1:1000
Goat anti-rabbit IgG-HRP, diluted
1:5000
Goat anti-mouse IgG(H+L) human adsHRP, diluted 1:5000

Cell Signaling Technology
SouthernBiotech

Identifiers
Cat#SC-32898
Cat#84580; RRID:AB_2728769
Cat#ABIN3047683
Cat#SC-50330;
RRID:AB_2250540
Cat#M6319; RRID:AB_477221
Cat#80471; RRID:AB_2734117
Cat#610662; RRID:AB_397989
Cat#Ab14734; RRID:AB_443084
Cat#Ab110324;
RRID:AB_10864110
Cat#LS-C409672
Cat#ab14715; RRID:AB_301433
Cat#ab134949;
RRID:AB_2800504
Cat#ab180136
Cat#ab108323;
RRID:AB_10863476
Cat#5125S; RRID:AB_1903890
Cat#4030-05; RRID:AB_2687483

SouthernBiotech

Cat#1031-05; RRID:AB_2794307

Table has been adapted from Louwagie, E.J., et al. iScience (2020).

Table 6. Diet- and combination-exposed offspring suffer from higher perinatal and
natural long-term mortality.
Group

N (total)

Perinatal moralities, N (%)

N (aged past

P1 to 12MO mortality, N

Controls
Diabetes-exposed

328
314

32 (9.8)
39 (12.4)

95
100

0 (0.0)
3 (3.0)

HF diet-exposed

321

*72 (22.4)

71

3 (4.2)

Combination-exposed

307

*79 (25.7)

69

7 (10.1)

P ≤ 0.05: *diet effect by 2-way ANOVA. Table has been adapted from Louwagie, E.J., et
al. iScience (2020).
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Table 7. Sex-specific changes in cardiac structure and function over time.
Age,
Sex
P1 ♀

7.1±0.2

Dietexposed
8.0±0.7

Combinatio
n-exposed
8.1±0.2

7.1±0.2
68.6±0.8
67.4±0.8
37.2±0.6
36.4±0.7
5.8±0.1
5.5±0.1
0.75±0.02
0.72±0.02
40.0±1.2
42.3±1.2
0.57±0.01
0.57±0.01
0.28±0.01
0.28±0.01
6.5±0.9

+7.5±0.2
67.8±0.7
+64.2±0.8
36.6±0.6
+33.9±0.6
6.0±0.2
+5.9±0.2
0.73±0.02
0.68±0.02
+42.9±1.2
45.8±1.7
0.58±0.01
0.61±0.02
0.27±0.01
0.28±0.01
7.6±1.1

7.3±0.2
*66.1±0.9
66.7±1.4
*35.3±0.7
35.9±1.1
*4.8±0.1
*4.8±0.1
*0.65±0.02
0.70±0.03
*36.6±1.1
*40.7±1.6
0.55±0.01
0.58±0.02
*0.22±0.01
*0.23±0.01
6.2±0.6

+8.0±0.2
*63.6±1.3
+64.3±1.1
*33.8±1.0
+34.4±0.9
*5.2±0.2
+*5.4±0.2
*0.52±0.02
0.68±0.01
+*40.1±1.5
*39.6±1.0
0.56±0.01
0.57±0.01
*0.24±0.01
*0.25±0.01
8.2±0.8

0.013
0.080
0.008
0.147
0.012
0.081
0.002
0.218
0.195
0.011
0.374
0.350
0.292
0.407
0.530
0.108

0.055
<0.001
0.770
0.001
0.992
<0.001
<0.0001
<0.0001
0.772
0.016
0.005
0.168
0.248
<0.0001
<0.001
0.877

0.361
0.401
0.663
0.560
0.566
0.438
0.531
0.937
0.607
0.797
0.092
0.939
0.132
0.287
0.294
0.612

7.9±0.7
73.7±1.8
71.9±2.1
43.1±1.6
42.1±2.0
30.6±1.8
31.8±2.2
1.92±0.18
1.78±0.12
367±21
367±17
1.43±0.08
1.39±0.05
0.26±0.01
0.30±0.02

5.6±0.9
78.4±2.3
69.0±3.0
47.7±2.1
39.8±2.3
27.5±1.8
27.8±1.8
1.57±0.09
1.72±0.14
319±19
400±25
1.40±0.08
1.62±0.09
0.28±0.01
0.33±0.02

6.9±1.2
72.9±1.9
73.6±2.2
42.4±1.7
42.1±1.9
27.0±1.4
29.2±1.9
1.84±0.08
1.92±0.17
^286±14
305±25
*1.21±0.07
1.33±0.10
0.29±0.01
0.29±0.01

7.8±0.8
75.3±3.7
69.0±2.6
45.0±3.4
39.2±2.2
24.6±2.6
26.6±2.9
1.98±0.19
1.72±0.09
326±34
382±31
*1.23±0.11
1.49±0.09
0.31±0.02
0.30±0.02

0.462
0.156
0.186
0.106
0.194
0.155
0.170
0.460
0.348
N/A
0.052
0.860
0.079
0.281
0.199

0.505
0.422
0.768
0.448
0.932
0.091
0.430
0.230
0.598
N/A
0.159
0.029
0.212
0.069
0.300

0.092
0.636
0.768
0.651
0.747
0.856
0.757
0.078
0.628
0.043
0.432
0.971
0.882
0.914
0.750

5.1±0.7

5.0±0.2

5.2±0.3

4.7±0.2

0.371

0.706

0.508

5.2±0.3

4.6±0.4

4.8±0.5

4.8±0.2

0.437

0.868

0.456

72.9±2.5

77.7±3.7

^83.7±2.0

75.2±2.4

N/A

N/A

0.043

69.7±3.3

75.2±1.6

*82.2±3.2

*78.3±3.4

0.782

0.011

0.113

43.6±2.3

48.8±3.9

^54.4±2.5

45.5±2.3

N/A

N/A

0.039

41.4±2.7

45.9±1.4

*53.6±3.7

*49.5±3.8

0.937

0.008

0.125

67.6±5.1

67.4±3.9

71.5±5.7

68.5±6.3

0.771

0.642

0.801

83.8±4.7

92.0±5.7

102.0±9,9

87.6±6.9

0.657

0.315

0.106

1.52±1.16

1.41±0.07

1.69±0.11

1.35±0.18

0.095

0.669

0.407

1.44±0.28

1.66±0.11

1.71±0.17

1.14±0.07

N/A

N/A

0.048

980±96

1027±71.9

996±88

917±106

0.865

0.619

0.503

Controls

Heart:body
wt ratio
(x10-3)

P1 ♂
P1 ♀
EF, %
P1 ♂
P1 ♀
FS, %
P1 ♂
P1 ♀
CO, mL/min
P1 ♂
P1 ♀
E:A ratio
P1 ♂
P1 ♀
LV mass, mg
P1 ♂
P1 ♀
IVSd, mm
P1 ♂
P1 ♀
PAAT:RVET
ratio
P1 ♂
3WK ♀ Heart:body
wt ratio (x103WK ♂
3)
3WK ♀
EF, %
3WK ♂
3WK ♀
FS, %
3WK ♂
3WK ♀
CO, mL/min
3WK ♂
3WK ♀
E:A ratio
3WK ♂
3WK ♀
LV mass, mg
3WK ♂
3WK ♀
IVSd, mm
3WK ♂
3WK ♀ PAAT:RVET
ratio
3WK ♂
10WK
Heart:body
♀
wt ratio
10WK
(x10-3)
♂
10WK
♀
EF, %
10WK
♂
10WK
♀
FS, %
10WK
♂
10WK
♀
CO, mL/min
10WK
♂
10WK
♀
E:A ratio
10WK
♂
10WK
LV mass, mg
♀

Diabetes
Diet
Interaction
(P value) (P value) (P value)
0.229
0.459
0.280

Diabetesexposed
8.2±0.5

Parameter
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10WK
♂
10WK
♀
10WK
♂
10WK
♀
10WK
♂
6MO ♀

IVSd, mm

PAAT:RVET
ratio
Heart:body
wt ratio
(x10-3)

6MO ♂
6MO ♀
EF, %
6MO ♂
6MO ♀
FS, %
6MO ♂
6MO ♀
CO, mL/min
6MO ♂
6MO ♀
E:A ratio
6MO ♂
6MO ♀
LV mass, mg
6MO ♂
6MO ♀
IVSd, mm
6MO ♂
6MO ♀ PAAT:RVET
ratio
6MO ♂
12MO
Heart:body
♀
wt ratio
12MO
(x10-3)
♂
12MO
♀
EF, %
12MO
♂
12MO
♀
FS, %
12MO
♂
12MO
♀
CO, mL/min
12MO
♂
12MO
♀
E:A ratio
12MO
♂
12MO
♀
LV mass, mg
12MO
♂
12MO
♀
IVSd, mm
12MO
♂
12MO
♀
PAAT:RVET
ratio
12MO
♂

1489±105

1415±63

1511±116

1374±153

0.333

0.930

0.769

2.08±0.19

2.39±0.16

2.29±0.20

2.09±0.33

0.783

0.834

0.249

2.40±0.17

2.35±0.11

2.48±0.18

2.35±0.17

0.573

0.809

0.787

0.35±0.02

0.35±0.02

0.35±0.02

0.36±0.04

0.857

0.933

0.701

0.37±0.02
4.7±0.1

0.36±0.01
5.7±2.0

0.34±0.03
4.8±0.1

0.32±0.03
4.8±0.0

0.369
0.549

0.068
0.593

0.756
0.525

5.1±0.2
74.4±1.8
70.4±3.2
45.0±1.7
42.2±2.8
58.8±3.3
69.9±6.5
1.65±0.12
1.62±0.16
1019±68
1591±153
2.0±0.1
2.6±0.2
0.41±0.02
0.45±0.03

4.3±0.3
79.0±2.1
69.7±1.9
49.5±2.2
41.2±1.5
55.7±2.0
80.1±3.7
1.64±0.14
1.50±0.18
952±56
1630±107
2.2±0.1
2.5±0.1
0.35±0.03
0.39±0.02

4.4±0.2
76.9±2.1
73.5±2.3
47.4±2.0
44.8±2.2
*67.1±4.7
85.5±4.4
1.47±0.14
1.50±0.12
1062±59
1639±124
1.9±0.1
2.4±0.2
0.40±0.02
0.40±0.03

5.2±0.4
70.6±2.9
72.1±3.3
41.8±2.6
43.6±2.8
*62.9±4.6
78.2±6.2
1.40±0.14
1.48±0.09
971±65
1487±43
2.0±0.1
2.2±0.1
0.39±0.03
0.46±0.03

N/A
N/A
0.709
N/A
0.647
0.339
0.743
0.730
0.687
0.238
0.651
0.266
0.581
0.227
N/A

N/A
N/A
0.315
N/A
0.302
0.049
0.224
0.125
0.693
0.643
0.701
0.551
0.191
0.582
N/A

0.022
0.018
0.896
0.022
0.974
0.894
0.095
0.749
0.748
0.858
0.448
0.768
0.799
0.293
0.035

4.0±0.4

4.3±0.3

4.0±0.3

4.0±0.2

0.601

0.611

0.667

3.1±0.2

3.6±0.3

^3.9±0.2

3.3±0.1

N/A

N/A

0.017

83.0±1.5

+74.5±3.4

80.0±2.6

+76.2±2.9

0.041

0.833

0.424

74.7±2.7

71.5±5.1

68.0±3.8

66.9±4.3

0.591

0.163

0.803

53.6±1.8

46.0±3.3

50.6±2.6

46.9±2.7

0.054

0.718

0.488

45.9±2.7

44.0±4.3

40.3±3.0

39.5±3.6

0.696

0.148

0.869

67.8±4.0

62.1±2.6

68.3±6.8

62.9±4.3

0.213

0.872

0.978

77.1±5.1

87.8±7.7

86.7±7.2

87.3±7.1

0.407

0.505

0.457

1.9±0.4

1.6±0.1

1.6±0.2

1.6±0.1

0.591

0.454

0.508

1.5±0.1

+1.4±0.2

1.9±0.2

+1.2±0.2

0.031

0.705

0.188

1231±163

1204±90

1431±132

1359±117

0.699

0.174

0.862

2021±198

2315±272

2325±130

2462±250

0.311

0.331

0.723

2.4±0.2

2.1±0.1

2.7±0.2

2.5±0.2

0.172

0.071

0.664

2.6±0.2

2.7±0.2

3.2±0.1

3.0±0.3

0.649

0.112

0.638

0.61±0.04

0.60±0.03

0.48±0.04

0.62±0.07

0.141

0.265

0.119

0.63±0.04

0.61±0.07

0.62±0.06

0.60±0.05

0.727

0.778

0.978
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Cardiac function was assessed by echocardiography at all five time points for both sexes.
For heart:body weight ratios, NP1=216-250 offspring/group; N3WK=27-41; N10WK=21-35;
N6MO=4-9;

N12MO=15-20.

For

echocardiographic

parameters,

NP1=119-144

offspring/group; N3WK=18-30; N10WK=10-19; N6MO=17-28; N12MO=15-18. ♀, females; ♂,
males; P1, postnatal day one; WK, weeks old; MO, months old; EF, ejection fraction; FS,
fractional shortening; CO, cardiac output; E:A ratio, mitral valve flow velocity from
early:late diastole; LV, left ventricle; IVSd, interventricular septal thickness during
diastole; PAAT, pulmonary artery acceleration time; RVET, right ventricular ejection time.
Data represent mean ± SE. Significant differences (p≤0.05): +diabetes or *diet effect by
2-way ANOVA, ^group effect significant by 1-way ANOVA and Dunnett's post hoc test
when interaction was significant by 2-way ANOVA. Table has been adapted from
Louwagie, E.J., et al. iScience (2020).
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Table 8. Summary of age-related changes in offspring from birth to aged
adulthood.
Normal
development from
P1 to 12MO

Exposure-related differences
Exposure-related differences
in females
in males
Diet-exposed (but not
combination-exposed) females
↑ 60-fold (females)
gain more weight from P1 to
Weight gain and 100-fold (males)
Not different from controls
12MO
Diabetes-exposed females lose
Diabetes-exposed males gain
↑ 34-fold (females)
20% of heart mass between
13% heart mass from 6MO to
Heart weight and 42-fold (males)
6MO to 12MO
12MO when controls plateau
Diet-exposed females have more
LV mass by ↑ 31-fold (females) (~35-fold) LV growth from P1 to
ECHO
and 48-fold (males)
12MO
Not different from controls
EF: ↑ 14% (females)
and 7% (males)
Systolic dysfunction at birth
Systolic dysfunction at birth
FS: ↑ 16%
resolves. Diabetes-exposed adult
improves.
Systolic
(females) and 10% females have decline in EF and Diet-exposed males have EF and
function
(males)
SF from 6MO to 12MO
SF peak prematurely at 10WK
Diastolic dysfunction at birth
E:A ratio: ↑ 3-fold
Diastolic dysfunction at birth
resolves. Diabetes-exposed adult
Diastolic
males have decline in E:A from
(females) and 2-fold
resolves by 3WK, then not
function
(males)
different from controls
6MO to 12MO
Cardiac
↑ 12-fold (females)
Not different from controls
Not different from controls
output
and 14-fold (males)
Basal
Rate of ↑ is higher in diet-exposed offspring, especially females
↑ 70-fold
respiration
from 6MO to 12MO
Maximal
↑ 55-fold
Not different from controls
Respiration
ATP-linked
Rate of ↑ is higher in diet-exposed females and combinationoxygen
exposed males
consumption
↑ 60-fold
(>100-fold)
Basal
acidification
↑ 70-fold
Rate of ↑ is lower in diabetes-exposed offspring (55-fold)
Maximal
acidification
↑ 20-fold
Not different from controls
Palmitate
oxidation
↑ 30-fold
Not different from controls
mtDNA copy
number
↑ 5-fold
Rate of ↑ is higher in diet-exposed offspring
Parameter

P1, postnatal day one; MO, months old; LV, left ventricle; ECHO, echocardiography;
EF, ejection fraction; FS, fractional shortening; E:A ratio, mitral valve flow velocity from
early:late diastole. Table has been adapted from Louwagie, E.J., et al. iScience (2020).
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Table 9. Summarized changes in mitochondrial respiratory complex function.
Age

P1

12MO

Complex Respiratory Control Ratio
Lower in all exposed females
I
Lower in diabetes-exposed
males
II
III
No significant differences
IV
I

No significant differences

II

Lower in HF diet-exposed
females

III

Lower in diabetes-exposed
females

IV

No significant differences

Fuel Responses

No significant differences

Lower in HF diet-exposed females
Controls: females > males
Lower in HF diet-exposed females
Controls: trended (p=0.107) females >
males
Trended lower (p=0.073) in HF dietexposed females
Trended lower in diabetes-exposed
(p=0.084) and HF diet-exposed
(p=0.068) males
Trended lower (p=0.054) in HF dietexposed females
Higher in diabetes-exposed males
Controls: females > males

Table has been adapted from Louwagie, E.J., et al. iScience (2020).

102

Table 10. Sex-specific differences in 12MO cardiac protein expression.
Protein

Group

DRP1

Controls
Diabetes-exposed
Diet-exposed
Combination-exposed
Controls
Diabetes-exposed
Diet-exposed
Combination-exposed
Controls
Diabetes-exposed
Diet-exposed
Combination-exposed
Controls
Diabetes-exposed
Diet-exposed
Combination-exposed
Controls
Diabetes-exposed
Diet-exposed
Combination-exposed
Controls
Diabetes-exposed
Diet-exposed
Combination-exposed
Controls
Diabetes-exposed
Diet-exposed
Combination-exposed
Controls
Diabetes-exposed
Diet-exposed
Combination-exposed
Controls
Diabetes-exposed
Diet-exposed
Combination-exposed
Controls
Diabetes-exposed
Diet-exposed
Combination-exposed
Controls
Diabetes-exposed
Diet-exposed
Combination-exposed
Controls
Diabetes-exposed
Diet-exposed
Combination-exposed
Controls
Diabetes-exposed
Diet-exposed
Combination-exposed
Controls
Diabetes-exposed
Diet-exposed
Combination-exposed

MFF

MTFP1

MFN1
(86kDa)

MFN2
(70kDa)

OPA1 (short
band)

DAP3

VDAC

CYPD

NDUFA2

SDHA

UQCRH

COX5B

ADRP

Females
Mean±SE
1.22±0.16
2.42±0.49
3.38±0.52
2.20±0.41
8.82±1.98
11.86±2.84
2.85±0.24
3.10±1.25
0.64±0.18
0.56±0.11
0.77±0.35
0.27±0.09
0.6 ±0.01
0.7 ±0.02
0.13±0.03
0.11±0.06
0.10±0.02
0.19±0.01
0.09±0.01
0.25±0.15
1.14±0.16
1.36±0.24
0.57±0.06
0.42±0.14
0.37±0.03
0.47±0.01
0.30±0.04
0.14±0.10
7.98±0.17
14.33±1.07
14.25±0.98
17.58±4.23
1.79±0.19
2.68±0.23
2.23±0.31
1.94±0.50
0.54±0.06
0.53±0.03
1.27±0.09
1.26±0.11
1.63±0.05
1.75±0.09
0.96±0.05
0.79±0.10
1.13±0.05
1.35±0.04
1.63±0.19
2.31±0.65
2.47±0.14
3.64±0.16
2.55±0.20
2.43±0.19
1.41±0.12
1.05±0.12
0.64±0.02
0.77±0.13
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Males
Mean±SE
6.28±0.24
12.74±1.61
8.67±1.26
4.08±0.28
1.68±0.25
1.46±0.47
1.01±0.28
0.71±0.14
0.18±0.02
0.16±0.00
0.43±0.05
0.45±0.06
0.21±0.02
0.24±0.02
0.20±0.03
0.22±0.04
0.13±0.02
0.08±0.02
0.10±0.02
0.08±0.01
1.91±0.31
1.66±0.26
1.10±0.07
0.93±0.14
0.47±0.02
0.46±0.04
0.45±0.07
0.37±0.02
6.28±0.24
12.74±1.61
8.67±1.26
4.08±0.28
7.47±0.73
9.13±1.00
8.03±0.76
5.83±0.56
0.54±0.06
0.53±0.03
1.27±0.09
1.26±0.11
1.07±0.09
1.14±0.23
1.09±0.10
0.92±0.10
2.07±0.22
1.82±0.28
1.89±0.08
1.74±0.11
2.19±0.06
2.45±0.25
2.18±0.22
2.30±0.19
1.28±0.07
0.65±0.04
0.64±0.03
0.71±0.22

P value
*<0.001
*0.004
*0.018
‡0.019
*0.023
*0.023
*0.007
0.130
0.060
*0.020
0.391
0.189
*0.002
*0.006
0.187
0.241
0.478
*0.010
0.741
0.326
0.090
0.439
‡0.005
0.065
‡0.050
0.808
0.134
0.074
*<0.001
*0.003
*0.001
*0.038
*0.002
*0.003
*0.002
*0.007
0.342
0.381
‡0.004
‡0.014
0.426
0.069
0.290
0.396
‡0.013
0.181
0.290
0.433
0.142
‡0.016
0.291
0.638
0.400
‡0.032
0.870
0.816

Protein expression is relative to β-actin. Sex-specific differences by T-test (P<0.05) are
marked by boldface and *. Statistically significant differences (P<0.05) less than 2-fold
different are instead marked by ‡. N = 3 males and 3 females/group. Table has been
adapted from Louwagie, E.J., et al. iScience (2020).

104

Chapter 3: Mitochondrial Transplantation Improves Cellular
Bioenergetics and Viability in Male Cardiomyocytes Exposed
to Pregestational Diabetes

This chapter, including figures where referenced, has been adapted from:
EJ Louwagie, TD Larsen, AL Wachal, TCT Gandy, ML Baack. Mitochondrial transfer
improves cardiomyocyte bioenergetics and viability in male rats exposed to
pregestational diabetes. International Journal of Molecular Sciences. 2021 Feb 27. DOI:
10.3390/ijms22052382. PMID: 33673574. PMCID: PMC7956857.

The original article is an open access article licensed under a Creative Commons
Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND
4.0). To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
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Abstract
Diabetes and obesity during pregnancy increase the risk of heart disease in
developing offspring by poorly understood mechanisms. Using a rat model, we
previously established that offspring exposed to late-gestational diabetes mellitus
(LGDM) and maternal high-fat (HF) diet develop cardiac dysfunction, impaired cellular
bioenergetics, and mitochondrial dysfunction. Here, we hypothesize that maternal
pregestational diabetes mellitus (PGDM) exacerbates mitochondrial dysfunction, which
plays a central, pathogenic role in neonatal cardiac disease. We adapted our model to
induce diabetes before breeding and used mitochondria transplants from normal rat
myocardium to neonatal rat cardiomyocytes (CM) in order to mechanistically evaluate
the role of mitochondria in cardiac disease in offspring of diabetic and obese mothers
(ODOM) to determine mitochondria specific effects outside that of potentially
programmed effects of cellular fuel transport, storage and enzymatic flux. We measured
echocardiography, cellular bioenergetics, ROS, and cell viability in order to 1) compare
myocardial outcomes in offspring exposed to PGDM vs those previously described with
LGDM, 2) determine the effect of normal mitochondria on cellular bioenergetics,
mitochondrial quality, and cell viability in ODOM. In contrast to our hypothesis, we found
that offspring exposed to PGDM have less perturbation is cellular bioenergetics than
those exposed to LGDM, possibly due to impaired viability and self-selection of healthier
cells for analyses. Regardless, exposed offspring have impaired systolic function, poor
ATP generation, significant lipid peroxidation, and faster apoptosis under metabolic
stress. Mitochondrial transplants did not affect mitophagy rates of host mitochondria, but
they did provide a respiratory boost to all cardiomyocytes and reduced apoptosis in
males. Findings highlight sex-specific differences in mitochondria-mediated
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mechanisms of developmentally programmed heart disease in ODOM and underscore
potential mechanisms for therapeutic benefits of mitochondrial transplants.

Introduction
Diabetes and obesity during pregnancy expose the fetus to excess circulating
fuels, inciting fetal hyperinsulinemia and heart disease in offspring at birth (36-42, 4447, 80, 87) and later in life (106, 109, 111, 112). Although pregestational diabetes
mellitus (PGDM) increases rates of cardiac malformations to a greater extent than lategestation diabetes (LGDM) (37, 73-77), both PGDM and LGDM lead to similar neonatal
cardiac phenotypes characterized by diastolic dysfunction and ventricular hypertrophy
most consistently of the interventricular septum (IVS) (43). Importantly, studies
investigating fetal exposure to LGDM and maternal high-fat (HF) diet from our own lab
(7-10, 256) and others (120, 123, 124, 126, 127, 135, 138) provide a foundation for our
central hypothesis that mitochondria play a central, pathogenic role in developmentally
programmed heart disease.
Mitochondria are key regulators of cardiac development, function, and disease
(13, 195). Their most well-known role, energy production, is critical to highly metabolic
organs like the heart. Beyond mitochondrial function, bioenergetics can be influenced by
external factors including glucose-, fatty acid- and insulin-mediated fuel transport,
storage and enzymatic flux. Over the course of development, myocardial metabolism
shifts from glycolytic to oxidative phosphorylation leading to increased reliance on
mitochondria (11, 256). Using a rat model of LGDM that exposes the developing pup to
maternal hyperglycemia, hyperlipidemia and fetal hyperinsulinemia only in the last 1/3 of
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pregnancy, we found newborns exposed to diabetes have larger hearts, diastolic, and
systolic dysfunction, and their isolated cardiomyocytes (CM) have evidence of
mitochondrial dysfunction including impaired bioenergetics (7, 256). Poorer respiration
and fatty acid oxidation (FAO) were worsened in combination with maternal HF diet (7,
256). Going further, we bypassed potentially confounding factors via permeabilizing
cells to directly interrogate mitochondrial complex function. In neonatal primary
cardiomyocytes (CM), we found complex I impairment which supports intrinsic,
programmed mitochondrial dysfunction (256).
Another important role of mitochondria is regulating cell growth, differentiation
and survival which is extremely important during development and ageing especially in
poorly regenerative organs like the heart (13, 257, 258). Dysfunctional mitochondria
consume more oxygen and generate more ROS production which regulates myocyte
differentiation during embryogenesis and the perinatal period (259). Dysfunctional
mitochondria also regulate cell survival. When mitochondria are damaged, a loss of
mitochondrial membrane potential (MMP) signals degradation via mitophagy (200).
Physiologic mitophagy is beneficial for culling dysfunctional mitochondria (32), but an
overload can cause cell death by mitochondria-mediated intrinsic apoptosis or
mitochondrial permeability transition (MPT)-driven necrosis (201). This is a wellrecognized cause of cardiac disease in ageing. Indeed, we previously showed that adult
male offspring exposed to LGDM have faster mitochondria-mediated CM death
following metabolic stress (256). However, we have not yet determined the effect of
PGDM on mitochondria-mediated cell fate in developing CM, a key remaining question
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to understanding the pathogenesis of cardiomyopathy and programmed heart disease
in ODOM.
We hypothesized that maternal PGDM, like LGDM, would cause similar or worse
mitochondrial dysfunction in developing CM to cause neonatal cardiac disease by two
mechanisms: 1) impaired bioenergetics, and 2) higher rate of mitochondria-mediated
cell death. We used an adapted rat model that induces diabetes before breeding to
affect not only the fetal period, but also the periconceptual and embryogenic period. To
mechanistically isolate the role of mitochondria in CM bioenergetic dysfunction and cell
fate, we employed mitochondrial transplantation, an emerging therapeutic tool in the
treatment of cardiomyopathy following ischemia-reperfusion injury (IRI) (141).
A great deal of work has gone into delineating the mechanisms, challenges, and
therapeutic potential of mitochondrial transplantation. Mounting in vitro and in vivo
models have shown that isolated mitochondria with intact respiration can be injected or
perfused into the heart where they are quickly internalized by CM (260-262) via actindependent endocytosis (263). Once inside host cells, donor mitochondria escape from
endosomes and fuse with the host mitochondrial network (264). This incorporation of
healthy donor mitochondria leads to improved cellular and cardiac function by
increasing myocardial respiration and ATP production (261, 265), upregulating
expression of cardioprotective cytokines and mitochondrial proteins involved in
respiration (265), and by replacing damaged mitochondrial (mt)DNA (263) to ultimately
limit ischemic damage and improve cardiac function (141, 266). Of particular clinical
relevance, neither intact autologous (syngeneic or self-derived) nor allogeneic (derived
from different individual of same species) mitochondria appear to elicit immune
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responses following injection (267), and our studies used mitochondrial transplantation
to primary isolated CM which are separated from immune modulators such as T-cells
and macrophages. Emerging studies highlight the potential benefits for mitochondriamediated disease. In addition to use for pediatric patients undergoing extracorporeal
membrane oxygenation (ECMO) following myocardial IRI in an ongoing clinical trial
(140), mitochondrial transplantation is being investigated for the treatment of heart
failure (268), diabetes-exacerbated IRI (269), acute limb ischemia (270), ischemic lung
injury (271), and Alzheimer’s disease (272). Here, we apply this emerging technique for
mitochondrial dysfunction in developmentally programmed heart disease.
The primary objective of this study was to determine if normal mitochondria can
rescue impaired bioenergetics in CM from diabetes-exposed male offspring which have
more mitochondrial dysfunction than females, especially when exposed to both diabetes
and high-fat diet (HFD) (9, 256). Secondarily, we sought to tease out the different
mitochondria-mediated mechanisms of cardiomyopathy in offspring exposed to PGDM
vs LGDM. To do so, we used a Sprague Dawley rat model of streptozotocin (STZ)induced PGDM, maternal HF diet, and the combination to produce newborn male
offspring of four distinct groups: controls, diabetes-, HF diet-, and combination-exposed.
Following echocardiography to evaluate cardiac structure and function, we transplanted
‘living,’ respiratory competent mitochondria into exposed newborn CM. Transplantation
recipients were then assessed for internalization of donor mitochondria, fusion and
mitophagy of donor and host mitochondria, and respiratory and glycolytic function.
Findings from the first cohort suggested that males exposed to PGDM had CM with
poorer viability. Recognizing females have better mitochondrial quality control
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mechanisms, we added a second cohort to evaluate mitochondria-mediated cell death
pathways in both male and female control and PGDM-exposed CM. Overall, our
findings delineate sex-specific mitochondria-mediated mechanisms of developmentally
programmed cardiac disease following exposure to PGDM and therapeutic response to
mitochondrial transplantation.
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Materials and Methods
Animal model of pregestational diabetes and maternal high-fat diet
This study followed guidelines set forth by the Animal Welfare Act, The National
Institutes of Health Guide for the Care and Use of Laboratory Animals, and was under
approval from the Sanford Institutional Animal Care and Use Committee (protocols 15310-21B and 167-04-23B). All animals were housed in a temperature-controlled, light-dark
cycled facility with free access to water and chow. Female, 8-10 week-old SpragueDawley rats (Harlan Laboratories Inc., Indianapolis, IN) received control diet (CD; TD2018
Teklad, Harlan Laboratories, Madison WI) or high-fat (HF) diet (TD95217 custom diet
Teklad, Harlan Laboratories) for at least 28 days before breeding. At least five days before
breeding, half of the dams received either placebo or 65mg/kg citrate-buffered
streptozotocin (STZ) to induce pregestational diabetes mellitus (PGDM), and thereafter
were treated with twice-daily sliding scale insulin to keep blood glucose levels from 200400mg/dL. Whole blood ketone levels were checked alongside blood sugars to ensure
adequate insulin dosing and prevent ketosis. One female who received STZ but did not
become diabetic (blood glucose levels >200mg/dL for ≥2 consecutive days) received a
second 65mg/kg STZ injection before developing diabetes and breeding. Dams were
weighed and had blood drawn at baseline (before beginning specified diet), 28 days after
beginning diet, and on postnatal day one (P1).
A first cohort of dams was bred with normal, CD-fed males and delivered
spontaneously to evaluate male postnatal day 1 (P1) offspring from four distinct groups:
controls (5 litters), diabetes-exposed (5), HF diet-exposed (6), and combination-exposed
(5). Contrary to our previous studies evaluating the effects of LGDM, data from this first
cohort showed very little -diabetes-related difference in cellular bioenergetics, probably
112

due to confounding by poor viability of CM from PGDM-exposed males leaving only a
sub-population of the healthiest CM in culture for normalization at the end of bioenergetics
analyses. Given this, a second cohort was added to focus on diabetes-mediated
differences in cell fate, and the cohort specifically included both sexes. Studying
mitochondria-mediated cell fate in both sexes was important because we previously found
females had better mitochondria quality control mechanisms (9, 256). This second cohort
consisted of 5 control and 5 diabetes-exposed litters, but one diabetic dam miscarried all
pups, leaving only 4 viable litters for analyses. Each experimental litter was matched with
a timed-pregnant litter of pups (P1 to P7 days of age; mean donor age, P4) from a nondiabetic, control-fed dam which served as donors of cardiac mitochondria for
transplantation. Following harvest of and humane euthanasia of pups by cervical
dislocation under isoflurane, experimental dams were euthanized by cardiac removal
under deep anesthesia in order to collect samples and count placentations, resorptions,
and retained stillbirths for accurate measure of perinatal mortality.
Echocardiography
Cardiac

structure

and

function

were

evaluated

on

P1

using

serial

echocardiography as previous detailed (7, 121, 256). Briefly, P1 offspring were
anesthetized under 1-3% isoflurane/oxygen and secured to a Vevo 2100 Imaging System
(FUJIFILM VisualSonics Inc., Toronto, Canada) then scanned using MS700 MicroScan
high-frequency transducer (FUJIFILM VisualSonics Inc.) to capture parasternal long axis
(PLAX), parasternal short axis (PSAX), and apical four chamber views in B mode
(brightness), M mode (motion), and pulsed-wave (PW) Doppler mode. A single technician
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who was not involved in data interpretation acquired all echocardiograms. Images were
analyzed using Vevo LAB software (FUJIFILM VisualSonics Inc.).
Neonatal ventricular cardiomyocyte isolation
Primary ventricular neonatal (P1) rat cardiomyocytes (CM) were separately
isolated as previous described (7, 9, 11, 256). In brief, newborn hearts were flushed with
1xPBS, weighed, and placed into ice-cold Hank’s Buffered Salt Solution. As soon as
possible, 3-5 male and female hearts/litter were pooled (separately by sex), minced and
digested in a 0.15M NaCl solution with 0.15% trypsin and 0.2% DNase I. To minimize
fibroblast contamination, initial isolates were suspended in Dulbecco’s Modified Eagle
Medium supplemented with 10% (vol/vol%) bovine serum and 1% (vol/vol%)
penicillin/streptomycin (DMEM-1), seeded onto an uncoated dish, and incubated for 1 hr
(37C, 5% CO2) before gentle tapping to remove CM (but not quickly-adhering fibroblasts).
CM were then counted by hemocytometry with Trypan Blue and seeded to 1) 0.1%
gelatin-coated FluoroDishes (Thermo Fisher Scientific, Waltham, MA) at 150,000 living
CM/dish for confocal microscopy, 2) 24-well Seahorse XFe24 Microplates (Agilent, Santa
Clara, CA) at 80,000 living CM/well for extracellular flux analyses, 3) 35mm plates at
1,000,000 CM/well for cytochrome C quantification, 4) 96-well black plates at 10,000
CM/well for ATP quantification, or 5) added directly to 1.5mL tubes at 300,000 CM/tube
for MDA quantification. CM for MDA quantification were assayed immediately, but seeded
CM were allowed to adhere for 4 hr before experimental use.
Mitochondrial isolation, treatment, and coincubation
Ventricular mitochondria were isolated from normal newborn donor rat
myocardium using Mitochondrial Isolation Kit for Tissue (Abcam Cat. #AB110168,
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Cambridge, MA). Immediately following euthanasia, approximately 8-10 newborn rat
hearts were pooled in ice-cold Wash Buffer and rinsed twice before removing atria and
being finely minced. Following Dounce homogenization, mitochondria were isolated from
whole ventricular homogenates by differential centrifugation per manufacturer’s
instructions. Importantly, samples were kept at 4C throughout the isolation process.
Although various methods have been used to isolate healthy respiring mitochondria,
numerous studies have shown superior quality by differential centrifugation (Table 11).
Final mitochondrial pellets were suspended in ice-cold respiration buffer (263) and
immediately quantified by DC protein assay (Bio-Rad, Hercules, CA) with Cytation3 plate
reader (BioTek, Winooski, VT) as previously described (9).
Isolated mitochondria were then aliquoted to be directly transplanted to
experimental CM, ‘killed’ (snap frozen in liquid nitrogen to disrupt mitochondrial
membranes and boiled at 95C for 5 min to denature all proteins) with or without treatment
with 0.2% DNase I (to degrade mtDNA). Isolated donor mitochondria were stained with
pHrodo Red Succinimidyl Ester (SE) (Life Technologies, Grand Island, NY) before
coincubation with CM. pHrodo Red SE fluoresces intensely red when pH drops, such as
occurs during cellular internalization. During pHrodo Red SE staining, mitochondria were
added to ice-cold respiration buffer containing 20ng/mL pHrodo Red SE for 10 min before
being washed four times with fresh, ice-cold respiration buffer (263). Supernatant from
the last wash was used as a negative transplant control to show that no unbound pHrodo
was transferred to CM (Figure 17A). Dilute hydrochloric acid was used to drop the media
pH (following coincubation) to 4 as a positive control to identify pHrodo Red SE-labeled
mitochondria outside of cells (Figure 17B). As described below, 30µg of mitochondria
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(live-respiring, ‘killed’, or ‘killed+DNase I-treated’) were added to each well containing
80,000 CM for Seahorse XFe24 bioenergetics assays, 60µg of pHrodo Red SE-labeled
mitochondria were added to FluoroDishes of 150,000 CM for confocal imaging, and 60µg
of unstained mitochondria were added to FluoroDishes for FCCP challenge. XFe24 wells
and FluoroDishes not receiving mitochondria instead received an equal volume placebo
injection of respiration buffer.

Figure 17. Validation of mitochondrial transplantation using pHrodo Red SElabeled rat mitochondria and mKate2-labeled mouse mitochondria.
(A-B) Representative images of CM stained with MitoTracker Green and LysoTracker
Blue and incubated with either the fourth wash supernatant from pHrodo-staining (A) or
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actual pHrodo-labeled donor mitochondria (B). As pHrodo Red SE is a pH-dependent
stain, media pH was dropped to 4 after 4 hr (middle) and 18hr (right) coincubation to
show presence of donor mitochondria both around and inside CM. (C) Representative
images of CM (top left), isolated myocardial mitochondria from mito::mKate2 mouse
(bottom left), and coincubation of the two after four (top middle) and 18 hours (top right).
Middle and right images were taken after washing off non-internalized mkate2
mitochondria but before trypsinization. (D) Real-time quantitative PCR (qPCR) of host
rat cardiomyocyte and donor mouse DNA show that species-specific mitochondrial
(mt)DNA-targeted probe/primer sets do not cross-react. (E) qPCR for mtDNA at
baseline (placebo injection) and after four and 18 hours of coincubation with mkate2
mouse mitochondria shows relative levels of internalized donor mitochondria relative to
total mtDNA (set at 100%). Data represent mean ± SEM. *p ≤ 0.05 by 1-way ANOVA.
N=3 experimental replicates. This figure has been adapted from Louwagie, E.J., et al.
Int J Mol Sci (2021).

MDA, ATP, and Cytochrome C quantification from primary isolated cardiomyocytes
Malondialedhye (MDA), ATP, and cytochrome C levels were quantified from
control and PGDM-exposed CM from the second cohort. MDA was quantified as a
surrogate marker for lipid peroxidation using a MDA assay kit (Abcam Cat. #AB118970)
as previously described (7). ATP levels with or without added ADP were quantified using
a Perkin Elmer ATPlite Luminescence Assay System (Thermo Fisher Scientific Cat. #50904-9890) per manufacturer’s instructions. After adding ADP or sham injection (DMEM1) and ATP standards to the black plate containing isolated CM, the plate was mixed by
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gentle orbital shaking for 1 min and then incubated at room temperature for 10 min to
allow CM time to phosphorylate ADP to ATP. MDA assay absorption and ATP assay
luminescence were measured using Cytation3 plate reader (BioTek). Cytochrome C was
quantified after 18 hr of CM culture to correlate with the last time point for transplant
imaging. Specifically, CM were trypsinized, washed three times with warm 1xPBS, and
permeabilized with 0.5% Triton X-100 (in 1xPBS) before being frozen at -80C. Cell lysates
were used to measure cytochrome C levels using R&D Systems Rat/Mouse Cytochrome
C Quantikine ELISA Kit (Thermo Fisher Scientific Cat. #MCTC0) per manufacturer’s
instructions and normalized to sample protein content.

Plasma analyses
Plasma fractions were stored at -80oC until analyses. TG, insulin, and C-peptide
were quantified by Triglyceride Colorimetric Assay Kit (ThermoFisher) and Rat Metabolic
Hormone Panel (MilliporeSigma Cat# RMHMAG-84K-02, Burlington, MA) as previously
described (7, 256).

ATP quantification for respiratory capacity and immunoblotting for purity of isolated
mitochondria
To demonstrate retained ability to respire and phosphorylate ADP to ATP, donor
mitochondrial isolates were evaluated using ATPlite Luminescence Assay System as
described above. The assay was done immediately following mitochondrial quantification
with care was taken during the final centrifugation to resuspend mitochondria
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in

respiration buffer made without ADP so that ATP content could be determined with or
without addition of ADP.
Purity of mitochondrial isolates was determined using Western blotting for
mitochondrial, nuclear, and cytoplasmic proteins as previously described (9, 256). In brief,
final mitochondrial isolates were pelleted, resuspended in RIPA buffer (150mM NaCl,
50mM Tris [pH=7.5], 1% Triton X-100, 0.5% deoxycholate, 0.1% sodium dodecyl sulfate)
supplemented with cOmplete Protease Inhibitor Cocktail (Roche, Indianapolis, IN) and
phosphatase inhibitor cocktail (Sigma-Aldrich, St. Louis, MO), and homogenized, frozen
at -80C (freeze-thaw cycle to ensure membrane rupture), thawed, and then sonicated (20
one-second pulses) before quantification by DC protein assay. Final Western blot
solutions were boiled at 95C for 5 min before loading into gels. Whole heart homogenates
were prepared in the same way. Final blots were imaged using Luminata Forte HRP
Chemiluminescence Substrate (Thermo Fisher, Waltham, MA) and ChemiDoc MP
Imaging System (Bio-Rad, Hercules, CA) with Image Lab Touch Software (version
2.2.0.08; Bio-Rad). All blots were run with 40µg protein per well. Antibody information is
shown in Table 12.

Mitochondrial transplantation and validation using mito::mKate2 transgenic mice
To confirm uptake of donor mitochondria into CM, mito::mKate2 transgenic mice
(Tg[CAG-mKate2]1Poche/J (273), stock #032188, JAX, Bar Harbor, ME) were used as
donors of cardiac mitochondria. Mito::mKate2 mice globally express the constitutively
fluorescent protein mKate2 which is localized to the N-terminal cytochrome c oxidase
subunit VIII [COX8A] (273) and therefore mitochondria fluoresce without confounding by
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dye leaching and at all pH levels (unlike pHrodo Red SE). Host CM were stained with
500nM MitoTracker Green FM and 1µM LysoTracker Blue DND-99. Hearts were
harvested from mito::mKate2 mice and mitochondria isolated as described above. After
capturing baseline images of rat CM stained with MitoTracker Green and LysoTracker
Blue, isolated mito::mKate2 mitochondria were seeded to CM and then imaged in both
2D and 3D planes (Z-stack) after 1, 4, and 18 hrs of co-incubation. As a negative control,
CM seeded with ‘killed+DNase I-treated’ mito::mKate2 mitochondria were imaged. After
4 and 18 hours of coincubation, the times at which mitochondrial internalization was
apparent by eye (Fig. 3.1C), co-incubated CM receiving mKate2 mitochondria or
respiration buffer placebo were washed twice to remove non-internalized mito::mKate2
mitochondria, trypsinized, washed three more times, and saved for qPCR quantification
of mtDNA within CM. Total genomic and mtDNA were isolated using QIAamp DNA Micro
Kit (Qiagen Cat. #56304) per manufacturer’s instructions. Probe-primer sets specific to
mouse and rat mtDNA sequences were selected (Table 13); mtDNA-encoded mouse
cytochrome B (mt-Cytb) was chosen to detect mito::mKate2 donor mtDNA and mtDNAencoded rat D-loop was chosen to quantify host mtDNA (7). After confirming lack of
species cross-reactivity using rat and mouse primers (Figure 17B), qPCR was performed
with 50ng DNA/reaction using ABsolute Blue QPCR Mix on an ABI7500 thermocycler
(both from Thermo Fisher Scientific). Data was analyzed as described by Quiros et al
2017 (274) using reference gene beta-2-microglobulin and is shown in Figure 17C).
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Live-cell confocal imaging and quantification of mitochondrial uptake, fusion, and
mitophagy
In order to quantify internalization of donor mitochondria and estimate fusion with
host mitochondria as well as mitophagy of host and donor mitochondria, CM were stained
with 500nM MitoTracker Green FM (Thermo Fisher Scientific) to identify host
mitochondria and 1μM LysoTracker Blue DND-22 (Thermo Fisher Scientific, Waltham,
MA) to identify host lysosomes. CM were coincubated with pHrodo red SE-stained donor
myocardial mitochondria. Three to 10 individual cells/dish were imaged at baseline (i.e.
before co-incubation) and following 1, 4, and 18hr of co-incubation with donor
mitochondria using a Nikon Eclipse A1R inverted confocal microscope (Nikon Instruments
Inc., Melville, NY) equipped with live-cell stage incubator (37C with humid 5% CO2) and
NIS-Elements software (Nikon Instruments Inc.). Images were cropped to exclude
artifacts and exported in TIF format for analysis. Methods of analysis have been
previously described (256). High-Content Screening Navigator (HCS) software (version
6.6.0; Perkin Elmer, Waltham, MA) Colocalization.V4 protocol was used to mask cells
and quantify internalization (pHrodo red SE-stained donor mitochondria), fusion (colocalization) of host and donor mitochondria, and mitophagy of both host and donor
mitochondria as estimated by co-localization with lysosomes. Region-of-interest (ROI)
masks were placed around individual CM to exclude non-internalized donor mitochondria
from analyses. To evaluate baseline CM and host mitochondria characteristics, HCS
Morphology.V4 protocol was used with parameters standardized between all cells.
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Seahorse XFe24 bioenergetics assays
Mitochondrial stress test (MST) and glycolytic stress test (GST) were performed
using a Seahorse XFe24 extracellular flux analyzer (Agilent, Santa Clara, CA) to assess
bioenergetics of untreated and mitochondria-treated CM. Untreated CM were obtained
from the same pooled CM as the treated and were similarly cultured, but instead of
receiving donor mitochondria, they received a placebo injection of respiration buffer.
Seahorse analyses methods have been previously described in detail (7, 11, 256). Four
hours after receiving placebo injection or 30µg of mitochondria, CM were washed twice
with MST or GST assay media and degassed (0% CO2) at 37C for 1hr. For each assay,
oxygen consumption rates (OCR) and extracellular acidification rates (ECAR) were
measured at assay start and after below injections to calculate respiratory and glycolytic
rates. Specific injection strategies detail final reagent concentrations and media types
below:
MST: Port A, 2µM oligomycin; Port B, 0.3µM FCCP; Port C, 2µM rotenone plus
4µM antimycin A; Port D, 2µM Hoechst 33342 for post run normalization of data
to the number of live cells in culture. MST media consisted of XF DMEM Media
(Agilent) supplemented with 4mM L-glutamine, 10mM D-(+)-glucose, and 1mM
pyruvate.
GST: Port A, 10mM glucose; Port B, 20µM monensin; Port C, 2µM rotenone plus
4µM antimycin A; Port D, 3.8mM 2-deoxyglucose plus 2µM Hoechst 33342 for
post run normalization of data. GST media consisted of unsupplemented XF
DMEM Media (Agilent). Proton efflux rate (PER) was calculated as described by
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Agilent Technologies, Inc.(275) using a calculated GST Media Buffer Factor of
2.68953299522399 mM/pH (276).

FCCP challenge to measure cellular response to oxidative stress
Methods for FCCP Challenge have previously been described in depth (256).
Here, following 18hr coincubation with live, respiring mitochondria or placebo of
respiration buffer, P1 CM were stained with 500nM MitoTracker Green FM, 1μM
LysoTracker Blue DND-22, and 50nM MitoTracker Red CMXRos (all three stains from
Invitrogen, Waltram, MA) in MST media and incubated for 20 min at 37C with humidified,
5% CO2. Following two washes in warmed 1xPBS, CM were incubated for 1hr in fresh
MST media to simulate conditions of the MST assay.
Imaging parameters were as previously described (256) with the only modification
of using a final FCCP concentration of 1.2µM which is higher than used for adult CM.
Representative video-images are shown in Figure 27. Quantification of mitochondrial
uptake, fusion, and mitophagy were done as previously described (above). FCCP
challenge videos were analyzed using HCS Navigator software (version 6.6.0;
PerkinElmer) Colocalization.V4 protocol to quantify MitoTracker Red CMXRos intensity
as an indicator of mitochondrial membrane potential (MMP) at baseline and after FCCP
uncoupling. Healthy neonatal CM were more resistant to FCCP-induced cell death than
previously assessed adult CM (256) even using doses 2-fold higher (1.2µM in P1 CM vs
0.6µM in adult CM) based on a dose response evaluated from 0.3 to 3.0µM. Therefore,
we could not compare rates of cell death using contraction or pyknosis as previously
described (256). To quantify FCCP-mediated cell death, video imaging was captured for
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25 min after FCCP treatment, then cells were fixed in 4% PFA, permeabilized, and labeled
with terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) and 4′,6diamidino-2-phenylindole (DAPI) to distinguish apoptotic cells. TUNEL reaction and
labeling was performed using Roche’s In Situ Cell Death Detection Kit, TMR Red
(MilliporeSigma Cat. #12156792910, Burlington, MA) by manufacturer’s instructions
followed by DAPI labeling. Images were captured with a Nikon A1 TIRF Ti-Eclipse
inverted confocal microscope (Nikon Instruments Inc., Melville, NY) at 40x magnification
and analyzed using HCS CompartmentalAnalysis.V4 protocol with apoptotic cells defined
as those having a total TUNEL fluorescent intensity >20,000 RFU.

124

Results
Pregestational diabetes and maternal high-fat (HF) diet incite maternal glucolipotoxcity
and increase perinatal mortality
Our lab has previously characterized maternal, placental, and fetal outcomes in a
rat model of STZ-induced late-gestation diabetes mellitus (LGDM), maternal HF diet,
and the combination (7-9, 121, 122, 256) which serves as a model to test the effects of
maternal hyperglycemia and hyperlipidemia alongside fetal hyperinsulinemia in last 1/3
of pregnancy. We have repeatedly shown that this combination increases perinatal
mortality and causes systolic, diastolic, bioenergetic, and mitochondrial dysfunction
including impaired respiration and dynamism as well as oxidative damage in P1
offspring. In this study, we evaluated the effects of PGDM using 398 offspring of 30
Sprague Dawley rat litters (10 control, 9 diabetes-exposed, 6 HF diet-exposed, and 5
combination-exposed). Maternal and newborn characteristics are shown in Table 14. As
expected, PGDM incites significant maternal hyperglycemia before breeding and
throughout pregnancy which expands exposure to implantation and organogenesis in
addition to later fetal growth and development. Maternal HF diet caused a trend towards
worse diabetes with greater maternal hyperglycemia (349±21 vs. 413±27, p=0.086 by ttest), sliding scale insulin needs (85±13 vs. 115±14 units throughout pregnancy,
p=0.163 by t-test), and circulating ketones (0.73±0.06 vs. 2.40±0.29, p<0.0001) which
can readily cross the placenta as an additional exposure for developing offspring.
Maternal HF diet did not increase dam weight, but it increased circulating maternal
triglycerides, especially in diabetic dams. As previously found with our LGDM model,
maternal HF diet also increased perinatal mortality 7- to 8-fold despite no change in
litter size (implantations). Unlike LGDM, PGDM-exposed offspring have greater
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birthweights and lower blood glucose levels than control offspring, reflecting more
profound fetal hyperinsulinemia seen here and in human infants of diabetic mothers
(277).

Offspring exposed to PGDM and HF diet manifest cardiac dysfunction
Neonatal (P1) cardiac structure and function were evaluated by morphometric
measures and echocardiography (Table 15 and Figure 18). Offspring exposed to
maternal diabetes had 4% greater heart:body weight ratios (Table 15) and significantly
lower systolic function as demonstrated by a 7.3% lower ejection fraction and 6.4%
lower fractional shortening (Figure 18A). Unlike offspring from our LGDM model (43,
256), diastolic function (per E:A ratio) was not different between exposure groups
(Figure 18B). Although heart rate was not different between groups, stroke volume was
14% lower in HF diet-exposed offspring (Figure 18C) leading to significantly lower
cardiac output (Figure 18D). As with LGDM (7, 256), combination-exposed offspring had
the poorest systolic and diastolic function as well as cardiac output. Unlike our LGDM
model (121, 256), pulmonary hypertension was not found (Table 15).
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Figure 18. Male offspring exposed to diabetic and high-fat (HF) diet during
pregnancy show significant cardiac dysfunction.
(A) Systolic function, (B) diastolic function, (C) heart rate and stroke volume were
determined in P1 offspring by echocardiography. (D) Cardiac output was calculated
from (C). N=12-19 offspring/group. Significant differences (p≤0.05): +diabetes or *diet
effect by 2-way ANOVA. E:A ratio, the ratio of ventricular filling velocities in early and
late diastole. This figure has been adapted from Louwagie, E.J., et al. Int J Mol Sci
(2021).

Mitochondria isolated from newborn rat hearts retain respiratory function, are highly
concentrated, and are relatively free of nuclear contamination
On average, 8-9 newborn hearts were pooled and used for mitochondrial
isolation, yielding an average of 1620±110µg mitochondria. To demonstrate respiratory
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competence of donor mitochondria isolated by our differential centrifugation method,
ATP levels were quantified with or without ADP added. Indeed, isolated mitochondria
retained respiratory capacity following the isolation process (Figure 19A). Protein
assays and immunoblotting were used to determine concentration and purity of
mitochondrial isolates per relative expression levels of mitochondrial proteins cyclophilin
D (CYPD) and voltage-dependent anion channel (VDAC, or porin), nuclear protein lamin
A, and cytoskeletal proteins β-actin and β-tubulin (Figure 19B). Compared to whole
newborn heart homogenate, CYPD and VDAC are more highly concentrated in
mitochondrial isolates, indicating concentrated myocardial mitochondria. Lamin A is
undetectable, indicating minimal nuclear contamination. Low levels of β-actin and βtubulin are present in mitochondrial isolate. Their presence may be expected as
mitochondria associate with these proteins for vital cell functions and may therefore
support retained mitochondrial function (278, 279).
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Figure 19. Isolated mitochondria retain respiratory capacity, are highly
concentrated, and are relatively free of nuclear contamination.
(A) Isolated mitochondria’s ATP levels quantified with and without added ADP; N=5
biological replicates. (B) Whole heart homogenate (left lanes) and mitochondrial isolates
(right lanes) (separated by dashed line) were evaluated by immunoblotting for
mitochondrial proteins cyclophilin D (CYPD) and voltage-dependent anion channel
(VDAC), nuclear protein Lamin A, and cytoskeletal elements β-actin and β-tubulin. Data
represent mean ± SEM. *Significant difference (p≤0.05) by 1-way ANOVA. This figure
has been adapted from Louwagie, E.J., et al. Int J Mol Sci (2021).

Mitochondrial transfer increases respiration in a dose dependent manner
Mitochondrial transplants increase CM respiration in a dose-dependent manner ,
but only up to an optimal dose (Figure 20). Plating 80,000 live CM/well to meet
recommended basal OCR and ECAR ranges (280) and measuring maximal respiratory
capacity by MST, we found that at this seeding density 30µg of mitochondria (by protein
assay) offered the greatest respiratory benefit for normal P1 CM (Figure 20).
Interestingly, treating cells with a larger dose actually led to a loss in benefit as
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evidenced by the lower maximal and reserve respiratory capacities in CM treated with
40 vs 30µg of donor mitochondria. Similarly yet unsurprisingly, ‘killing’ donor
mitochondria before transplantation led to less respiratory benefit; this is reflected by a
lower gain in maximal respiratory capacity with 25μg of living-respiring vs 25µg of killed
mitochondria. Based on these results, mitochondria for transplants in confocal imaging
studies (internalization, mitophagy, and FCCP challenge) which use 150,000 live CM
were proportionally dosed with 60µg mitochondria.

Figure 20. Donor mitochondria improve respiratory function of cardiomyocytes
up to an optimal dose.
Basal (left), maximal (center), and reserve respiratory capacity (right) were measured
after 80,000 CM were treated with 15, 25, 30, or 40µg live, respiring mitochondria or 25µg
‘killed’ mitochondria. Placebo group received respiration buffer containing no
mitochondria, and MST assay was run after four hours coincubation. Data represent
Mean ± SEM. N=2-3 per group. *p < 0.05 by 1-way ANOVA vs placebo control. This figure
has been adapted from Louwagie, E.J., et al. Int J Mol Sci (2021).
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Control and exposed CM are similar at baseline
To rule out morphologic differenced in experimental CM and host mitochondria
(size, number, shape) that could cause functional differences between groups, we used
confocal microscopy and high-throughput image analyses to compare baseline structural
differences (Figure 21). CM and mitochondria size and shape were similar between
groups with exception of diet-exposed CM which have approximately 20% smaller
mitochondria by cross-sectional area (Figure 21D).
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Figure 21. Control and exposed cardiomyocytes and mitochondria are
morphometrically similar at baseline.
(A) Representative images of cardiomyocytes from all groups stained with MitoTracker
Green and LysoTracker Blue. Masked cells were evaluated using automated HCS
software for cell size (B), number and size of host mitochondria (C-D), and
mitochondrial morphology (E). Mitochondrial circularity (‘roundness’) and morphology
were defined by P2A ratio (perimeter^2 / [4π*area]) and LWR (length:width ratio),
respectively. Data represent mean ± SEM. N=5-6 biological replicates per group using 3
to 10 randomly selected cells per replicate. Significant differences (p≤0.05): *dietspecific effect by 2-way ANOVA. This figure has been adapted from Louwagie, E.J., et
al. Int J Mol Sci (2021).

Donor mitochondria are increasingly internalized by CM over time
CM stained with MitoTracker Green (for host mitochondria) and LysoTracker
Blue (for lysosomes) were co-incubated with isolated donor mitochondria labeled with
pHrodo Red SE which fluoresces with lower pH after internalization. Imaging at
baseline, 1, 4 and 18hrs allows quantification of mitochondrial internalization, fusion,
and mitophagy over time. Both control and exposed CM increasingly internalize and
retain donor mitochondria for at least 18 hours (Figure 22A-B). Combination-exposed
CM have fewer mitochondria at baseline, but after co-incubation with donor
mitochondria the number rises over time (Figure 22C) leading to 50% more
mitochondria by 18hr. While this may be the result of MitoTracker Green label leaching
to internalized donor mitochondria, it could also represent stimulated mitochondrial
biogenesis. Authors believe the latter may be the case given the average number of
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total mitochondria within the cell at 18 hr is higher than the sum of baseline host and
total donor mitochondria at 18 hr (Figure 22C). Linear regression analysis demonstrates
that diabetes-exposed CM have faster uptake of donors in the first four hours of
coincubation (Figure 22D) leading to approximately double the number of donor
mitochondria per cell at 4 hr than control or HF-diet exposed CM (Figure 22B). Although
control CM have a slower rate of internalization in the first 4 hours, they catch up by 18
hr, so that the overall number of internalized mitochondria are similar.
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Figure 22. Donor mitochondria are internalized by cardiomyocytes at faster
rates with diabetes exposure.
(A) Representative confocal live-cell images of MitoTracker Green and LysoTracker
Blue stained cardiomyocytes co-incubated with pHrodo Red SE stained donor
mitochondria. Numbers of internalized donor mitochondria (A) and host mitochondria
(B) over time. (C) Linear regression analyses were used to determine the rates of donor
mitochondria internalization in the first four hours of coincubation (left) and across the
full 18 hours (right). Data represent mean ± SEM. N=5-6 males/group. Significant
differences (p≤0.05): +diabetes effect by 2-way ANOVA, ^group effect by 1-way ANOVA
and Dunnett's post hoc test when diabetes and diet interaction was present by 2-way
ANOVA. This figure has been adapted from Louwagie, E.J., et al. Int J Mol Sci (2021).

Internalized donor mitochondria fuse with host mitochondria and stimulate mitophagy
Rates of colocalization over time were quantified as markers of mitochondrial
fusion (co-localization of donor and host mitochondria) and mitophagy (co-localization of
mitochondria with lysosomes) as shown in Figure 23A. In both control and exposed CM,
fusion of host and donor mitochondria is highest after one hour of internalization and
thereafter decreases over time (Figure 23B). The number of lysosomes/cell at baseline
is not different (Figure 23C), and although there is a trend towards more baseline
mitophagy (host mitochondria co-localizing with lysosomes) in diabetes and
combination exposed CM, the difference is not significant. After mitochondrial
transplant, the average number of host lysosomes increases significantly from baseline
to 18hr in control (P=0.031) and combination-exposed CM (P=0.020) (Figure 23C). In all
groups, mitophagy of donor mitochondria increases over time (p<0.060) while
134

mitophagy of host mitochondria decreases (Figure 23D). PGDM-exposed CM have a
higher level of mitophagy of donor mitochondria than controls after four hours of coincubation (P=0.033).

Figure 23. Mitochondrial transplantation leads to mitochondrial fusion and
decreased mitophagy of host mitochondria.
(A) Representative confocal live-cell images of colocalized host and donor mitochondria
indicating fusion (first panel), donor mitochondria (red) and host lysosomes (blue) and
host mitochondria (green) and lysosomes (blue) representing mitophagy. Graphs
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illustrate (B) co-localization coefficient of donor and host mitochondria, a marker of
mitochondrial fusion, (C) total numbers of host lysosomes and (D) lysosomes
colocalized with donor (left) and host (right) mitochondria, a marker of mitophagy, at
baseline, 1, 4 and 18 hr post mitochondrial transplants. Linear slopes represent fusion,
lysosome production and mitophagy rates over time. Point data represent mean ± SEM.
N=5-6 males/group. +Significant diabetes effect (p≤0.05) by 2-way ANOVA. Significant
differences within groups at different time points are indicated in text above. Scale,
10µm. This figure has been adapted from Louwagie, E.J., et al. Int J Mol Sci (2021).

Diabetes and diet-exposed male cardiomyocytes have greater glycolytic capacities
Cellular bioenergetics without and with mitochondrial treatment were measured
in male offspring from all four groups in Cohort 1 and in control and PGDM-exposed
male and female offspring (siblings) in Cohort 2. Because diabetes impairs cellular
glycolysis (22) and we previously found impaired glycolytic capacities in LGDM-exposed
offspring (256), we used a glycolytic stress test (GST) to evaluate effects thereon of
mitochondrial transplantation in our model of PGDM exposure (Figure 24). In contrast to
previous findings from the LGDM model (7, 256), maximal and reserve glycolytic
capacities were actually higher in PGDM-exposed and diet-exposed male CM (Figure
24A). PER was calculated to differentiate lactate-derived acidification (anaerobic
glycolysis) from CO2-derived acidification (aerobic respiration after glucose) which
confirmed that higher glycolytic capacity in these exposed males is due to anaerobic
glycolysis rather than respiration (Figure 24B). Although the trend for males was similar,
differences were not found and females and did not reach statistical significance in

136

smaller Cohort 2 (Figures 24C-D). Other than a small decline in baseline anaerobic
glycolysis in PGDM-exposed females, mitochondrial transplant did not change glycolytic
capacity in any group (Figure 24D).

Figure 24. Male cardiomyocytes exposed to pregestational diabetes and maternal
high-fat diet are more glycolytic than controls.
Glucose-stimulated basal, monensin + rotenone-antimycin A-stimulated maximal, and
reserve glycolytic capacities in all four groups of male cardiomyocytes (CM) (A) and
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control and diabetes-exposed CM of both sexes (C). Proton efflux rate (PER)
differentiates acidification due to lactate (anaerobic glycolysis) vs CO2 (aerobic
respiration) in both cohorts (B, D). N=4-6 per sex per group. Data represent mean ±
SEM. P ≤ 0.05: +diabetes or *diet effect by 2-way ANOVA, #mitochondrial effect by 1way ANOVA. This figure has been adapted from Louwagie, E.J., et al. Int J Mol Sci
(2021).

Diabetes-exposed male CM consume more oxygen for ATP production, even with a
respiratory boost from mitochondrial transplantation
Respiratory capacity is an essential component of mitochondrial function and
was evaluated by mitochondrial stress test (MST). Unlike previous studies of CMs
exposed to LGDM (256), basal, maximal, and reserve respiratory capacities (Figure 25A
and C), as well as respiratory control ratio (RCR) and proton leak (Figure 25B) were
similar among groups. However, diabetes-exposed male CM had higher ATP-linked
oxygen consumption suggesting inefficient ATP production, higher ROS production, and
oxidative damage (Figure 25B). In our second cohort evaluating control and PGDMexposed CM from both sexes, we found that PGDM-exposed females also have
respiratory capacity similar to controls (Figure 25C), and do not have higher ATP-linked
oxygen consumption like male counterparts (Figure 25D).
In male CM (Cohort 1), mitochondrial transplants improve maximal respiration
and reserve capacity in nearly every group, reaching significance in PGDM- and
combination-exposed CM. This is most reflected by a very robust increase in respiratory
reserve capacity and RCR in combination-exposed CM (Figure 25A-B). Findings from
Cohort 2 replicate findings of PGDM-exposed males from in Cohort 1 and expand to
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female offspring which have been notably less affected in past studies of LGDM (9,
256). Like males, PGDM-exposed female CM treated with donor mitochondria have a
significant increase in respiratory reserve capacity (Figure 25C). However, these
PGDM-exposed females also have an increase in proton leak which may lead to
incomplete coupling of substrate oxygen to ATP generation, is a major contributor of
ROS production (281), and may increase the risk of apoptotic cell death (Figure 25D).
All three are examined below.
We were puzzled by the perceived lack of bioenergetic impairment found in
Cohort 1 males that were exposed to PGDM compared to males exposed to LGDM.
Certainly, in utero exposures were similar or worse with PGDM with developing
offspring exposed to higher levels of glucose and ketones for a much longer period
(Table 14). Yet, CM had relatively little measured respiratory impairment. Because the
Seahorse XFe24 instrument used in this experiment normalizes measured output to the
of number live cells at the end of the run, it is possible that bioenergetics data was
confounded by more “die off” of vulnerable cells in culture before or during the assay
itself. Indeed, by observation, plate imaging at the end of the run showed far fewer cells
than originally seeded. Thus, we used Cohort 2 to examine whether PGDM-exposure
affected cell viability.
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Figure 25. PGDM-exposed males but not females use more oxygen for ATP
production, and while mitochondrial transplantation may benefit males, they may
put females at greater risk of ROS production.
(A) Basal, FCCP-stimulated maximal, and reserve respiratory capacities and (B)
respiratory control ratios, oxygen consumed in ATP production, and proton leak of male
CM were all determined by mitochondrial stress test (MST) with and without added
mitochondria. These same values were also calculated from female PGDM-exposed
CM (C-D). N=4-6 per group. Data represent mean ± SEM. P ≤ 0.05: +diabetes effect by
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2-way ANOVA, #mitochondrial effect by 1-way ANOVA. This figure has been adapted
from Louwagie, E.J., et al. Int J Mol Sci (2021).

PGDM-exposed CM have inefficient ATP production, more oxidative damage, and are
at higher risk of apoptosis under metabolic stress
Using our second cohort of PGDM-exposed offspring of both sexes, we
investigated ATP production, oxidative damage, and cellular responses to mitochondrial
stress (Figure 26). In the first test, cellular ATP levels were quantified with and without
addition of ADP to determine baseline levels of ATP and phosphorylation capacity of
CM (Figure 26A). Although control and PGDM-exposed cells had similar baseline ATP
content, control cells had a more robust increase in ATP levels in the presence of ADP,
indicating better respiratory health. Indeed, there was little to no increase in ATP levels
with ADP added to PGDM-exposed cells. Demonstrating impaired phosphorylation of
ADP despite increased oxygen consumption for ATP production (per MST assay)
suggests risk of ROS production and downstream oxidative damage. One common
pathway of oxidative damage in mitochondria is lipid peroxidation, which can be
quantified indirectly per levels of the degradation byproduct malondialdehyde (MDA)
(27). MDA levels were 70% higher in PGDM-exposed CM (Figure 26B); this difference
was primarily due to PGDM-exposed males who had MDA levels over 150% higher than
controls. Although mitochondrial protein cytochrome C levels were not different between
groups (Figure 26C), authors sought to determine whether differences in ATP
production and baseline oxidative stress had functional consequences such as lowered
capacity for CM to handle acute metabolic stress leading to apoptosis and cell death.
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Figure 26. PGDM-exposed cardiomyocytes suffer from impaired phosphorylation
and increased lipid peroxidation.
(A) Cellular ATP levels with and without addition of ADP. Left two columns show media
without and with ADP added. (B) Malondialdehyde (MDA) was measured as a surrogate
marker for lipid peroxidation. (C) Cytosolic cytochrome C levels of cardiomyocytes at
baseline, i.e. not under stress. N = 8-10 per group (sexes combined). Data represent
mean ± SEM. *P ≤ 0.05 by 1-way ANOVA (A) or T-test (B). This figure has been
adapted from Louwagie, E.J., et al. Int J Mol Sci (2021).

To determine if PGDM exposure had an impact on cell viability under stressful
metabolic conditions, CM were subjected to an FCCP Challenge (256) to measure the
rate of mitochondrial membrane potential (MMP) loss (Figure 27) and apoptosis (Figure
28) following exposure to FCCP, a respiratory uncoupler that maximizes respiration
without ATP production. We found that even before FCCP-induced respiratory stress,
PGDM-exposed CM of both sexes have greater MMP (Figure 27C). Interestingly,
females of both groups have significantly higher MMP than males that may reflect the
superior mitochondrial function and lack of respiratory boost from mitochondrial
transplants found in females (241).Interestingly, control females and PGDM-exposed
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CM of both sexes that were treated with mitochondrial transplants had lower MMP at
baseline. Baseline differences affected rates of MMP loss after FCCP exposure (Figure
27D); CM that started from higher levels (females and PGDM-exposed offspring) fell
faster. Although both control and PGDM-exposed male CM lost MMP at a slower rate
than females, it is important to consider that male CM started off with lower MMP than
females and therefore had ‘less to lose.’ Next, it was imperative to determine whether
these consequences increase the risk of stress-induced apoptosis as previously found
in LGDM-exposed adult males (256)
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Figure 27. Females and PGDM-exposed cells have stronger MMP, but they lose it
faster following metabolic stress.
(A) Representative images of CM stained with MitoTracker Green, Hoechst, and
MitoTracker Red CMXRos. Once treated with FCCP, mitochondria lose their MMP and
trigger cell death through intrinsic apoptosis. (B) MMP loss was analyzed before and
following FCCP-induced stress by linear regression analysis. (C) Baseline MMP and (D)
rate of MMP loss were determined by quantifying MitoTracker Red fluorescence before
and over the 25 minutes following FCCP. N=4-5 per sex per group. Data represent
mean ± SEM. P ≤ 0.05: +diabetes, #mitochondrial, or δsex-specific effect (only lower
sex marked) by 1-way ANOVA. This figure has been adapted from Louwagie, E.J., et al.
Int J Mol Sci (2021).

Mitochondrial transplants reduce stress-induced apoptosis in males but increase it in
females
Quantifying TUNEL-positive cells after FCCP Challenge demonstrates that
PGDM-exposed CM suffer from significantly greater rates of stress-induced apoptosis
than controls; this is highlighted by more than double the number of TUNEL-positive
cells in this group (17±7% vs. 41±15%; Figure 28A-B). Interestingly, males had
significantly more apoptosis than females regardless of exposure (P=0.005). Effects of
mitochondrial transplantation were also sex-specific (P=0.049) (Figure 28B).
Transplants reduced the level of TUNEL-positive cells by 4 and 6.7% in control and
PGDM-exposed males, respectively. However, the reverse effect was seen in females;
transplants increased the level of TUNEL-positive cells by 6.5 and 12.2% in control and
PGDM-exposed females, respectively (Figure 28C).
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Figure 28. PGDM-exposed cardiomyocytes of both sexes are at greater risk of
stress-induced apoptosis; mitochondrial transplantation improves this risk in
males but makes it worse in females.
(A) Representative cardiomyocytes in culture are labeled with DAPI and TUNEL which
indicates apoptotic cell death. DNase I treatment, which induces single- and doublestrand DNA breaks in permeabilized cells was used as a positive control, and the
TUNEL labeling reaction without enzyme was used as a negative control. (B) Bar
graphs represent mean and SEM of percentage of TUNEL-positive cells following FCCP
Challenge with sexes combined (left) and separated (middle). Although not demarcated
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on the graph, there was a sex-specific difference in TUNEL-positive cells with higher
numbers in males regardless of group (P=0.005 by 1-way ANOVA). (C) The difference
in TUNEL-positive cells that were pretreated with mitochondrial transplantation before
FCCP challenge is shown by sex and group. N=4-5 (litters) per sex per group with
TUNEL analysis using an average of 138±10 cells per plate from 7-10 systematically
imaged fields. Data represent mean ± SEM. *p ≤ 0.05 by 1-way ANOVA. This figure has
been adapted from Louwagie, E.J., et al. Int J Mol Sci (2021).

Respiratory boost of mitochondrial transplantation required living, respiring donor
mitochondria
Finding that mitochondrial transplant increased CM respiration despite many of
the donor mitochondria colocalizing with lysosomes made us wonder whether recycled
cell membranes, enzymes, complex proteins of even mtDNA could incite a similar
response. To test this, we compared responses to living, respiring mitochondria vs. two
controls (Figure 29). The first control used mitochondria ‘killed’ by snap freezing in liquid
nitrogen to rupture membranes and then heated at 95C for 5 min to denature
mitochondrial complex proteins; importantly, mtDNA may withstand both of these
treatments. The second control used ‘killed’ mitochondrial that were also treated with
DNase I to digest mtDNA followed by a short heating to denature the DNase I. Like live
respiring mitochondria, both controls were also cooled on ice and administered to cells
in respiratory buffer. Respiratory buffer alone was used as a negative control. As
expected, adding ‘killed’ mitochondria reduced most of the respiratory boost seen by
transplants with live, respiring mitochondria. However, even CM treated with ‘killed’
mitochondria consistently had higher basal, maximal, and reserve respiratory capacities
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compared to sham treated CM (Figure 29). Not until going further to digest mtDNA did
we virtually eliminate any respiratory boost provided by the transplant process. Findings
show living, respiring mitochondria offer the most oxidative support to host cells, but
mtDNA alone may offer some respiratory benefit.

Figure 29. Respiratory benefits of mitochondrial transplantation require living
donor mitochondria with intact mtDNA.
Basal (A), FCCP-stimulated maximal (B), and reserve (C) respiratory capacities of CM
treated with sham (solid), living, respiring mitochondria (black hashing), ‘killed’
mitochondria (red hashing), and ‘killed’ plus DNase-treated mitochondria (diagonal).
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N=4-6 per group. Data represent mean ± SEM. P ≤ 0.05: #mitochondrial effect by 1-way
ANOVA. This figure has been adapted from Louwagie, E.J., et al. Int J Mol Sci (2021).

Discussion
In this study we show that newborn male offspring exposed to PGDM have
cardiac dysfunction and hypertrophy with inefficient ATP production and greater risk of
stress-induced cell death. Mitochondrial transplants can partially reverse the cellular
phenotype in males but not females. These findings demonstrate a central, underlying
role for mitochondria in developmentally programmed heart disease that is not only
exposure-related, but also sex-specific. This study also sheds important light on
mitochondria-mediated mechanisms that extend beyond impaired bioenergetics to
include oxidative stress and faster cell death under metabolic stress.
Unlike our previous findings demonstrating significant bioenergetic dysfunction in
offspring exposed to LGDM (7, 256), newborn offspring exposed to PGDM had less
apparent impairment in CM respiration. Bioenergetics data shows that PGDM-exposed
males consume more oxygen for ATP production, but this higher oxygen consumption
does not result in improved ATP generation. Instead it leads to more oxidative damage
and faster mitochondria-mediated apoptosis following FCCP Challenge (‘heart attack in
a dish’) Given that 1) Seahorse XFe normalizes bioenergetics to the number of live cells
at the end of the assay, 2) the assay itself exposes cells to FCCP, 3) FCCP increases
cell death in PGDM-exposed CM, and 4) there were fewer live cells in the PGDM group
at the end of the run despite equal plating, we surmise that bioenergetics data reported
in this study is confounded by differences in cell viability. Regardless, PGDM-exposed
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male CM have higher oxygen consumption, poor ATP production, excess ROS and
poorer viability under respiratory stress. All suggest mitochondria play a significant role.
Diving deeper to uncover additional mitochondrial mechanisms of
developmentally programmed heart disease, we augmented our bioenergetics assays
and FCCP Challenge with mitochondrial transplantation. After extensive validation, we
found that mitochondrial transplants not only provide a respiratory boost for male
PGDM-exposed CM, but they also improve survival following metabolic stress.
Interestingly, findings are sex-specific, and female recipients of mitochondrial
transplants actually experience greater rates of apoptosis. Findings support central
roles of mitochondria in developmental programmed heart disease that vary by sex and
may be improved by mitochondrial transplantation.
It is well recognized that PGDM causes higher rates of cardiac malformations
than LGDM in humans, purportedly due to diabetic exposure throughout organogenesis
(37, 73-77). Excluding malformations, offspring exposed to either PGDM and LGDM
have similar clinical phenotypes that most commonly consist of hypertrophic
cardiomyopathy with increased IVS thickness and poor diastolic function (43). Although
systolic dysfunction has been reported (38, 40-42), its occurrence is less consistent
than diastolic dysfunction and likely results from distinct, albeit potentially overlapping,
mechanisms. Further, diastolic dysfunction by definition includes a level of pulmonary
congestion (282) that was previously seen in our LGDM model (7, 256) but was not
detected here. The transient cardiomyopathy seen in offspring of diabetic mothers often
results from the increased IVS thickness obstructing cardiac outflow (283). However,
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our PGDM-exposed offspring have systolic dysfunction despite having IVS thickness
similar to controls suggesting functional rather than structural causes.
Mitochondrial health is essential to cardiac function, and we hypothesize that
mitochondria play central, pathogenic, and targetable roles in developmentally
programmed heart disease. Some of the important roles of mitochondria include ATP
generation, ROS production and neutralization, and regulation of cell fate. Although
simplistic, the adage of the mitochondrion as the ‘powerhouse of the cell’ is especially
true in cardiomyocytes, and the mitochondrial reticulum must expand to the point at
which it fills ~35% of the volume of the ventricular myocardium (13, 253). Inefficient ATP
production can lead to contractile (systolic) dysfunction (196, 284), and this association
is present in PGDM-exposed offspring in this study. Although we found similar baseline
levels of ATP in CM isolates, PGDM-exposed offspring had impaired phosphorylation of
ADP to ATP; this occurs despite consuming more oxygen in the process. Although in
skeletal rather than cardiac muscle, Petersen et al reported blunted insulin-stimulated
mitochondrial ADP phosphorylation in insulin-resistant adults born to diabetic mothers
(114). In our own studies, we have shown disruptions to cardiac insulin signaling
pathways in offspring exposed to LGDM and maternal HF diet (10), so it is plausible that
similar mechanisms are at play and even more severely affected in our PGDM model.
On top of inefficient ATP production, CM from PGDM-exposed offspring bear
significantly more evidence of oxidative damage. Mitochondria are not only the biggest
producer of ROS in the heart, but mitochondrial production of hydroxyl radicals damage
mitochondrial proteins, mtDNA, and membrane lipids; the latter is termed lipid
peroxidation and may impair FA oxidation and other normal mitochondrial functions (27,
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28). Other studies have linked lipid peroxidation to systolic dysfunction (7, 56, 285) as
well as structural cardiac change (157). Cardiolipin, a fatty acid found almost exclusively
in the inner mitochondrial membrane, is highly susceptible to peroxidation due to its
high degree of unsaturation (286) and is intimately involved with the release of
cytochrome C, a precursor to mitochondria-mediated intrinsic apoptosis (287). Although
we found high levels of lipid peroxidation in PGDM-exposed CM, we did not see
differences in cytochrome C levels in isolated CM fractions. This may have been more
noticeable in whole myocardium since cells that accumulate cytochrome C are at risk of
cell death and isolation and culture selects for the healthiest cells. Using an FCCP
Challenge paired with TUNEL staining, we subjected control and PGDM-exposed CM to
additional oxidative stress and then measured MMP loss and levels of downstream
apoptosis to show PGDM-exposed CM have faster MMP loss and more cell death
under stress.
Adding a mechanistic component, we used mitochondrial transplantation in these
experiments to determine if transferring normal mitochondria to the host cells would
improve bioenergetics and reduce apoptotic cell death. Indeed, mitochondrial
transplants improved respiration in all cells and lowered apoptosis rates in PGDMexposed male CM. However, benefits of mitochondrial transplants were sex-specific.
Specifically, transplanting healthy mitochondria before exposure to stress decreased
apoptosis in males but actually increased it in females. Previous studies of
mitochondrial transplantation in the context of treating ischemia-reperfusion injury (IRI)
have yielded similar results: mitochondrial transplants reduce oxidative stress-induced
apoptosis, evidenced by a lower number of TUNEL-positive cells (265) and reduced
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caspase activity (261) following IRI which was associated with reduced myocardial
necrosis by histologic staining (266). Of note, the first study was performed in male
rabbits whereas the latter two used female rabbits and female pigs, respectively. All
three were done using adult offspring, and there are certainly well described metabolic
differences in neonatal and adult CM (11, 198). It is therefore possible that the
discrepant effects of mitochondrial transplant found in females in our study (greater cell
death) compared to IRI studies (reduced cell death) are the result of age- or speciesspecific differences.
It is likely that the reduction in stress-induced cell death found in male PGDMexposed CM results from multiple mechanisms. One apparent mechanism is boosted
respiratory capacity, which we found here. Others have found similar results. In a 2015
study by Pacak et al that examined mechanisms of mitochondrial internalization,
authors showed that mitochondrial transplantation improved respiration of recipient
HeLa cells (263). A 2018 study by Kim et al found that mitochondrial transplantation to
mesenchymal stem cells (MSC) not only improved respiratory capacities, but also
enhanced MMP and reduced ROS levels 48 hours after transplantation (288). Although
we were unable to measure the direct effects of transplants on ROS handling, our
FCCP Challenge revealed both baseline and stress-induced differences in MMP that
were improved or worsened by mitochondrial transplants in a sex-specific manner. A
secondary finding from our study is that mtDNA may confer an important therapeutic
benefit following mitochondrial transplants. While our ‘killed’ and ‘killed plus DNasetreated’ mitochondria controls show that live, respiring mitochondria offset much of the
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boost in cellular respiration, it was not until denaturing mtDNA that we negated
respiratory effects to recipient cells altogether.
Future studies should use neonatal animal models to determine if cellular
changes identified in this study are reflected on a cardiac level and persist long-term.
Despite mounting studies supporting efficacy (260-263, 265, 267-269, 289-292),
scientifically valid challenges have been articulately expressed; the most substantive
question is how mitochondria escape Ca2+-induced permeability transition pore opening
when traveling via vasculature to CM (142, 293-295). It is therefore imperative that both
beneficial and harmful mechanisms be completely delineated, especially considering
that the method is already being used to treat young children (140, 290). Additional
future studies may investigate mechanisms of developmentally programmed heart
disease, specifically whether changes in mitochondria are inherited, result from in utero
conditions, or most likely result from a combination. We have previously found distinct,
epigenetic signatures with maternal LGDM and HF diet that vary by solo (LGDM or HF
diet individually) and combination exposure (8, 10). PGDM may convey unique
inheritable changes to mitochondrial genes or even mtDNA, and understanding these
changes will aid in prevention. Finally, considering the lipid peroxidation found in this
study, investigating additional markers of oxidative damage such as damage to mtDNA
or nuclear DNA through 8-oxoguanine quantification (156) may prove valuable.

Limitations of the Study
Similar to our studies of LGDM exposure (7, 256), cardiometabolic and
mitochondrial findings are limited to the heart and should be evaluated in other highly
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metabolic tissues like the nervous system and liver before they can be applied
elsewhere. Mitochondrial transplantation was beneficial to PGDM-exposed males in that
it reduced stress-induced apoptosis, but many parameters of mitochondrial and cellular
health were not examined and could actually be worsened by transplants; our data
specifically suggests that females may have a negative response. For example, transfer
of mtDNA, which we suspect benefits recipient cells, may actually be harmful. In a wellconducted 2012 study by Oka et al, authors found that mtDNA has inflammatory
properties and may contribute to development of cardiomyopathy when not properly
contained within mitochondria or upon escape from lysosomes (296). MtDNA may
therefore be contributing to the increased apoptosis in recipient female CM, and future
studies are needed to definitively rule out this possibility. Because pyknosis and
retraction are less reliable markers of cell death of neonatal compared to adult CM
(256), TUNEL labeling was performed following FCCP Challenge (213, 254, 297). While
this technique was valuable in quantifying stress-induced apoptosis, TUNEL labeling
may also detect severe necrosis, particularly in the context of outer mitochondrial
membrane rupture (298, 299) making it insensitive as to specific type of mitochondriamediated cell death.
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Conclusions
Ultimately, prenatal exposure to PGDM leads to impaired cardiac function that is
worsened by maternal HF diet and associated with inefficient energy production,
oxidative damage, and greater mitochondria-mediated cell death, especially in male
offspring. Although the clinical phenotypes of human newborns exposed to PGDM and
LGDM are similar, results from this and our previous model show that the underlying
cardiometabolic and mitochondrial mechanisms are distinct albeit potentially
overlapping. Using mitochondrial transplantation to focus on mitochondrial function of
CM, we found that donor mitochondria provide a respiratory boost to CM of all groups
and reduce stress-induced apoptosis in males. While these findings support a
pathogenic role of mitochondria in exposed offspring, future work should tease apart
these sexually dimorphic changes, particularly our finding of reduced apoptosis in males
yet increased apoptosis in females. Overall, our study identifies targetable mitochondria
functions – chiefly energy production and oxidative stress – that through targeted
intervention may improve long-term cardiac health in these at-risk infants.
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Table 11. Methods of mitochondrial isolation.
Paper
Kesner et al
2016 (300);
Nitzan et al
2019 (272)

Lin et al 2013
(301)

Isolation
Method
Differential
Centrifugation
(Dounce
homogenization)

Differential
Centrifugation
(Dounce)

Source

Quant method

HeLa
Protein assay
(DsRed2-mito)

Liver

Protein assay,
Confocal
counting

Differential
Centrifugation
(automated,
glass-grinding
homogenization;
(303))
Djafarzadeh
Differential
and Jakob 2017 Centrifugation
(304)
(automated glass
homogenization)

Left ventricle,
skeletal
muscle, liver,
HeLa cells,

Protein assay,
Spinning disk
confocal
microscopy

Skeletal
muscle

Protein assay

Kitani et al
2014 (305)

Differential
Centrifugation
(Needle
homogenization)

Endometrial
gland-derived
mesenchymal
cells (DsRedmito)

Protein assay

Kim et al 2018
(288)

Differential
Centrifugation
(Needle
homogenization)

MSCs

Protein assay

Preble 2014
(306, 307),
Pacak 2015
(263), Cowan
2016 (260) and
2017 (264),
Kaza 2017
(262),
RamirezBarbieri 2018
(267),
Guariento 2019
(266),
Moskowitzova
2019 (271,
308), Orfany
2019 (270),
Weixler 2020
(268), Blitzer
2020 (289),
Doulamis 2020
(269)

Differential
Filtration
(‘McCully
Method’)

Skeletal
muscle, liver,
cardiac
fibroblasts

McCully 2007
(302) and 2009
(261),
Masuzawa et al
2013 (265)

Purity / Functional
Tests
WB for purity
Citrate synthase
activity for membrane
integrity and viability
EM to show isolated
mitochondria
interacting with hose
cell PM
WB for purity
Confocal microscopy
for MMP retention

Confocal microscopy
for presence and MMP
retention
Clark electrodes
(Oxytherm) for
respiratory function
High-res oxygraph
electrodes for complex
I-IV function
Cytochrome C assay to
demonstrate intact
OMM
Confocal microscopy
for presence
EM for intact
membranes
Zetasizer measurement
for function/viability
(indicated by negative
surface charge)

MTgreen and MTred
CMXRos for viability
(MMP retention)
WB for purity
EM to show intact
membranes
ATP
quant
(luminescence assay)
Protein assay,
EM to show intact
particle size
membranes
counting,
MTred CMXRos for
Coulter cell
viability (MMP
counter,
retention)
hemocytometry, ATP quant
Spinning disk
(luminescence assay)
confocal
and Clark electrodes
microscopy
(Oxytherm) for
respiratory function
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Notes
Mitochondrial Isolation buffer
(320mM sucrose, 5mM Tris-HCl,
pH 7.4, 2mM EGTA)

Isolated with Suspension buffer
(0.5M HEPES-KOH, 1M KCl, 1M
MgCl2, 0.5M EGTA, 0.5M EDTA,
protease cocktail, phosphatase
inhibitor I, phosphatase inhibitor
II, 0.25M sucrose, pH 7.6)
Mito suspended in Respiration
Buffer (250mM sucrose, 2mM
KH2PO4, 10mM MgCl2, 20mM
K-HEPES Buffer (pH 7.2) and
0.5mM K-EGTA (pH 8.0))

Mito were isolated and
suspended in Homogenization
buffer (20mM HEPES-KOH (pH
7.4), 220mM mannitol and 70mM
sucrose)

Mito kept in SHE buffer [0.25M
sucrose, 20mM HEPES (pH 7.4),
2mM EGTA, 10mM KCl, 1.5mM
MgCl2 and 0.1% defatted bovine
serum albumin (BSA)]
Full iso methods in supp. (see
EndNote)
RAPID Method: tissue
dissociation-homogenization 
enzymatic digestion (Subtilisin A)
 differential filtration
Mito isolated with “Homogenizing
Buffer” (pH 7.2, 300mM sucrose,
10mM K-HEPES, and 1mM KEGTA) and suspended in “vehicle
solution” (250mM sucrose; 10mM
K+-HEPES pH 7.2; 0.5mM K+EGTA, pH 8.0) or Respiration
Buffer (250mM sucrose, 2mM
KH2PO4, 10mM MgCl2, 20mM
K-HEPES Buffer (pH 7.2) and
0.5mM K-EGTA (pH 8.0))

Sims 1990
(309)

Density
Gradient
(Percoll)
Centrifugation
(Dounce)

Hartwig et al
2008 (310)

Density
Liver
Gradient
(Sucrose) VS
Zone
Electrophoresis
VS DifferentialGradient Hybrid
Method (but with
a blade)

Kitani et al
2014 (311)

Magnetic bead
isolation
(Needle
homogenization)

Brain

Endometrial
gland-derived
mesenchymal
cells (DsRedmitochondria)

Protein assay

Clark electrodes for
respiratory function
Cytochrome C oxidase
and Lactate DH assays
for intact membranes
EM for purity (showed
synaptosome and
Percoll contaminates)
Protein assay
SDH assay for purity
(yields: density (ZE was best choice)
gradient > ZE > WB and EM for purity
Hybrid method) (highest level of
contamination by
gradient methods)
JC-1 uptake for intact
membranes (Best to
worst: ZE > hybrid
method > density
gradient)
Protein assay
Flow cytometry for
purity
EM for intact
membranes
Zetasizer measurement
for function/viability
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1-3 hours required for isolation
Mito fractions were contaminated
with synaptosomes and Percoll
(not fully removed by washes)

First two methods were
homogenized with a Teflon Potter
apparatus (similar to a Dounce),
third with a rotating blade
homogenizer

Table 12. Antibodies used in Western blotting analyses.
Antibody
Anti-VDAC1/Porin, diluted 1:1000
Anti-CYPD, diluted 1:1000

Source
Abcam
Abcam

Anti-LaminA/C, diluted 1:1000

Cell Signaling
Technology
Cell Signaling
Technology
Cell Signaling
Technology
SouthernBiotech

Anti-β-Actin (HRP-conj.), diluted
1:1000
Anti-β-Tubulin (HRP-conj), diluted
1:1000
Goat anti-rabbit IgG-HRP, diluted
1:5000
Goat anti-mouse IgG(H+L)
human ads-HRP, diluted 1:5000

SouthernBiotech

Identifiers
Cat#Ab14734; RRID:AB_443084
Cat#Ab110324;
RRID:AB_10864110
Cat#2032S; RRID:AB_2136278
Cat#5125S; RRID:AB_1903890
Cat#5346; RRID:AB_1950376
Cat#4030-05; RRID:AB_2687483
Cat#1031-05; RRID:AB_2794307

Table 13. Probe-primer sets used in mito::mKate2 mouse validation experiments.
Gene

Species

Source

Identifier, Assay ID, and/or Sequence

B2m

Rat,
Mouse
Rat

Integrated DNA Technologies

NM_012512.2; Rn03928990_g1

Integrated DNA Technologies

Rlp4

Mouse

Bio-Rad

mt-CytB

Mouse

Bio-Rad

Custom-designed assay;
Probe: /56-FAM/TTGGTTCAT
/ZEN/CGTCCATACGTTCCCCTTA/3IABkFQ/
Primer 1:
GATTAGACCCGTTACCATCGAGAT
Primer 2: GGTTCTTACTTCAGGGCCATCA
ENSMUST00000034966;
qMmuCEP0034839
ENSMUST00000082421;
qMmuCEP0033357

mtDNA
D-loop
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Table 14. Model characteristics.
Controls

PGDMexposed

Combination
Diet-exposed -exposed

Diabetes
(P value)

Baseline wt, g

152±3

170±20

149±5

174±12

0.057

0.973

0.771

Post-diet wt, g

217±8

219±11

224±7

237±7

0.370

0.150

0.505

94±5
Ketones, mmol/L 5-10 0.8±0.1
Insulin need, U
0±0

^349±21

94±2

^413±27

N/A

N/A

0.049

0.7±0.1
+85±13

0.6±0.0
0±0

^2.4±0.3
+115±14

N/A
<0.0001

N/A
0.120

<0.0001
0.120

TG, mg/dL

70±10

63±7

*161±25

*383±115

0.075

0.002

0.060

Litter size, pups

14±1

12±1

13±2

13±1

0.508

0.894

0.508

2.9±1.9

12.0±3.1

*15.4±5.7

*19.3±2.5

0.097

0.014

0.491

6.3±0.1

^6.9±0.1

6.4±0.1

6.3±0.2

N/A

N/A

0.02

91.4±2.6

+76.5±2.1

*94.6±4.9

+*90.5±2.5

0.007

0.015

0.124

756±168

+4505±1113

1062±295

+5201±1709

0.002

0.635

0.853

C-peptide, pg/mL 5

2864±616

+6150±690

2660±1149

+3419±768

0.027

0.097

0.148

1

108±11

138±24

Parameter

N

Dams

Glucose, mg/dL

Perinatal
mortality rate, %
Cohort 1 (Males)

P1 weight, g
Glucose, mg/dL
Insulin, pg/mL

TG, mg/dL

Parameter

Cohort 2

P1 weight, g
Glucose, mg/dL
1

Insulin, pg/mL

5-9
3266
2437
5

5-6

Diet
(P value)

Interaction
(P value)

110±21

129±18

0.776

0.219

0.844

Controls
Females

Males

PGDM-exposed
Females
Males

Diabetes
(P value)

Sex
(P value)

Interaction
(P value)

6.0±0.9

6.3±0.1

+6.5±0.1

+6.9±0.1

<0.0001

0.012

0.726

83.3±2.1

88.3±2.1

+78.4±3.0

+84.0±2.4

0.018

0.068

0.763

4-5

1625±358

1263±376

+4102±1179

+3606±788

0.002

0.558

0.927

4-5

2723±376

2467±362

+4277±768

+4937±879

0.003

0.745

0.463

5-6

138±13

108±11

94±19

110±21

0.212

0.682

0.179

N
4680
4680

1

C-peptide,
pg/mL
1
TG, mg/dL

1Pooled

serum samples from both cohorts. Perinatal mortality was calculated from both

cohorts. TG, triglycerides; P1, perinatal day one; N/A, not applicable; PGDM,
pregestational diabetes mellitus. Insulin need was from gestational day (GD)0 to GD22.
Significant differences (p≤0.05): +diabetes or *diet effect by 2-way ANOVA, ^group
effect remained significant by 1-way ANOVA and Dunnett post hoc test when significant
interaction by 2-way ANOVA. Sex-specific differences are indicated by p-value but are
unmarked.
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PGDM-exposed (both sexes)

Male Offspring

Table 15. Offspring morphometric and echocardiographic results.
Parameter
Heart:body wt
ratio (x10-3)
EF, %
FS, %
E:A ratio
HR, bpm
SV, µL
CO, mL/min
LV mass, mg
IVSd, mm
LV diastolic
diameter, mm
LV diastolic
volume, µL
PAAT:RVET
ratio

N

Controls

PGDMexposed

Dietexposed

Combination- Diabetes
exposed
(P value)

Diet
(P value)

Interaction
(P value)

37-61

7.3±0.1
76.1±1.5
43.6±1.4
0.71±0.03
254±5
24.1±0.9
6.1±0.2
44.8±1.5
0.60±0.03

+7.5±0.1
+69.0±1.6
+37.6±1.3
0.73±0.01
262±6
24.6±1.1
6.4±0.2
49.1±4.3
0.57±0.02

+7.1±0.1
73.6±2.0
41.9±1.7
0.72±0.02
258±8
*20.9±0.8
*5.4±0.3
41.3±1.6
0.60±0.02

+7.5±0.1
+66.1±1.4
+35.2±1.0
0.65±0.03
260±7
*20.4±0.8
*5.3±0.3
46.2±2.8
0.57±0.02

0.008
<0.0001
<0.0001
0.364
0.512
0.997
0.754
0.083
0.160

0.3.7
0.125
0.148
0.146
0.967
<0.001
0.002
0.223
0.967

0.536
0.903
0.819
0.073
0.693
0.579
0.541
0.909
0.943

2.88±0.04

+3.02±0.04

*2.76±0.05

+*2.84±0.04

0.022

0.003

0.596

31.8±1.2

+35.6±1.2

*28.8±1.3

+*30.8±1.0

0.021

0.003

0.483

0.18±0.01

Parameter
Heart:body wt
ratio (x10-3)
EF, %
FS, %
E:A ratio

N

0.22±0.02
Controls
Females

Males

0.20±0.01
0.21±0.01
PGDM-exposed
Females
Males

0.534
Diabetes
(P value)

0.709
Sex
(P value)

0.091
Interaction
(P value)

7.5±0.1
75.0±0.8
42.4±0.7

7.3±0.1
75.4±3.1
43.6±2.9

7.6±0.1
76.9±1.1
44.4±1.0

7.6±0.1
75.2±0.8
42.6±0.7

0.372
0.559
0.698

0.236
0.646
0.846

0.506
.0496
0.290

0.73±0.02

0.79±0.02

0.79±0.06

0.79±0.02

0.4772

0.540

0.488

SV, µL

283±7
23.5±1.4

262±8
23.6±1.8

291±9
+27.7±1.1

287±9
+25.3±0.9

0.062
0.0374

0.146
0.424

0.312
0.3835

CO, mL/min

6.7±0.5

6.2±0.6

+8.1±0.4

+7.2±0.3

0.018

0.185

0.736

LV mass, mg

30.5±1.2
0.40±0.01

34.0±2.1
0.51±0.04

+42.7±4.0
+0.57±0.05

+40.7±2.4
+0.54±0.03

0.002
0.022

0.780
0.327

0.350
0.075

2.85±0.07

2.86±0.08

+3.02±0.05

+2.95±0.04

0.042

0.593

0.533

31.4±2.0

31.5±2.3

36.0±1.4

33.8±1.2

0.062

0.564

0.524

0.29±0.01

0.27±0.03

0.29±0.02

0.25±0.02

0.678

0.148

0.575

12-19

44-61

HR, bpm

IVSd, mm
LV diastolic
diameter, mm
LV diastolic
volume, µL
PAAT:RVET
ratio

10-15

EF, ejection fraction; FS, fractional shortening; E:A ratio, ratio of ventricular filling
velocities in early to late diastole; HF, heart rate; SV, stroke volume; CO, cardiac output;
LV, left ventricle; IVSd, interventricular septum thickness during diastole; PAAT:RVET
ratio, ratio of pulmonary artery acceleration time to right ventricular ejection time.
Significant differences (p≤0.05): +diabetes or *diet effect by 2-way ANOVA.

161

Chapter 4: Summary
Summary of Findings
Our work to date shows that prenatal exposure to maternal late-gestation
diabetes (LGDM) and HF diet leads to profound mitochondrial and cardiac dysfunction
in newborn offspring that improves over time yet reemerges in late adulthood,
predisposing these offspring to faster cardiomyocyte (CM) death under stress. This
translates to human populations, as newborns exposed to diabetes (both PGDM and
LGDM) have cardiac hypertrophy and dysfunction worsened by maternal obesity or
hyperlipidemia. Developmentally programmed consequences are sex-specific;
interestingly, females appear to be more severely affected by maternal HF diet while
males appear to be more severely affected by maternal diabetes. In most cases,
combination-exposed offspring demonstrate the most severe cardiometabolic and
mitochondrial phenotypes, both at birth and later in adulthood.
Diabetes-exposed 12MO offspring have impaired cardiac function manifested by
lower systolic function in exposed females and lower diastolic function in exposed
males. Importantly, this cardiac dysfunction is preceded by bioenergetic dysfunction in
the absence of other cardiometabolic risk factors. Significant bioenergetic impairments
are in respiration and FAO, the two oxidative pathways mediated directly by
mitochondria, and therefore support a programmed, pathogenic role of mitochondria.
Further, PGDM-exposed males have faster mitochondrial membrane potential (MMP)
loss and mitochondria-mediated cell death under stress. In diet-exposed adult females,
a decrease in cardiac OXPHOS incites an exaggerated increase in mitochondrial
biogenesis between 6MO and 12MO, resulting in a greater number of mitochondria with
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impaired respiratory complex function. This increased number of dysfunctional
mitochondria leads to higher basal and maximal respiration but also a depleted
respiratory reserve capacity. Clinically, this may translate to impaired ability to increase
ATP production under ischemic conditions such as IRI, leading to more damage from
acute myocardial infarction (AMI). This translates to human studies that show a greater
risk of death from AMI in adults born to obese mothers (112). Taken together, these
studies suggest that both maternal diabetes and obesity cause long-term, mitochondriamediated cardiac consequences, and offspring exposed to the combination (ODOM) not
only suffer from greater rates of adverse cardiac events, but also are more likely to die
from these events as a result of programmed mitochondrial dysfunction.
Using mitochondrial transplantation of normal, functional, ventricular
mitochondria into neonatal CM exposed to pregestational diabetes mellitus (PGDM)
and/or maternal HF diet, we sought to determine whether mitochondria are responsible
for the impaired cardiac function seen in ODOM. Because we previously found
bioenergetic and cardiac dysfunction in newborns prenatally exposed to LGDM, we also
sought to characterize differences between PGDM- and LGDM-exposed offspring, if
present (43). Male offspring born to mothers with PGDM had larger hearts and systolic
(but not diastolic) dysfunction per lower ejection and shortening fractions. Males born to
mothers on HF diet had greater mortality and lower stroke volumes leading to reduced
cardiac output. Once again, combination-exposed offspring were the most severely
affected with the highest perinatal mortality rates, largest hearts, worst systolic function,
and lowest cardiac output. Using live-cell imaging to compare rates of mitochondrial
internalization and mitophagy of host and donor mitochondria, we found that donor
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mitochondria are internalized by cardiomyocytes of all groups, and mitochondrial uptake
is initially fastest in PGDM-exposed CM. Internalized mitochondria then either fuse with
host mitochondria or lysosomes where they presumably undergo mitophagy. In this
study, we showed that transplantation provides a significant respiratory boost to all
cells, particularly combination-exposed male CM. However, we were surprised not to
find the same respiratory impairment in PGDM-exposed CM as we did in LGDMexposed CM, especially because PGDM exposed the developing offspring to more
severe hyperglycemia over a longer period of time which included implantation and
organogenesis. It is possible that PGDM caused placental insufficiency by exposing the
developing trophoblasts to hyperglycemia as well. This has not yet been studied. It is
also possible that PGDM impaired CM viability and that our isolation and culture
techniques selected only the “healthiest” remaining cells, diminishing differences by
methodologic means. Regardless of these limitations, our mitochondrial stress test of
PGDM-exposed CM showed greater oxygen consumption for ATP production, which
suggests greater ROS production that could have negative consequences on cell health
and viability, specifically under oxidative stress. This prompted the addition of a second
cohort of PGDM-exposed newborn offspring to answer these important questions.
Our initial cohort focused on male offspring because we previously showed that
males are more severely affected by maternal diabetes as is common with
developmental programming in general. Our previous work and that of others has also
shown that females have better mitochondrial quality control and resistance to damage
than males (9, 241, 256, 312, 313). Our second cohort consisted of both male and
female offspring exposed to PGDM in order to 1) determine if sex-specific differences
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were present and had masked the bioenergetic phenotype seen in LGDM-exposed
offspring (i.e. were females the main contributors to impaired bioenergetics previous
found using pooled sexes? Did male CM have poorer viability confounding energetics
data? (7)), and 2) determine if the cardiac dysfunction seen in PGDM-exposed males
was the result of other mitochondria-mediated processes, particularly ROS production
and impaired viability under oxidative stress. Findings from our second cohort showed
that while bioenergetic differences were not as pronounced, PGDM-exposed offspring,
particularly males, had severely impaired ability to generate ATP, had significantly
higher levels of MDA indicating oxidative membrane damage, and had reduced viability
per increased apoptosis under metabolic stress. Again, mitochondrial transplantation
provided a respiratory boost to both sexes, and to all groups for that matter. Further,
mitochondrial therapy reduced stress-induced apoptosis of male CM, but it actually
increased oxygen consumption and apoptosis of female CM. Findings may reflect
intrinsic sex-specific differences in mitochondrial function and well as developmentally
programmed heart disease.

Important Considerations, Limitations, and Future Directions
In our studies evaluating long-term programming, we excluded many potential
systemic risk factors that contribute to cardiac disease (overt obesity, diabetes, vascular
disease). This, along with the fact that our experiments examined effects of isolated CM
which removes external confounding factors, supports the conclusion that long-term
mitochondrial dysfunction is responsible for the lower cardiac function in these offspring.
However, it is possible that other underlying factors contributed. We did not find
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explanatory differences in levels of ICAM or E-Selectin, two markers of vascular
damage, but other vascular parameters such as sympathetic or parasympathetic
responses or vascular calcification, fibrosis or reactivity may have been affected, putting
strain on the heart. Similarly, while overt diabetes was not found, we did not perform
hyperinsulinemic-euglycemic clamps which are a more sensitive measure of early
insulin resistance and could have contributed to the lower cardiac function at 12MO. We
did not see obesity develop, but we did not quantify total body fat or lean mass. Future
studies into these areas may add useful, mechanistic understanding of developmental
programming and guide clinical management of ODOM.
Few studies have evaluated developmental programming as late in development
as done here, but we expect further aging would exacerbate the findings in our model.
For example, Sprague Dawley rats have a lifespan of approximately three years. If we
subjected two year old exposed offspring to our FCCP challenge, we may find even
greater disparities in cell survival between control and PGDM-exposed offspring as well
as faster cell death in HF diet-exposed offspring. Future studies may investigate
additional, potentially programmed cardiac roles of mitochondria in the adult heart
including calcium handling, tricarboxylic acid cycle flux or anaplerosis, and
mitohormesis. Of these, the former is functionally tied to mitochondrial permeability
transition-driven necrosis and would be of particular interest. A more complete
understanding of how mitochondria are developmentally programmed by maternal
diabetes and obesity would help guide preventative strategies and development of
mitochondria-targeted therapeutics.
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Mitochondrial transplantation which was used here to mechanistically evaluate
cellular function is currently under clinical investigation to determine its therapeutic
efficacy in ischemic myocardial damage in pediatric patients (140). Specifically, the
clinical trial’s subjects are children two months to two years old on extracorporeal
membrane oxygenation (ECMO) support due to ischemic damage from cardiac
operations or myocardial infarction. These enrollment requirements reflect the fact that
approximately 79% of ECMO patients in this age group (2 months to 2 years) end up
there for essential cardiac or postoperative support. Tragically, the average 1-year
survival rate of this ECMO population is only 58% (314). The trial is not set to finish until
2022, but results to date look promising. Of the 16 patients treated so far, results have
been posted on 11 (315). Eight of these 11 showed improvement in systolic function
and were successfully weaned off ECMO. Of the three who unfortunately did not
survive, two had already sustained irreversible end-organ damage before undergoing
transplantation and one passed away from an infection. Eight of 11 is a 73% survival
rate, which is an absolute increase in survival of 15%. Although an extensive amount of
work has demonstrated the cardiac benefits of mitochondrial transplantation in animal
models (258-261, 263, 265-267, 289-292), the exact mechanisms have yet to be
delineated. Our findings show that mitochondrial transplantation improves
cardiomyocyte bioenergetics and cell survival under metabolic stress only in males.
Mitochondrial dynamics allow for the exchange of mitochondrial contents including
mtDNA (316), providing a means for internalized mitochondria to ‘share’ either healthy
or damaged mtDNA with the host cell’s mitochondrial network. Our ‘killed, DNasetreated’ donor control supports this as a contributory mechanism. Future studies using
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our diabetes and HF diet model should investigate these mechanisms in animal models
as well as determine if mitochondrial transplantation can prevent the greater
mitochondria-mediated death seen in our aged adult offspring.
Lastly, future studies should investigate the source of mitochondrial dysfunction
in offspring hearts – direct mother-to-offspring inheritance, in utero damage by fuelmediated influences, or most likely a combination of the two – to determine the most
critical windows of intervention for diabetic and obese pregnancies. Using the same
litters of animals raised for our Aim 2 (Chapter 3) experiments, we saved whole hearts
from dams and their offspring, ovaries from each dam, and mitochondrial pellets from
each of these tissues as sources of nuclear and mitochondrial DNA. Using standardized
DNA extraction methods or kits, such as Qiagen’s DNeasy Kit for Tissue, we are able to
extract whole cellular (i.e. both nuclear and mitochondrial) DNA from these tissues and
mtDNA from the frozen mitochondrial pellets that can be compared by 8-oxodG DNA
immunoprecipitation sequencing (OxiDIP-Seq) for oxidative DNA damage, RNA-Seq for
transcriptomic profiling, and bisulfite sequencing for mtDNA methylation patterns. As
mentioned above, increasing evidence suggests epigenetic regulation of the
mitochondrial genome through DNA methylation (147-150) and nuclear modification (8,
126, 127). Indeed, the Baack lab previously used their LGDM model to demonstrate
tissue-specific genome-wide changes in histone acetylation and methylation signatures
(8) and transcriptomic profiles (10) and used systems biology approaches to
demonstrate changes in promoters that regulate cellular bioenergetics and
mitochondrial function. Although these studies found important, intricate exposurespecific changes, neither was able to investigate changes to the mitochondrial genome,
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oxidative DNA damage resulting from maternal mitochondrial dysfunction, or sexspecific epigenetic changes. These are important questions that, once answered, would
indicate not only the source, but also critical timing of induced mitochondrial damage.
I expect sequencing studies to show different methylation and transcriptome
patterns between maternal and neonatal samples, yet similar/identical patterns between
maternal ovaries and cardiac tissue. If bisulfite sequencing is inconclusive or not the
central hub of mitochondrial programming, transcriptomic changes in either nuclear or
mtDNA expression may still be found using RNA-Seq. Regardless, given the paucity of
studies, the mitochondrial epitranscriptome is an area worth investigating now and in
future studies (317). From OxiDIP-Seq, I expect to find increased oxidative damage in
all hearts and ovaries exposed to maternal HF diet that is worsened in combination with
maternal PGDM. Different maternal-offspring patterns would support our hypothesis that
neonatal mitochondria are damaged by excess in utero fuels and fetal insulin
production. While it is well-known that mitochondrial function varies by cell type (318),
the tissue-specific responses to excess macronutrient exposure are not fully
understood. This includes mitochondria from oocytes/ova vs. cardiac tissue. If maternal
gametes and cardiomyocytes respond with similar epigenetic changes, this paints a
grim picture for ODOM because they are likely inheriting mitochondrial dysfunction from
their mothers that may transcend generations (7, 17, 126, 146). Ultimately,
understanding the inheritance and genetic regulation of mitochondrial dysfunction in
cardiomyopathy of ODOM will lead us closer to improved prevention and potential
therapeutic targets.
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Contributions to the Field and Overall Implications
While the clinical components of maternal diabetes and obesity on offspring
cardiac function are well-characterized in newborns and being unraveled at older ages,
a better understanding of the underlying mechanisms is needed in order to prevent and
treat these cardiac consequences. Here we take necessary steps to investigate
mitochondria-mediated mechanisms of both short- and long-term cardiac
consequences. In our first studies, we identify and support a central, causative role of
impaired mitochondrial bioenergetics and oxidative stress responses leading to cardiac
dysfunction in exposed adult offspring that may translate to greater mortality following
acute myocardial infarction. Thus, the present dissertation not only helps unravel these
complex mechanisms but also supports an important preventative target—mitochondria.
As human ODOM age, findings in this area will be of the utmost importance in
developing novel interventions to reduce risks from developmentally programmed heart
disease.
Taking these findings farther, we used our model of PGDM and maternal HF diet
to determine if impaired mitochondrial bioenergetics were responsible for the cardiac
dysfunction seen in our exposed newborn male offspring. Although we did find cardiac
hypertrophy and systolic dysfunction with PGDM exposure, we were surprised not to
find diffuse bioenergetic impairments that were present in our LGDM model. However,
these initial experiments implicated involvement by other mitochondria-mediated
mechanisms: ROS production and mitochondria-mediated cell death under oxidative
stress. We determined that cardiomyocytes from our PGDM-exposed offspring are
subject to greater ROS-induced mitochondrial damage and have greater rates of
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apoptosis under stress. Considering the oxidative burst and required switch to aerobic
metabolism after birth, these mitochondrial impairments likely play a significant role in
the cardiac dysfunction seen in PGDM-exposed newborns.
From a practical clinical perspective, results herein indicate that clinicians should
focus on getting both maternal hyperlipidemia and hyperglycemia under control, even
before conception to minimize damage to offspring cardiac mitochondria. If not possible
before conception, these studies (PGDM vs LGDM) show that limiting dietary fat intake
and improving glycemic control may still improve cardiac outcomes through
mitochondria-mediated pathways. Although much work remains to be done, and many
questions need answers, mitochondria appear to be central, potentially pathogenic
mediators of developmentally programmed heart disease and henceforth should be
considered pathologically and therapeutically in future studies.
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